Top

Koji Sasaki, MD, PhD

Department of Leukemia, Division of Cancer Medicine

About Dr. Koji Sasaki

Dr. Koji Sasaki has the expertise, training, expertise and motivation necessary to successfully carry out the proposed research project. He has a broad background in hematology, with extensive training and expertise in hematologic malignancy during fellowship in Japan and the United States as well as statistical data analysis including deep learning and artificial intelligence (AI) during his PhD graduate training. During high school in Japan, Dr. Sasaki learned graduate level of mathematics including partial differential equations and matrix data calculations. His interest has been in the creation of mathematical model to assist decision-making for physicians and patients. During the medical school at Tokyo Medical and Dental University and early my career, Dr. Sasaki focused on learning medicine and hematology to be a well-established physician in this field, and decided to pursue further career in the U.S after the successful completion of Japanese medicine and hematology fellowship. During the fellowship at MD Anderson Cancer Center, he experienced the cutting-edge of therapeutic interventions and the graduate school training deepened his understanding and knowledge of mathematics and statistics. This lead to successful publications at high-impact journals, and helps colleagues with complex statistical analysis. Dr. Sasaki's long term research interests involve the development of AI for the best treatment option among appropriate therapeutic interventions under supervision of board-certified physicians. He has built a prototype of AI with neural network analysis for patients with chronic myeloid leukemia in chronic phase (CML-CP) for the best treatment decision. The abstract was accepted as oral presentation at the Annual Meeting of American Society of Hematology in 2016. The wide applicability of AI approach with enthusiastic commitment from Department of Bioinformatics at MD Anderson Cancer Center, in addition to Department of Leukemia, will ensure the success of the development of AI for this purpose, and allow for the future broad application of the AI project to acute myeloid leukemia and other hematologic malignancies.

Primary Appointment

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Chair, Professor, Department of Laboratory Medicine, Institute of Science Tokyo, Tokyo, Tokyo

Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2018	Tokyo Medical and Dental University, Tokyo, JP, Medicine, Ph.D
2006	Tokyo Medical and Dental University, Tokyo, JP, MD

Postgraduate Training

2016-2017	Clinical Fellowship, Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
2015-2016	Clinical Fellowship, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
2013-2015	Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas
2010-2013	Clinical Residency, Medicine, Mount Sinai Beth Israel, New York, New York
2008-2010	Clinical Fellowship, Hematology, Tokyo Medical and Dental University, Tokyo
2006-2008	Clinical Residency, Tokyo Medical and Dental University, Tokyo

Licenses & Certifications

2017	The American Board of Hematology
2016	The Japanese Board of Hematology
2015	Full Texas Medical License
2014	The Japanese Board of Internal Medicine
2013	The American Board of Internal Medicine
2006	Full Japanese Medical License

Experience & Service

Faculty Academic Appointments

Assistant Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2023

Extramural Institutional Committee Activities

Member, Data and Biospecimen Access Committee (DBAC), The University of Texas MD Anderson Cancer Center, 2022 - Present

Editorial Activities

Editor, Journal of hematology & oncology, 2025 - Present

Editor, American journal of hematology, 2025 - Present

Editor, Blood cancer journal, 2025 - Present

Editor, Scientific reports, 2024 - Present

Editor, Acta Haematologica, 2022 - Present

Honors & Awards

2018	20th Tanaka Michiko Clinical Research Scholarship Award, Tokyo Medical and Dental University
2017	19th Annual John Goldman Conference on CML Best Clinical Abstract Award, iCMLf - ESH
2016	2016 American Society of Hematology Abstract Achievement Award
2016	2016 Society of Hematologic Oncology Honorable Distinction Poster Award
2015	2015 American Society of Hematology Abstract Achievement Award
2015	2015 Future Leaders Award for Clinical Research in Hematology, Celgene
2015	2015 Merit Award at 2015 American Society of Clinical Oncology Annual Meeting
2015	2015 Society of Hematologic Oncology Best Poster Award – First Place
2014	2014 American Society of Hematology Abstract Achievement Award
2014	2014 Oncology Trainee Travel Award at 2014 ASCO Annual Meeting
2010	2010 N Program Scholarship Award, Tokio Marine & Nichido Fire Insurance Co., Ltd

Professional Memberships

Japanese Society of Medical Oncology

2021 - Present

Japanese Society of Hematology

2019 - Present

American Association for Cancer Research

2018 - Present

American Society of Hematology

2013 - Present

American Society of Clinical Oncology

2012 - Present

American College of Physicians

2012 - Present

Japanese Society of Hematology

2008 - Present

Selected Presentations & Talks

Regional Presentations

Data-Driven Research: The impact of CCyR in MDS and The risk of Myelopathy in ALL. Conference. Zeev Estrov Leukemia Research Meeting, US.

National Presentations

2022. Clinical Applications of Artificial Intelligence in Medicine. Conference. 8th Taiwan-Japan Hematology Forum. Taipei, US.
2018. ASH 60th Annual Meeting. Invited. ASH 60th Annual Meeting. San Diego, CA, US.
2018. iCMLf 20th John Goldman Int'l Conference. Invited. iCMLf 20th John Goldman Int'l Conference. Miami, FL, US.

International Presentations

2022. Luncheon Seminar: Ph+Leukemia: CML / Ph+ALL. Conference. Otsuka Pharmaceiticals. Fukuoka, JP.
2021. Luncheon Seminar: Ph+Leukemia: CML / Ph+ALL. Conference. Otsuka Phamaceuticals. Sendai, JP.
2020. Luncheon Seminar: Ph+Leukemia: CML / Ph+ALL. Conference. Otsuka Pharmaceiticals. Kyoto, JP.
2019. Luncheon Seminar: Ph+Leukemia: CML / Ph+ALL. Conference. Otsuka Pharmaceiticals. Tokyo, JP.
2018. Luncheon Seminar: Ph+Leukemia: CML / Ph+ALL. Invited. Otsuka Pharmaceuticals. Tokyo, JP.

Formal Peers

2022. Lecture on the present and future treatments for Ph+ leukemia in Japan and US. Invited. Fukuoka, JP.
2017. New Therapy with TKI in Tokyo, Japan. Invited. Tokyo, JP.
2017. Hematology Seminar in Osaka, Japan. Invited. Osaka, JP.
2017. Ph+ Leukemia Symposium in Akita, Japan. Invited. Akita, JP.
2017. Hematology Forum 2017 in Saitama, Japan. Invited. Saitama, JP.

Less

Grant & Contract Support

Date:	2023 - 2030
Title:	A Phase II multicenter, open-label, single-arm dose escalation study of Asciminib monotherapy in 2nd Line Chronic Phase – Chronic Myelogenous Leukemia
Funding Source:	Novartis
Role:	PI

Date:	2018 - 2022
Title:	The Application of Machine Learning in Leukemia
Funding Source:	XSEDE Startup Funding National Science Foundation
Role:	PI
ID:	BCS180018

Date:	2018 - 2019
Title:	NO TITLE PROVIDED
Funding Source:	Leukemia Texas
Role:	PI
ID:	FP00006045

Selected Publications

Peer-Reviewed Articles

Bataller Torralba, A, Sasaki, K, Urrutia, S, Montalban Bravo, G, Bazinet, A, Chien, KS, Hammond, DE, Bouligny, IM, Swaminathan, M, Issa, GC, Short, NJ, Daver, N, DiNardo, C, Kadia, TM, Jabbour, EJ, Ravandi-Kashani, F, Roboz, G, Savona, MR, Griffiths, EA, McCloskey, J, Odenike, O, Oganesian, A, Keer, HN, Azab, M, Kantarjian, HM, Garcia-Manero, G. Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40164584.
Fiskus, WC, Mill, CP, Piel, J, Collins, M, Hentemann, M, Cuglievan, B, Birdwell, C, Das, K, Hou, H, Davis, JA, Jain, A, Malovannaya, A, Kadia, TM, Daver, N, Sasaki, K, Takahashi, K, Hammond, D, Reville, PK, Flores, L, Loghavi, S, Su, X, DiNardo, C, Bhalla, K. Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40089460.
Willekens, C, Bazinet, A, Chraibi, S, Bataller Torralba, A, Decroocq, J, Arani, N, Carpentier, B, Rausch, C, Lebon, D, Maiti, A, Gauthier, N, Short, NJ, Bonnet, S, Sasaki, K, Khalife-Hachem, S, Swaminathan, M, Micol, JB, Pasquier, F, Marzac, C, Roos-Weil, D, Pascal, L, Daver, N, Kadia, TM, Bouscary, D, Ravandi-Kashani, F, Pages, A, Kantarjian, HM, De Botton, S, DiNardo, C. Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 40246832.
Reville, PK, Wang, B, Marvin-Peek, J, Yuan, B, Kuo, YA, Garza, AI, Root, J, Qiao, W, Arruda, A, Veletic, I, Liu, Y, Short, NJ, DiNardo, C, Kadia, TM, Daver, N, Lorenzi, PL, Sasaki, K, Kornblau, SM, Minden, MD, Ravandi-Kashani, F, Kantarjian, HM, Abbas, HA. Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes. Blood 145(25):3015-3029, 2025. e-Pub 2025. PMID: 40179376.
Braish, JS, Montalban Bravo, G, Ravandi-Kashani, F, Short, NJ, Kadia, TM, Ohanian, M, Chien, KS, Masarova, L, Sasaki, K, Yilmaz, M, Logahvi, S, Daver, N, Borthakur, G, Jabbour, EJ, Schneider, H, Romero, LT, Kantarjian, HM, Garcia-Manero, G. Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome. Leukemia Research 153, 2025. e-Pub 2025. PMID: 40252309.
Saul, EE, Urrutia, S, Yang, H, Montalban Bravo, G, Tang, G, Toruner, GA, Patel, KP, Luthra, R, Bueso-Ramos, CE, Wang, S, Chien, KS, Sasaki, K, Atluri, H, Goulart, H, Thakral, B, Garcia-Manero, G, Kanagal Shamanna, R. A Case of Cryptic CBFB::MYH11 Acute Myeloid Leukemia With Noncanonical Breakpoints Detected by Optical Genome Mapping. JNCCN Journal of the National Comprehensive Cancer Network 23(6), 2025. e-Pub 2025. PMID: 40345240.
Braish, JS, Montalban Bravo, G, Ravandi-Kashani, F, Short, NJ, Kadia, TM, Ohanian, M, Chien, KS, Masarova, L, Sasaki, K, Yilmaz, M, Logahvi, S, Daver, N, Borthakur, G, Jabbour, EJ, Schneider, H, Romero, LT, Kantarjian, HM, Garcia-Manero, G. Safety and efficacy of the combination of azacitidine with venetoclax after hypomethylating agent failure in higher-risk myelodysplastic syndrome. Leukemia Research 153, 2025. e-Pub 2025. PMID: 40252309.
Cortes, JE, Lang, F, Rea, D, Hochhaus, A, Breccia, M, Goh, YT, Heinrich, MC, Hughes, TP, Janssen, JJ, Le Coutre, PD, Minami, H, Sasaki, K, DeAngelo, DJ, Sánchez-Ollé, G, Pognan, N, Cao, M, Hoch, M, Mauro, M. Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase. Leukemia 39(5):1124-1134, 2025. e-Pub 2025. PMID: 40204896.
Hochhaus, A, Kim, DW, Cortes, JE, Sasaki, K, Mauro, M, Hughes, TP, Breccia, M, Talpaz, M, Minami, H, Goh, YT, DeAngelo, DJ, Lang, F, Ottmann, OG, Heinrich, MC, Gómez-García de Soria, V, Le Coutre, PD, Sánchez-Ollé, G, Cao, M, Pognan, N, Kapoor, S, Hoch, M, Rea, D. Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results: CHRONIC MYELOID LEUKEMIA. Leukemia 39(5):1114-1123, 2025. e-Pub 2025. PMID: 40204892.
Sasaki, K, Garcia-Manero, G, Nigo, M, Jabbour, EJ, Ravandi-Kashani, F, Wierda, WG, Jain, N, Takahashi, K, Montalban Bravo, G, Daver, N, Thompson, PA, Pemmaraju, N, Kontoyiannis, DP, Sato, J, Karimaghaei, S, Soltysiak, KA, Raad, II, Kantarjian, HM, Carter, B. Artificial Intelligence Assessment of Chest Radiographs for COVID-19. Clinical Lymphoma, Myeloma and Leukemia 25(5):319-327, 2025. e-Pub 2025. PMID: 39710565.
Haddad, FG, Sasaki, K, Senapati, J, Hu, S, Dellasala, S, Issa, GC, Jabbour, EJ, Kantarjian, HM. Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase. Clinical Lymphoma, Myeloma and Leukemia 25(4):254-257, 2025. e-Pub 2025. PMID: 39592322.
DiNardo, C, Jen, WY, Takahashi, K, Kadia, TM, Loghavi, S, Daver, N, Xiao, L, Reville, PK, Issa, GC, Short, NJ, Sasaki, K, Wang, S, Mullin, JK, Pierce, S, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Ferrajoli, A, Swaminathan, M, Ohanian, M, Abbas, HA, Hammond, D, Burger, JA, Haddad, FG, Montalban Bravo, G, Chien, KS, Masarova, L, Yilmaz, M, Jain, N, Andreeff, M, Garcia-Manero, G, Kornblau, SM, Ravandi-Kashani, F, Jabbour, EJ, Konopleva, M, Kantarjian, HM. Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia. Leukemia 39(4):854-863, 2025. e-Pub 2025. PMID: 40000842.
Bazinet, A, Bataller Torralba, A, Kadia, TM, Daver, N, Short, NJ, Yilmaz, M, Sasaki, K, DiNardo, C, Borthakur, G, Issa, GC, Bouligny, IM, Pierce, S, Garcia-Manero, G, Ravandi-Kashani, F, Kantarjian, HM. A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia. Cancer 131(6), 2025. e-Pub 2025. PMID: 40097915.
Takaoka, K, Komrokji, RS, Chien, KS, Montalban Bravo, G, Salman, JB, Urrutia, S, Bataller Torralba, A, Bazinet, A, Kekedjian, J, Al Ali, NH, Sallman, D, Padron, E, Xie, Z, Kanagal Shamanna, R, Tang, G, Yang, H, Rodriguez-Sevilla, JJ, Garcia-Manero, G, Sasaki, K. Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion. Leukemia Research 150, 2025. e-Pub 2025. PMID: 39938357.
Kantarjian, HM, Short, NJ, Jain, N, Haddad, FG, Kadia, TM, Yilmaz, M, Ferrajoli, A, Sasaki, K, Alvarado, Y, Pemmaraju, N, Senapati, J, Garris, R, Ravandi-Kashani, F, Jabbour, EJ. Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. American journal of hematology 100(3):402-407, 2025. e-Pub 2025. PMID: 39757533.
Jen, WY, Marvin-Peek, J, Kantarjian, HM, Alvarado, Y, Borthakur, G, Jabbour, EJ, Wierda, WG, Kadia, TM, Daver, N, DiNardo, C, Short, NJ, Jain, N, Ferrajoli, A, Kornblau, SM, Yilmaz, M, Ohanian, M, McCue, D, Burger, JA, Hammond, DE, Patel, K, Issa, GC, Pemmaraju, N, Sasaki, K, Maiti, A, Abbas, HA, Chien, KS, Takahashi, K, Haddad, FG, Bose, P, Masarova, L, Montalban Bravo, G, Swaminathan, M, Brandt, M, Pierce, S, Garcia-Manero, G, Ravandi, F. Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. Cancer 131(1), 2025. e-Pub 2025. PMID: 39584789.
Haddad FG, Sasaki K, Senapati J, Xiao L, Park G, Abuasab T, Venugopal S, Rivera D, Bazinet A, Babakhanlou R, Kim K, Ong F, Desikan S, Pemmaraju N, Loghavi S, Borthakur G, DiNardo C, Abbas HA, Short NJ, Daver N, Jabbour E, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia T. Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis. JCO Oncol Pract 20(12):OP2400027, 2024. e-Pub 2024. PMID: 39013130.
Urrutia, S, Kantarjian, H, Ravandi-Kashani, F, Bueso-Ramos, CE, Kanagal-Shamanna, R, Jabbour, EJ, Montalban-Bravo, G, Short, NJ, Daver, N, Borthakur, G, DiNardo, CD, Kadia, TM, Masarova, L, Bose, P, Pemmaraju, N, Garcia-Manero, G, Sasaki, K. Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis. Journal of Hematology and Oncology 17(1), 2024. e-Pub 2024. PMID: 39548557.
Haddad FG, Sasaki K, Nasr L, Short NJ, Kadia T, Dellasala S, Cortes J, Nicolini FE, Issa GC, Jabbour E, Kantarjian H. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase. Cancer 130(19):3344-3352, 2024. e-Pub 2024. PMID: 38804723.
Senapati J, Kantarjian HM, Bazinet A, Reville P, Short NJ, Daver N, Borthakur G, Bataller A, Jabbour E, DiNardo C, Haddad F, Sasaki K, Popat U, Oran B, Alousi AM, Loghavi S, Shpall E, Garcia-Manero G, Ravandi F, Kadia TM. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer 130(19):3333-3343, 2024. e-Pub 2024. PMID: 38809547.
Sasaki K, Kantarjian H, Montalban-Bravo G, Hammond D, Jabbour E, Kanagal-Shamanna R, Chien K, Garcia-Manero G. Eosinophilia During Lenalidomide Therapy in Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 24(9):629-633, 2024. e-Pub 2024. PMID: 38777652.
McCall D, Abuasab T, Rodriguez-Sevilla JJ, Mohamed SF, Patnaik A, Devireddy K, Arani N, Sheikh I, Jamshidi R, Gibson A, Roth M, Nunez C, Garcia M, Chien KS, Loghavi S, Pierce SA, Sasaki K, Issa G, Cuglievan B, Kantarjian H, Garcia-Manero G. Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysis. Leuk Res 144:107563, 2024. e-Pub 2024. PMID: 39178611.
Akiyama H, Kantarjian H, Jabbour E, Issa G, Haddad FG, Short NJ, Hu S, Ishizawa J, Andreeff M, Sasaki K. Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia. Int J Hematol 120(2):203-211, 2024. e-Pub 2024. PMID: 38748089.
Jabbour E, Haddad FG, Sasaki K, Carter BZ, Alvarado Y, Nasnas C, Nasr L, Masarova L, Daver N, Pemmaraju N, Short NJ, Skinner J, Kadia T, Borthakur G, Garcia-Manero G, Ravandi F, Issa GC, Andreeff M, Kantarjian H. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer 130(15):2652-2659, 2024. e-Pub 2024. PMID: 38591430.
Cortes JE, Sasaki K, Kim DW, Hughes TP, Etienne G, Mauro MJ, Hochhaus A, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, JJWM J, Talpaz M, de Soria VGG, le Coutre P, DeAngelo DJ, Damon A, Cacciatore S, Polydoros F, Agrawal N, Rea D. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor. Leukemia 38(7):1522-1533, 2024. e-Pub 2024. PMID: 38755421.
Short NJ, Jabbour E, Nasr LF, Jain N, Haddad FG, Issa GC, Sasaki K, Senapati J, Kebriaei P, Garris R, Konopleva M, Ravandi F, Kantarjian H. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. Am J Hematol 99(7):1423-1426, 2024. e-Pub 2024. PMID: 38607091.
Haddad FG, Nasnas C, Sasaki K, Paul S, Issa GC, Rausch C, Jabbour E, Kantarjian H. Using Proton Pump Inhibitors is not Associated With Adverse Outcomes in Patients With Chronic Myeloid Leukemia Treated With Dasatinib. Clin Lymphoma Myeloma Leuk 24(7):484-487, 2024. e-Pub 2024. PMID: 38503634.
Braish JS, Kugler E, Jabbour E, Woodman K, Ravandi F, Nicholas S, Jain N, Kantarjian H, Sasaki K. Incidence and Clinical Presentation of Severe Neurotoxicity from Nelarabine in Patients with T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 24(11):783-788, 2024. e-Pub 2024. PMID: 39013740.
Gener-Ricos G, Bataller A, Rodriguez-Sevilla JJ, Chien KS, Quesada AE, Almanza-Huante E, Hammond D, Sasaki K, DiNardo C, Kadia T, Daver N, Borthakur G, Issa GC, Short NJ, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentage. Cancer 130(20):3452-3462, 2024. e-Pub 2024. PMID: 38896064.
Ali MA, Aiman W, Kantarjian H, Jabbour E, Ravandi F, Jain N, Short NJ, Sasaki K. Efficacy of Chemotherapy-Free Regimens in the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 24(10):e376-e384, 2024. e-Pub 2024. PMID: 38972767.
Bataller A, Gener-Ricos G, Almanza-Huante E, Chien KS, Urrutia S, Bazinet A, Rodriguez-Sevilla JJ, Hammond D, Sasaki K, Takahashi K, DiNardo CD, Ravandi F, Borthakur G, Kadia TM, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm. Blood Adv 8(11):2695-2706, 2024. e-Pub 2024. PMID: 38513082.
Gener-Ricos G, Bewersdorf JP, Loghavi S, Bataller A, Goldberg AD, Sasaki K, Famulare C, Takahashi K, Issa GC, Borthakur G, Kadia TM, Short NJ, Senapati J, Carter BZ, Patel KP, Kantarjian H, Andreeff M, Stein EM, DiNardo CD. TP53 Y220C mutations in patients with myeloid malignancies. Leuk Lymphoma:1-5, 2024. e-Pub 2024. PMID: 38856690.
Haddad FG, Sasaki K, Issa GC, Jabbour E, Kantarjian H. The presence of additional cytogenetic abnormalities (ACAs) or Philadelphia chromosome variants do not adversely affect the achievement of treatment-free remission in chronic myeloid leukemia. Am J Hematol 99(6):1175-1176, 2024. e-Pub 2024. PMID: 38546372.
Sasaki K, Ravandi F, Kadia T, DiNardo CD, Yilmaz M, Short N, Jabbour E, Patel KP, Loghavi S, Pierce S, Borthakur G, Kantarjian H. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia. Clin Lymphoma Myeloma Leuk 24(6):375-381, 2024. e-Pub 2024. PMID: 38431521.
Jen WY, Sasaki K, Loghavi S, Wang SA, Qiao W, Borthakur G, Ravandi F, Kadia TM, Issa GC, Short NJ, Yilmaz M, Daver NG, DiNardo CD. Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression. Br J Haematol 204(6):2259-2263, 2024. e-Pub 2024. PMID: 38603594.
Fiskus W, Piel J, Collins M, Hentemann M, Cuglievan B, Mill CP, Birdwell CE, Das K, Davis JA, Hou H, Jain A, Malovannaya A, Kadia TM, Daver N, Sasaki K, Takahashi K, Hammond D, Reville PK, Wang J, Loghavi S, Sen R, Ruan X, Su X, Flores LB, DiNardo CD, Bhalla KN. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor. Blood 143(20):2059-2072, 2024. e-Pub 2024. PMID: 38437498.
Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, Borthakur G, Loghavi S, Patel K, Tang G, Sasaki K, Short NJ, Yilmaz M, Issa GC, Alvarado Y, Montalban-Bravo G, Maiti A, Abbas HA, Takahashi K, Pierce S, Jabbour E, Garcia-Manero G, Ravandi F. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica 109(11):3543-3556, 2024. e-Pub 2024. PMID: 38695144.
Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol 99(5):836-843, 2024. e-Pub 2024. PMID: 38400519.
Nasnas PE, Jabbour EJ, Sasaki K, Issa GC, Masarova L, Short NJ, Haddad FG. Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia. Acta Haematol 148(1):105-110, 2024. e-Pub 2024. PMID: 38574468.
Bazinet A, Desikan SP, Li Z, Rodriguez-Sevilla JJ, Venugopal S, Urrutia S, Montalban-Bravo G, Sasaki K, Chien KS, Hammond D, Kanagal-Shamanna R, Ganan-Gomez I, Kadia TM, Borthakur G, DiNardo CD, Daver NG, Jabbour EJ, Ravandi F, Kantarjian H, Garcia-Manero G. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax. Clin Cancer Res 30(7):1319-1326, 2024. e-Pub 2024. PMID: 38300723.
Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study. Lancet Haematol 11(4):e276-e286, 2024. e-Pub 2024. PMID: 38452788.
Bataller A, DiNardo CD, Bazinet A, Daver NG, Maiti A, Borthakur G, Short N, Sasaki K, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups. Am J Hematol 99(4):792-796, 2024. e-Pub 2024. PMID: 38361282.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol 11(4):e287-e298, 2024. e-Pub 2024. PMID: 38548404.
Tajiri M, Gentsu T, Yamaguchi M, Sasaki K, Ueshima E, Okada T, Sugimoto K, Murakami T. A Case of Life-threatening Rupture of Small Renal Angiomyolipoma with an Unidentified Intratumoral Aneurysm during Follow-up. Interv Radiol (Higashimatsuyama) 9(1):20-25, 2024. e-Pub 2024. PMID: 38525001.
Chien KS, Ong F, Kim K, Li Z, Kanagal-Shamanna R, DiNardo CD, Takahashi K, Montalban-Bravo G, Hammond D, Sasaki K, Pierce SA, Kantarjian HM, Garcia-Manero G. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms. Cancer Med 13(5):e7093, 2024. e-Pub 2024. PMID: 38497538.
Bataller A, Montalban-Bravo G, Bazinet A, Alvarado Y, Chien K, Venugopal S, Ishizawa J, Hammond D, Swaminathan M, Sasaki K, Issa GC, Short NJ, Masarova L, Daver NG, Kadia TM, Colla S, Qiao W, Huang X, Kanagal-Shamanna R, Hendrickson S, Ravandi F, Jabbour E, Kantarjian H, Garcia-Manero G. Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study. Lancet Haematol 11(3):e186-e195, 2024. e-Pub 2024. PMID: 38316133.
Birdwell CE, Fiskus W, Kadia TM, Mill CP, Sasaki K, Daver N, DiNardo CD, Pemmaraju N, Borthakur G, Davis JA, Das K, Sharma S, Horrigan S, Ruan X, Su X, Khoury JD, Kantarjian H, Bhalla KN. Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia 38(3):545-556, 2024. e-Pub 2024. PMID: 38086946.
Wang B, Reville PK, Yassouf MY, Jelloul FZ, Ly C, Desai PN, Wang Z, Borges P, Veletic I, Dasdemir E, Burks JK, Tang G, Guo S, Garza AI, Nasnas C, Vaughn NR, Baran N, Deng Q, Matthews J, Gunaratne PH, Antunes DA, Ekmekcioglu S, Sasaki K, Garcia MB, Cuglievan B, Hao D, Daver N, Green MR, Konopleva M, Futreal A, Post SM, Abbas HA. Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat Commun 15(1):1821, 2024. e-Pub 2024. PMID: 38418901.
Jabbour E, Haddad FG, Short NJ, Senapati J, Jain N, Sasaki K, Jorgensen J, Wang SA, Alvarado Y, Wang X, DiNardo C, Masarova L, Kadia T, Garris RS, Ravandi F, Kantarjian H. Phase II Study of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia in Remission. Blood 143(5):417-421, 2024. e-Pub 2024. PMID: 37879077.
Matsuo T, Wurster S, Jiang Y, Sasaki K, Tarrand J, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with leukaemia in the era of mould-active azoles: increasing incidence, frequent breakthrough infections and lack of improved outcomes. J Antimicrob Chemother 79(2):297-306, 2024. e-Pub 2024. PMID: 38073151.
Nahmod KA, Sasaki K, Ok CY, Loghavi S. Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution. Am J Hematol 99(2):329-330, 2024. e-Pub 2024. PMID: 37243496.
Bataller A, Abuasab T, McCall D, Wang W, Cuglievan B, Issa GC, Jabbour E, Short N, DiNardo CD, Tang G, Garcia-Manero G, Kantarjian HM, Sasaki K. Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineage-directed therapies. Haematologica 109(1):293-297, 2024. e-Pub 2024. PMID: 37646654.
Atallah, E, Mauro, M, Sasaki, K, Levy, MY, Koller, PB, Yang, D, Laine, D, Sabo, J, Gu, E, Cortes, JE. Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase. Future Oncology 20(38):3065-3075, 2024. e-Pub 2024. PMID: 39387441.
Marvin-Peek J, Sasaki K, Kontoyiannis DP, Adachi J, Ohanian M, Takahashi K, Issa GC, Kornblau S, Abbas HA. Nontuberculosis mycobacteria (NTM) infections in patients with leukemia: a single center case series. Front Med (Lausanne) 11:1402897, 2024. e-Pub 2024. PMID: 39149601.
Rivera D, Cui W, Gao J, Peker D, Zhang QY, Dewar R, Qiu L, Konoplev S, Hu Z, Sasaki K, Hu A, E S, Liu M, Fang H, Wang W, Tang G, Apperley JF, Hochhaus A, Cortes JE, Khoury JD, Medeiros LJ, Jabbour E, Hu S. Aleukemic Chronic Myeloid Leukemia without Neutrophilia and Thrombocytosis at Initial Presentation: a Report from the BCR::ABL1 Pathology Group. Mod Pathol:100406. e-Pub 2023. PMID: 38104892.
Barnett KR, Mobley RJ, Diedrich JD, Bergeron BP, Bhattarai KR, Monovich AC, Narina S, Yang W, Crews KR, Manring CS, Jabbour E, Paietta E, Litzow MR, Kornblau SM, Stock W, Inaba H, Jeha S, Pui CH, Mullighan CG, Relling MV, Pruett-Miller SM, Ryan RJH, Yang JJ, Evans WE, Savic D. Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators. Cell Genom 3(12):100442, 2023. e-Pub 2023. PMID: 38116118.
Kantarjian H, Welch MA, Sasaki K. Early mortality after chemotherapy as a quality indicator-the leukemia perspective. Blood Cancer J 13(1):176, 2023. e-Pub 2023. PMID: 38040680.
Sasaki K, Haddad FG, Short NJ, Jain N, Issa G, Jabbour E, Kantarjian H. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019. Cancer 129(23):3805-3814, 2023. e-Pub 2023. PMID: 37769040.
Sasaki K, Ravandi F, DiNardo C, Welch MA, Kadia T, Kantarjian H. Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 23(12):905-910, 2023. e-Pub 2023. PMID: 37730483.
Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Venetoclax Abrogates the Prognostic Impact of Splicing Factor Gene Mutations in Newly Diagnosed Acute Myeloid Leukemia. Blood 142(19):1647-1657, 2023. e-Pub 2023. PMID: 37441846.
Senapati J, Fiskus WC, Daver N, Wilson NR, Ravandi F, Garcia-Manero G, Kadia T, DiNardo CD, Jabbour E, Burger J, Short NJ, Alvarado Y, Jain N, Masarova L, Issa GC, Qiao W, Khoury JD, Pierce S, Miller D, Sasaki K, Konopleva M, Bhalla KN, Borthakur G, Pemmaraju N. Phase 1 Results of Bromodomain and Extraterminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. Clin Cancer Res 29(21):4352-4360, 2023. e-Pub 2023. PMID: 37585491.
Meredith DM, Cooley LD, Dubuc A, Morrissette J, Sussman RT, Nasrallah MP, Rathbun P, Yap KL, Wadhwani N, Bao L, Wolff DJ, Ida C, Sukhanova M, Horbinski C, Jennings LJ, Farooqi M, Gener M, Ginn K, Kam KL, Sasaki K, Kanagal-Shamanna R, Alexandrescu S, Brat D, Lu X. ROS1 alterations as a potential driver of gliomas in infant, pediatric, and adult patients. Mod Pathol 36(11):100294, 2023. e-Pub 2023. PMID: 37532182.
Sasaki K. Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes. Lancet Haematol 10(11):e872, 2023. e-Pub 2023. PMID: 37914477.
Sasaki K, Morita K, Kantarjian H, Garcia-Manero G, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Wierda W, Daver N, Takahashi K, DiNardo C, Bravo GM, Issa GC, Pierce SA, Soltysiak KA, Tingen MS, Cortes JE. Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results. Clin Lymphoma Myeloma Leuk 23(11):e369-e378, 2023. e-Pub 2023. PMID: 37690903.
Montalban-Bravo G, Kanagal-Shamanna R, Li Z, Hammond D, Chien K, Rodriguez-Sevilla JJ, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol 203(4):581-592, 2023. e-Pub 2023. PMID: 37608562.
Gener-Ricos G, Haddad FG, Sasaki K, Issa GC, Skinner J, Masarova L, Borthakur G, Alvarado Y, Garcia-Manero G, Jabbour E, Kantarjian H. Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. Clin Lymphoma Myeloma Leuk 23(10):742-748, 2023. e-Pub 2023. PMID: 37308342.
Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. Am J Hematol 98(10):E281-E284, 2023. e-Pub 2023. PMID: 37515433.
Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian H. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol 98(10):1619-1626, 2023. e-Pub 2023. PMID: 37485584.
Hammond D, Loghavi S, Wang SA, Konopleva MY, Kadia TM, Daver NG, Ohanian M, Issa GC, Alvarado Y, Short NJ, Sasaki K, Pemmaraju N, Montalban-Bravo G, Lachowiez CA, Maiti A, Garcia-Manero G, Jabbour EJ, Borthakur G, Ravandi F, Takahashi K, Pierce SR, Kantarjian HM, DiNardo CD. Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents. Blood Cancer J 13(1):148, 2023. e-Pub 2023. PMID: 37735426.
Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. The role of therapy in the outcome of patients with myelofibrosis. Cancer 129(18):2828-2835, 2023. e-Pub 2023. PMID: 37243913.
Bazinet A, Kantarjian H, Arani N, Popat U, Bataller A, Sasaki K, DiNardo CD, Daver N, Yilmaz M, Abbas HA, Short NJ, Issa G, Jabbour E, Pierce SA, Chen J, Garcia R, Konopleva M, Garcia-Manero G, Alousi A, Shpall EJ, Champlin RE, Borthakur G, Ravandi F, Kadia T. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol 98(9):1383-1393, 2023. e-Pub 2023. PMID: 37334870.
Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol. e-Pub 2023. PMID: 37665752.
Richard-Carpentier G, Rausch CR, Sasaki K, Hammond D, Morita K, Takahashi K, Tang G, Kanagal-Shamanna R, Bhalla K, Dinardo CD, Borthakur G, Pemmaraju N, Shpall EJ, Alousi A, Daver NG, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM, Kadia TM. Characteristics and clinical outcomes of patients with acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2). Haematologica 108(9):2331-2342, 2023. e-Pub 2023. PMID: 36951163.
Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol 98(8):1196-1203, 2023. e-Pub 2023. PMID: 37183966.
Hill HA, Jain P, Ok CY, Sasaki K, Chen H, Wang ML, Chen K. Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma. Cancer Res Commun 3(8):1435-1446, 2023. e-Pub 2023. PMID: 37538987.
Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen J, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad FG, Pierce S, Nogueras Gonzalez G, Maiti A, Sasaki K, Yilmaz M, Thompson P, Wierda W, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian H, Ravandi F. Undetectable Measurable Residual Disease is Associated with Improved Outcomes in AML Irrespective of Treatment Intensity. Blood Adv 7(13):3284-3296, 2023. e-Pub 2023. PMID: 36884300.
Haddad FG, Kantarjian HM, Bidikian A, Jabbour EJ, Short NJ, Ning J, Xiao L, Pemmaraju N, DiNardo CD, Kadia TM, Marx KR, Garcia-Manero G, Ravandi F, Sasaki K, Issa GC. Association between bariatric surgery and outcomes in chronic myeloid leukemia. Cancer 129(12):1866-1872, 2023. e-Pub 2023. PMID: 36882573.
Nguyen D, Kantarjian HM, Short NJ, Qiao W, Ning J, Cuglievan B, Daver NG, DiNardo CD, Jabbour EJ, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva MY, Andreeff M, Ravandi-Kashani F, Sasaki K, Issa GC. Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation. Cancer 129(12):1856-1865, 2023. e-Pub 2023. PMID: 36892949.
DiNardo CD, Venugopal S, Lachowiez C, Takahashi K, Loghavi S, Montalban-Bravo G, Wang X, Carraway H, Sekeres M, Sukkur A, Hammond D, Chien K, Maiti A, Masarova L, Sasaki K, Alvarado Y, Kadia T, Short NJ, Daver N, Borthakur G, Ravandi F, Kantarjian HM, Patel B, Dezern A, Roboz G, Garcia-Manero G. Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome. Blood Adv 7(11):2378-2387, 2023. e-Pub 2023. PMID: 35973199.
Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol 10(6):e433-e444, 2023. e-Pub 2023. PMID: 37187201.
Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol 7:e2200707, 2023. e-Pub 2023. PMID: 37196217.
Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol 16(1):44, 2023. e-Pub 2023. PMID: 37131217.
Bidikian A, Jabbour E, Issa GC, Short NJ, Sasaki K, Kantarjian H. Chronic Myeloid Leukemia Without Major Molecular Response After 2 Years of Treatment with Tyrosine Kinase Inhibitor. Am J Hematol 98(4):639-644, 2023. e-Pub 2023. PMID: 36606715.
Bataller A, Chien KS, Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Urrutia S, Almanza-Huante E, Gener-Ricos G, Ravandi F, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G. PHF6 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia. Leuk Res 127:107044, 2023. e-Pub 2023. PMID: 36801700.
Urrutia S, Li Z, Almanza E, Bataller A, Kanagal-Shamanna R, Senapati J, Sasaki K, Chien K, Montalban-Bravo G, DiNardo C, Borthakur G, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. Leukemia 37(6):1397-1400, 2023. e-Pub 2023. PMID: 37185307.
Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel KP, Kanagal-Shamanna R, Champlin R, Khouri IF, Dellasala S, Pierce SA, Kantarjian H. The Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-line BCR::ABL1 Tyrosine Kinase Inhibitors. Am J Hematol 98(4):658-665, 2023. e-Pub 2023. PMID: 36683287.
Siddiqui M, Konoplev S, Issa G, Kantarjian H, Daver N, Ravandi F, Kadia T, Tang G, Wang SA, Thakral B, Medeiros LJ, Pozdnyakova O, Pierce S, Montalban-Bravo G, Chien K, Hammond D, Sasaki K, Garcia-Manero G, Hasserjian RP. Biologic Features and Clinical Outcomes in Newly Diagnosed Myelodysplastic Syndrome with KMT2A rearrangements. Am J Hematol 98(4):E91-E94, 2023. e-Pub 2023. PMID: 36661399.
Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 7(6):933-942, 2023. e-Pub 2023. PMID: 36322818.
Bataller A, Haddad FG, Issa GC, Sasaki K, Jabbour E, Borthakur G, Ferrajoli A, Short NJ. Sudden lymphoid blast crisis after tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia: cautionary tales for appropriate molecular monitoring. Leuk Lymphoma 64(3):1-4, 2023. e-Pub 2023. PMID: 36657414.
Mill CP, Fiskus W, Das K, Davis JA, Birdwell CE, Kadia TM, DiNardo CD, Daver N, Takahashi K, Sasaki K, McGeehan GM, Ruan X, Su X, Loghavi S, Kantarjian H, Bhalla KN. Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia 37(6):1336-1348. e-Pub 2023. PMID: 36977823.
Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, Sasaki K, Breccia M, Talpaz M, Ottmann O, Minami H, Goh YT, DeAngelo DJ, Heinrich MC, Gómez-García de Soria V, le Coutre P, Mahon FX, JJWM J, Deininger M, Shanmuganathan N, Geyer MB, Cacciatore S, Polydoros F, Agrawal N, Hoch M, Lang F. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia 37(5):1048-1059, 2023. e-Pub 2023. PMID: 36949155.
Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol 98(3):493-501, 2023. e-Pub 2023. PMID: 36600670.
Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, García-Gutiérrez V, Kapoor S, Allepuz A, Quenet S, Bédoucha V, Mauro MJ. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia 37(3):617-626, 2023. e-Pub 2023. PMID: 36717654.
Bazinet A, Darbaniyan F, Kadia TM, Venugopal S, Kanagal-Shamanna R, DiNardo CD, Borthakur G, Jabbour EJ, Daver NG, Pemmaraju N, Konopleva MY, Ravandi F, Sasaki K, Chien KS, Hammond D, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia. Cancer 129(4):560-568, 2023. e-Pub 2023. PMID: 36458426.
Hayata M, Ichikawa T, Nishida T, Sasaki K, Aoki R, Minosaki Y. Early caffeine therapy on the prevention of severe hyperkalemia in preterm infants. Pediatr Int 65(1):e15526, 2023. e-Pub 2023. PMID: 36905304.
Paul S, Kantarjian H, Sasaki K, Marx K, Jain N, Savoy JM, DiPippo A, Jammal N, Bravo GM, Kadia T, Garcia-Manero G, Short NJ, Ravandi F, Jabbour E. Intrathecal Prophylaxis with 12 Versus 8 Administrations Reduces the Incidence of Central Nervous System Relapse in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Am J Hematol 98(1):E11-E14, 2023. e-Pub 2023. PMID: 35633516.
Yap TA, Daver N, Mahendra M, Zhang J, Kamiya-Matsuoka C, Meric-Bernstam F, Kantarjian HM, Ravandi F, Collins ME, Francesco MED, Dumbrava EE, Fu S, Gao S, Gay JP, Gera S, Han J, Hong DS, Jabbour EJ, Ju Z, Karp DD, Lodi A, Molina JR, Baran N, Naing A, Ohanian M, Pant S, Pemmaraju N, Bose P, Piha-Paul SA, Rodon J, Salguero C, Sasaki K, Singh AK, Subbiah V, Tsimberidou AM, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P, Heijnen CJ, Kavelaars A, Marszalek JR, Konopleva M. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med 29(1):115-126, 2023. e-Pub 2023. PMID: 36658425.
Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HM. Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer 129(7):1017-1029. e-Pub 2023. PMID: 36715486.
Cortes JE, Rea D, Mauro MJ, Tran D, Wang P, Jadhav K, Yocolly A, Sasaki K. Health care resource utilization in 3L?+?patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib. J Med Econ 26(1):1-26, 2023. e-Pub 2023. PMID: 37431294.
Darbaniyan F, Zheng H, Kanagal-Shamanna R, Lockyer P, Montalban-Bravo G, Estecio M, Lu Y, Soltysiak KA, Chien KS, Yang H, Sasaki K, Class C, Ganan-Gomez I, Do KA, Garcia-Manero G, Wei Y. Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Exp Hematol 115:44-53, 2022. e-Pub 2022. PMID: 36150563.
Babakhanlou R, Kadia T, Chien K, Sasaki K, Thompson PA. Aplastic anemia following the severe acute respiratory syndrome coronavirus-2 vaccine. EJHaem 4(1):288-290, 2022. e-Pub 2022. PMID: 36718353.
Fiskus W, Daver N, Boettcher S, Mill CP, Sasaki K, Birdwell CE, Davis JA, Das K, Takahashi K, Kadia TM, DiNardo CD, Burrows F, Loghavi S, Khoury JD, Ebert BL, Bhalla KN. Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. Leukemia 36(11):2729-2733, 2022. e-Pub 2022. PMID: 36151141.
Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, Daver NG, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Takahashi K, Malla R, Quagliato K, Kanagal-Shamanna R, Popat UR, Andreeff M, Garcia-Manero G, Konopleva MY, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol 40(33):JCO2102823, 2022. e-Pub 2022. PMID: 35704787.
Jabbour E, Sasaki K, Haddad FG, Issa GC, Skinner J, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Borthakur G, Pemmaraju N, Pierce S, Kantarjian H. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol 97(11):1413-1418, 2022. e-Pub 2022. PMID: 36054032.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CD. Contemporary outcomes in IDH-mutated AML: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol 97(11):1443-1452, 2022. e-Pub 2022. PMID: 36054614.
Sasaki K, Jabbour E, Montalban-Bravo G, Darbaniyan F, Do KA, Class C, Short NJ, Kanagal-Shamana R, Kadia T, Borthakur G, Pemmaraju N, Cortes J, Ravandi F, Alvarado Y, Chien K, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Soltysiak K, Yang H, Kantarjian HM, Garcia-Manero G. Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS. NEJM Evid 1(10):EVIDoa2200034, 2022. e-Pub 2022. PMID: 38319837.
Bidikian A, Kantarjian H, Jabbour E, Short NJ, Patel K, Ravandi F, Sasaki K, Issa GC. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J 12(10):144, 2022. e-Pub 2022. PMID: 36307398.
Hughes TP, Cortes JE, Réa D, Mauro MJ, Hochhaus A, Kim DW, Sasaki K, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, JJWM J, Talpaz M, Coutre PL, Kapoor S, Cacciatore S, Polydoros F, Agrawal N, Mahon FX. CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S300, 2022. e-Pub 2022. PMID: 36163936.
Nichols ED, Jabbour E, Jammal N, Chew S, Bryan J, Issa G, Garcia-Manero G, Sasaki K, DiPippo A, Kantarjian H. Real-life incidence of thrombotic events in leukemia patients treated with ponatinib. Am J Hematol 97(9):E350-E352, 2022. e-Pub 2022. PMID: 35759571.
Sakhdari A, Class C, Montalban-Bravo G, Sasaki K, Bueso-Ramos CE, Patel KP, Routbort MJ, Loghavi S, Ok CY, Quesada A, Khoury JD, Konoplev SN, Kantarjian HP, Garcia-Manero G, Medeiros LJ, Kanagal-Shamanna R. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Mod Pathol 35(9):1212-1219, 2022. e-Pub 2022. PMID: 35504958.
Tefferi A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, DiNardo CD, Kadia TM, Ravandi F, Sasaki K, Begna KH. A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy. Am J Hematol 97(9):1127-1134, 2022. e-Pub 2022. PMID: 35702875.
Yang H, Garcia-Manero G, Sasaki K, Montalban-Bravo G, Tang Z, Wei Y, Kadia T, Chien K, Rush D, Nguyen H, Kalia A, Nimmakayalu M, Bueso-Ramos C, Kantarjian H, Medeiros LJ, Luthra R, Kanagal-Shamanna R. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia 36(9):2306-2316, 2022. e-Pub 2022. PMID: 35915143.
Jabbour EJ, Short NJ, Jain N, Jammal N, Jorgensen J, Wang S, Wang X, Ohanian M, Alvarado Y, Kadia T, Sasaki K, Garris R, Garcia-Manero G, Ravandi F, Kantarjian HM. Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10-4 and higher. Am J Hematol 97(9):1135-1141, 2022. e-Pub 2022. PMID: 35713551.
Short NJ, Borthakur G, Pemmaraju N, Dinardo CD, Kadia TM, Jabbour E, Konopleva M, Macaron W, Ning J, Ma J, Pierce S, Alvarado Y, Sasaki K, Takahashi K, Estrov Z, Masarova L, Issa GC, Montalban-Bravo G, Andreeff M, Burger JA, Miller D, Alexander L, Naing A, Garcia-Manero G, Ravandi F, Daver N. A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leuk Lymphoma 63(9):1-10, 2022. e-Pub 2022. PMID: 35442137.
Nogami A, Sasaki K. Therapy Advances in Immunotherapies for Hematological Malignancies. Int J Mol Sci 23(19):11526, 2022. e-Pub 2022.
Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain N. TP53-altered CLL Treated with Firstline Bruton's Tyrosine Kinase Inhibitor-based Therapy: A Retrospective Analysis. Am J Hematol 97(8):1005-1012, 2022. e-Pub 2022. PMID: 35567779.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Am J Hematol 97(8):1035-1043, 2022. e-Pub 2022. PMID: 35583199.
Kim K, Konopleva M, DiNardo CD, Borthakur G, Loghavi S, Tang G, Daver N, Pemmaraju N, Jabbour E, Rausch CR, Yilmaz M, Sasaki K, Short NJ, Jain N, Brandt M, Pierce S, Garcia-Manero G, Ravandi F, Kantarjian H, Kadia TM. Urgent Cytoreduction for Newly Diagnosed AML patients Allows Acquisition of Pretreatment Genomic Data and Enrollment on Investigational Clinical Trials. Am J Hematol 97(7):885-894, 2022. e-Pub 2022. PMID: 35413152.
Haddad FG, Sasaki K, Issa GC, Garcia-Manero G, Ravandi F, Kadia T, Cortes J, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo C, Jain N, Daver N, Short NJ, Jabbour E, Kantarjian H. Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors. Am J Hematol 97(7):856-864, 2022. e-Pub 2022. PMID: 35357036.
Sasaki K, Ravandi F, Kadia T, DiNardo C, Borthakur G, Short N, Jain N, Daver N, Jabbour E, Garcia-Manero G, Khoury J, Konoplev S, Loghavi S, Patel K, Montalban-Bravo G, Masarova L, Konopleva M, Kantarjian H. Prediction of Survival with Intensive Chemotherapy in Acute Myeloid Leukemia. Am J Hematol 97(7):865-876, 2022. e-Pub 2022. PMID: 35384048.
Haddad F, Kantarjian H, Issa GC, Jabbour E, Sasaki K. Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia. Leuk Lymphoma 63(7):1-4, 2022. e-Pub 2022. PMID: 35361036.
Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol 97(6):E201-E204, 2022. e-Pub 2022. PMID: 35266566.
Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia 36(5):1448, 2022. e-Pub 2022. PMID: 35411096.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematol 9(5):e350-e360, 2022. e-Pub 2022. PMID: 35483396.
Yilmaz M, Kantarjian H, Short NJ, Reville P, Konopleva M, Kadia T, DiNardo C, Borthakur G, Pemmaraju N, Maiti A, Jabbour E, Jain N, Issa G, Takahashi K, Sasaki K, Ohanian M, Pierce S, Tang G, Loghavi S, Patel K, Wang SA, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating agent and venetoclax with FLT3 inhibitor "triplet" therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer J 12(5):77, 2022. e-Pub 2022. PMID: 35501304.
Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia T, DiNardo C, Jabbour E, Pierce S, Qazilbash M, Konopleva M, Kantarjian H. Characteristics and Outcomes of Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm Treated with Frontline HCVAD. Blood Adv 6(10):3027-3035, 2022. e-Pub 2022. PMID: 35061885.
Masarova L, Bose P, Pemmaraju N, Daver NG, Sasaki K, Chifotides HT, Zhou L, Kantarjian HM, Estrov Z, Verstovsek S. Improved survival of patients with myelofibrosis in the last decade: Single-center experience. Cancer 128(8):1658-1665, 2022. e-Pub 2022. PMID: 35077575.
Reville PK, Sasaki K, Kantarjian HM, Daver NG, Yilmaz M, Dinardo CD, Short NJ, Borthakur G, Pemmaraju N, Mehta RS, Pierce S, Konoplev SN, Khoury JD, Garcia-Manero G, Konopleva MY, Jabbour E, Ravandi F, Kadia TM. Improved Outcomes Among Newly Diagnosed Patients with FLT3-ITD Mutated AML Treated with Contemporary Therapy: Revisiting the ELN Adverse Risk Classification. Am J Hematol 97(3):329-337, 2022. e-Pub 2022. PMID: 34981570.
Sasaki Y, Kantarjian HM, Short NJ, Wang F, Furudate K, Uryu H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Takahashi K, Jabbour E. Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia 36(5):1253-1260, 2022. e-Pub 2022. PMID: 35132195.
Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, Jain N, Daver N, Jabbour E, Garcia-Manero G, Bravo GM, Masarova L, Pierce S, Konopleva M, Ravandi F, Tefferi A, Kantarjian H. Prediction of Early (4-week) Mortality in Acute Myeloid Leukemia with Intensive Chemotherapy. Am J Hematol 97(1):68-78, 2022. e-Pub 2022. PMID: 34716921.
Fiskus W, Boettcher S, Daver N, Mill CP, Sasaki K, Birdwell CE, Davis JA, Takahashi K, Kadia TM, DiNardo CD, Jin Q, Qi Y, Su X, McGeehan GM, Khoury JD, Ebert BL, Bhalla KN. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c). Blood Cancer J 12(1):5, 2022. e-Pub 2022. PMID: 35017466.
Sasaki K, Kantarjian H, Jabbour E. Prediction for sustained deep molecular response for treatment-free remission. Leuk Lymphoma 63(1):5-6, 2022. e-Pub 2022. PMID: 34930078.
Saxena K, Jabbour E, Issa G, Sasaki K, Ravandi F, Maiti A, Daver N, Kadia T, DiNardo CD, Konopleva M, Cortes JE, Yilmaz M, Chien K, Pierce S, Kantarjian H, Short NJ. Impact of frontline treatment approach on outcomes of myeloid blast phase CML. J Hematol Oncol 14(1):94, 2021. e-Pub 2021. PMID: 34130720.
Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia 35(12):3421-3429, 2021. e-Pub 2021. PMID: 34007049.
Venugopal S, Maiti A, DiNardo CD, Qiao W, Ning J, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine. Leuk Lymphoma 62(14):3501-3505, 2021. e-Pub 2021. PMID: 34474640.
Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, García-Gutiérrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, Bédoucha V, Hochhaus A. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 138(21):2031-2041, 2021. e-Pub 2021. PMID: 34407542.
Tanaka T, Morita K, Loghavi S, Wang F, Furudate K, Sasaki Y, Little L, Gumbs C, Matthews J, Daver N, Pemmaraju N, DiNardo CD, Sasaki K, Yilmaz M, Kadia TM, Ravandi F, Konopleva MY, Kantarjian HM, Champlin RE, Al-Atrash G, Garcia-Manero G, Wang SA, Futreal PA, Takahashi K. Clonal Dynamics and clinical implications of Post-Remission Clonal Hematopoiesis in Acute Myeloid Leukemia (AML). Blood 138(18):1733-1739, 2021. e-Pub 2021. PMID: 34115096.
Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer 127(20):3772-3781, 2021. e-Pub 2021. PMID: 34255353.
Venugopal S, Shoukier M, Konopleva M, Dinardo CD, Ravandi F, Short NJ, Andreeff M, Borthakur G, Daver N, Pemmaraju N, Sasaki K, Montalban-Bravo G, Marx KR, Pierce S, Popat UR, Shpall EJ, Kanagal-Shamanna R, Garcia-Manero G, Kantarjian HM, Kadia TM. Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy. Cancer 127(19):3541-3551, 2021. e-Pub 2021. PMID: 34182597.
Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Darbaniyan F, Jabbour E, Bueso-Ramos C, Wei Y, Chien K, Kadia T, Ravandi F, Borthakur G, Soltysiak KA, Routbort M, Patel K, Pierce S, Medeiros LJ, Kantarjian HM, Garcia-Manero G. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes. Cancer 127(19):3552-3565, 2021. e-Pub 2021. PMID: 34161603.
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer 127(17):3113-3124, 2021. e-Pub 2021. PMID: 33914911.
Sasaki K, Kantarjian HM, Morita K, Short NJ, Konopleva M, Jain N, Ravandi F, Garcia-Manero G, Wang S, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Garris R, Takahashi K, O'Brien SM, Jabbour EJ. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer 127(18):3381-3389, 2021. e-Pub 2021. PMID: 34138471.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol 39(25):2768-2778, 2021. e-Pub 2021. PMID: 34043428.
Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi F. Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J 11(9):162, 2021. e-Pub 2021. PMID: 34588432.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol 7(8):1213-1219, 2021. e-Pub 2021. PMID: 34110383.
Abbas HA, Reville PK, Geppner A, Rausch CR, Pemmaraju N, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo C, Bueso-Ramos C, Pierce S, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian H, Kadia TM. Clinical and molecular characterization of myeloid sarcoma without medullary leukemia. Leuk Lymphoma 62(14):3402-3410. e-Pub 2021. PMID: 34380367.
Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 127(15):2648-2656, 2021. e-Pub 2021. PMID: 33793964.
Morita K, Kantarjian HM, Sasaki K, Issa GC, Jain N, Konopleva M, Short NJ, Takahashi K, DiNardo CD, Kadia TM, Garcia-Manero G, Daver N, Montalban Bravo G, Cortes JE, Ravandi F, Jabbour E. Outcome of patients with chronic myeloid leukemia in lymphoid blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia treated with hyper-CVAD and dasatinib. Cancer 127(15):2641-2647, 2021. e-Pub 2021. PMID: 33823073.
Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia. Cancer 127(14):2489-2499, 2021. e-Pub 2021. PMID: 33793970.
Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, Burger J, Ferrajoli A, Estrov Z, O'Brien S, Keating M, Wierda WG, Jain N. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. Br J Haematol 194(1):61-68, 2021. e-Pub 2021. PMID: 33973230.
Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 127(12):2025-2038, 2021. e-Pub 2021. PMID: 33740268.
Sasaki K, Jabbour E, Short NJ, Jain N, Ravandi F, Pui CH, Kantarjian H. Acute lymphoblastic leukemia: A population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017. Am J Hematol 96(6):650-658, 2021. e-Pub 2021. PMID: 33709456.
Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, Jabbour E, Kantarjian HM. De novo acute myeloid leukemia: A population- based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer 127(12):2049-2061, 2021. e-Pub 2021. PMID: 33818756.
Venugopal S, Maiti A, DiNardo CD, Loghavi S, Daver NG, Kadia TM, Rausch CR, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Ravandi F, Kantarjian HM, Konopleva MY. Decitabine and Venetoclax for IDH1/2-mutated Acute Myeloid Leukemia. Am J Hematol 96(5):E154-E157, 2021. e-Pub 2021. PMID: 33580980.
Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa G, Daver N, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-Ramos C, Cortes J, Sasaki K. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk 21(5):338-344, 2021. e-Pub 2021. PMID: 33597098.
Morita K, Jain N, Kantarjian H, Takahashi K, Fang H, Konopleva M, El Hussein S, Wang F, Short NJ, Maiti A, Sasaki K, Garcia-Manero G, Konoplev S, Ravandi F, Khoury JD, Jabbour E. Outcome of T-cell Acute Lymphoblastic Leukemia/Lymphoma: Focus on Near-ETP Phenotype & Differential Impact of Nelarabine. Am J Hematol 96(5):589-598, 2021. e-Pub 2021. PMID: 33639000.
Montalban-Bravo G, Hammond D, DiNardo CD, Konopleva M, Borthakur G, Short NJ, Ramos-Perez J, Guerra V, Kanagal-Shamanna R, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov Z, Pierce S, Kantarjian H, Garcia-Manero G. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia 35(5):1494-1499, 2021. e-Pub 2021. PMID: 33846541.
Montalban-Bravo G, Kanagal-Shamanna R, Darbaniyan F, Tariq Siddiqui M, Sasaki K, Wei Y, Yang H, Chien KS, Naqvi K, Jabbour E, Kadia TM, Daver N, DiNardo C, Ravandi F, Pemmaraju N, Bose P, Verstovsek S, Pierce S, Bueso-Ramos C, Patel K, Do KA, Kantarjian H, Garcia-Manero G. Clinical, Genomic, and Transcriptomic Differences between Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS). Am J Hematol 96(7):E246-E249, 2021. e-Pub 2021. PMID: 33811786.
Dalle IA, Paranal R, Zarka J, Paul S, Sasaki K, Li W, Ning J, Short NJ, Ohanian M, Cortes JE, Jabbour EJ, Issa GC. Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. Haematologica 106(4):1097-1105, 2021. e-Pub 2021. PMID: 33297667.
Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CD. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173-2183, 2021. e-Pub 2021. PMID: 33885753.
Maiti A, DiNardo CD, Wang SA, Jorgensen J, Kadia TM, Daver NG, Short NJ, Yilmaz M, Pemmaraju N, Borthakur G, Bose P, Issa GC, Ferrajoli A, Jabbour EJ, Jain N, Garcia-Manero G, Ohanian M, Takahashi K, Montalban-Bravo G, Masarova L, Burger JA, Thompson PA, Verstovsek S, Sasaki K, Andreeff M, Rausch CR, Montalbano KS, Pierce S, Qiao W, Ning J, Kantarjian HM, Konopleva MY, Ravandi F. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv 5(7):1876-1883, 2021. e-Pub 2021. PMID: 33792630.
Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur G, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau S, Montalban Bravo G, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour EJ, Masarova L, Thompson PA, Wang S, Konoplev S, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, DiNardo CD, Konopleva MY. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica 106(3):894-898, 2021. e-Pub 2021. PMID: 32499238.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality. Am J Hematol 96(3):282-291, 2021. e-Pub 2021. PMID: 33264443.
Kanagal-Shamanna R, Montalban-Bravo G, Katsonis P, Sasaki K, Class CA, Jabbour E, Sallman D, Hunter AM, Benton C, Chien KS, Luthra R, Bueso-Ramos CE, Kadia T, Andreeff M, Komrokji RS, Al Ali NH, Short N, Daver N, Routbort MJ, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, Do KA, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian H, Garcia-Manero G. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis. Blood Cancer J 11(3):52, 2021. e-Pub 2021. PMID: 33677472.
Montalban-Bravo G, Darbaniyan F, Kanagal-Shamanna R, Ganan-Gomez I, Class CA, Sasaki K, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien KS, Bueso-Ramos C, Do KA, Kantarjian H, Garcia-Manero G. Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. Leuk Res 101:106511, 2021. e-Pub 2021. PMID: 33517186.
Montalban-Bravo G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, Hammond D, Shilpa P, Naqvi K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Konopleva M, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Pierce S, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G. Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia. Am J Hematol 96(2):E50-E53, 2021. e-Pub 2021. PMID: 33156969.
Sasaki K, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver N, Takahashi K, Naqvi K, DiNardo C, Montalban-Bravo G, Kanagal-Shamanna R, Issa G, Jain P, Skinner J, Rios MB, Pierce S, Soltysiak KA, Sato J, Garcia-Manero G, Cortes JE. The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes. Am J Hematol 96(2):241-250, 2021. e-Pub 2021. PMID: 33180322.
Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver N. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer 127(3):381-390, 2021. e-Pub 2021. PMID: 33119202.
Morita K, Jabbour E, Ravandi F, Borthakur G, Khoury JD, Hu S, Garcia-Manero G, Wierda W, Issa G, Daver N, Pemmaraju N, Montalban-Bravo G, Soltysiak KA, Pierce S, Bueso-Ramos C, Cortes J, Sasaki K. Clinical Outcomes of Patients With Chronic Myeloid Leukemia With Concurrent Core Binding Factor Rearrangement and Philadelphia Chromosome. Clin Lymphoma Myeloma Leuk 21(5):338-344, 2021. e-Pub 2021.
Yilmaz M, Kantarjian HM, Toruner G, Yin CC, Kanagal-Shamanna R, Cortes JE, Issa G, Short NJ, Khoury JD, Garcia-Manero G, Ravandi F, Kadia T, Konopleva M, Wierda WG, Jain N, Estrov Z, Sasaki K, Pierce S, O'Brien SM, Jabbour EJ. Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis. Leuk Lymphoma 62(1):224-228, 2021. e-Pub 2021. PMID: 32955970.
Aitken MJL, Benton CB, Issa GC, Sasaki K, Yilmaz M, Short NJ. Two Cases of Possible Familial Chronic Myeloid Leukemia in a Family with Extensive History of Cancer. Acta Haematol 144(5):585-590, 2021. e-Pub 2021. PMID: 33735874.
Samra B, Kantarjian HM, Sasaki K, Alotaibi AS, Konopleva M, O'Brien S, Ferrajoli A, Garris R, Nunez CA, Kadia TM, Short NJ, Jabbour E. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant. Acta Haematol 144(3):285-292, 2021. e-Pub 2021. PMID: 33238261.
Sasaki K, Kantarjian HM, Issa GC, Garcia-Manero G, Kadia TM, Wierda WG, Yilmaz M, DiNardo CD, Skinner J, Khouri R, Pemmaraju N, Nasnas P, Dellasala SE, Pierce SA, Cortes JE, Jabbour E. Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors. Blood 136, 2020. e-Pub 2020.
DiNardo CD, Maiti A, Rausch CR, Pemmaraju N, Naqvi K, Daver NG, Kadia TM, Borthakur G, Ohanian M, Alvarado Y, Issa GC, Montalban-Bravo G, Short NJ, Yilmaz M, Bose P, Jabbour EJ, Takahashi K, Burger JA, Garcia-Manero G, Jain N, Kornblau SM, Thompson PA, Estrov Z, Masarova L, Sasaki K, Verstovsek S, Ferrajoli A, Weirda WG, Wang SA, Konoplev S, Chen Z, Pierce SA, Ning J, Qiao W, Ravandi F, Andreeff M, Welch JS, Kantarjian HM, Konopleva MY. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol 7(10):e724-e736, 2020. e-Pub 2020. PMID: 32896301.
Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia T, Daver N, Pemmaraju N, Konopleva M, Borthakur G, Takahashi K, Patel K, Soltysiak KA, Chien KS, Sakurai K, Pierce S, Kantarjian HM, Garcia-Manero G. Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3). Am J Hematol 95(12):E326-E329, 2020. e-Pub 2020. PMID: 32886803.
Shoukier M, Borthakur G, Jabbour E, Ravandi F, Garcia-Manero G, Kadia T, Matthews J, Masarova L, Naqvi K, Sasaki K, Verstovsek S, Cortes J. The effect of eltrombopag in managing thrombocytopenia associated with tyrosine kinase therapy in patients with chronic myeloid leukemia and myelofibrosis. Haematologica 106(11):2853-2858, 2020. e-Pub 2020. PMID: 33054123.
Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna R. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol 33(9):1678-1689, 2020. e-Pub 2020. PMID: 32238878.
Major CK, Kantarjian H, Sasaki K, Borthakur G, Kadia T, Pemmaraju N, DiNardo C, Short NJ, Daver N, Jabbour E, Champlin R, Garcia-Manero G, Konopleva M, Andreeff M, Kornblau S, Wierda W, Pierce S, Ravandi F, Cortes J. Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years. Leuk Lymphoma 61(13):3120-3127, 2020. e-Pub 2020. PMID: 32755333.
Sasaki K, Kantarjian H, Wierda W, Ravandi-Kashani F, Jorgensen J, Wang SA, Khoury J, Daver N, Burger J, Di Nardo CD, Jain N, Short NJ, Estrov Md Z, Konopleva Md PhD M, Ohanian DO M, Garcia-Manero G, Kadia T, Alvarado-Valero Y, Yilmaz M, Pierce S, Garris R, Ingram A, Cortes J, O'Brien S, Jabbour E. Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Am J Hematol 95(7):734-739, 2020. e-Pub 2020. PMID: 32170867.
Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. e-Pub 2020. PMID: 32589978.
Masarova L, Bose P, Pemmaraju N, Daver NG, Zhou L, Pierce S, Sasaki K, Kantarjian HM, Estrov Z, Verstovsek S. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer 126(19):4322-4331, 2020. e-Pub 2020. PMID: 32697338.
Montalban-Bravo G, Kanagal-Shamanna R, Class CA, Sasaki K, Ravandi F, Cortes JE, Daver N, Takahashi K, Short NJ, DiNardo CD, Jabbour E, Borthakur G, Naqvi K, Issa GC, Konopleva M, Khoury JD, Routbort M, Pierce S, Do KA, Bueso-Ramos C, Patel K, Kantarjian H, Garcia-Manero G, Kadia TM. Outcomes of Acute Myeloid Leukemia with Myelodysplasia Related Changes depend on diagnostic criteria and therapy. Am J Hematol 95(6):612-622, 2020. e-Pub 2020. PMID: 32112433.
Abou Dalle I, Ghorab A, Patel K, Wang X, Hwang H, Cortes J, Issa GC, Yalniz F, Sasaki K, Chihara D, Price A, Kadia T, Pemmaraju N, Daver N, DiNardo C, Ravandi F, Kantarjian HM, Borthakur G. Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia. Blood Cancer J 10(5):48, 2020. e-Pub 2020. PMID: 32366841.
Short NJ, Kantarjian H, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes J, Konopleva M, Issa GC, Kornblau SM, Garcia-Manero G, Garris R, Higgins J, Pratt G, Williams LN, Valentine CC, Rivera VM, Pritchard J, Salk JJ, Radich J, Jabbour E. Ultra-accurate Duplex Sequencing for the assessment of pretreatment ABL1 kinase domain mutations in Ph+ ALL. Blood Cancer J 10(5):61, 2020. e-Pub 2020. PMID: 32457305.
Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CD. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv 4(7):1311-1320, 2020. e-Pub 2020. PMID: 32251497.
Montalban-Bravo G, Class CA, Ganan-Gomez I, Kanagal-Shamanna R, Sasaki K, Richard-Carpentier G, Naqvi K, Wei Y, Yang H, Soltysiak KA, Chien K, Bueso-Ramos C, Do KA, Kantarjian H, Garcia-Manero G. Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes. Leukemia 34(3):872-881, 2020. e-Pub 2020. PMID: 31719677.
Yilmaz M, Kantarjian H, Wang X, Khoury JD, Ravandi F, Jorgensen J, Short NJ, Loghavi S, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien S, Jabbour E. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival. Am J Hematol 95(2):144-150, 2020. e-Pub 2020. PMID: 31682008.
Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian HM, Garcia-Manero G. Impact of the Variant Allele Frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the Outcomes of Patients with Newly Diagnosed Acute Myeloid Leukemia. Cancer 126(4):765-774, 2020. e-Pub 2020. PMID: 31742675.
Chien KS, Class CA, Montalban-Bravo G, Wei Y, Sasaki K, Naqvi K, Ganan-Gomez I, Yang H, Soltysiak KA, Kanagal-Shamanna R, Do KA, Kantarjian HM, Garcia-Manero G. LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. Leuk Lymphoma 61(6):1493-1499, 2020. e-Pub 2020. PMID: 32036728.
Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero G. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv 4(3):482-495, 2020. e-Pub 2020. PMID: 32027746.
Maiti A, Franquiz MJ, Ravandi F, Cortes JE, Jabbour EJ, Sasaki K, Marx K, Daver NG, Kadia TM, Konopleva MY, Masarova L, Borthakur G, DiNardo CD, Naqvi K, Pierce S, Kantarjian HM, Short NJ. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias. Acta Haematol 143(6):1-7, 2020. e-Pub 2020. PMID: 32289808.
Sasaki K. [Chronic myeloid leukemia: update on treatment and survival prediction]. Rinsho Ketsueki 61(9):1179-1186, 2020. e-Pub 2020. PMID: 33162514.
Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CD. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol 10:582213, 2020. e-Pub 2020. PMID: 33585199.
Sasaki K, Kantarjian HM, Jabbour EJ. Reply to Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope?. Cancer 125(21):3891-3892, 2019. e-Pub 2019. PMID: 31291004.
Sasaki K, Kantarjian HM, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Jabbour EJ, DiNardo C, Pemmaraju N, Daver N, Dalle IA, Short N, Yilmaz M, Bose P, Naqvi K, Pierce S, Yalniz F, Cortes JE, Ravandi F. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer 125(21):3755-3766, 2019. e-Pub 2019. PMID: 31310323.
Alfayez M, Richard-Carpentier G, Jabbour E, Vishnu P, Naqvi K, Sasaki K, Cortes J, Pemmaraju N. Sudden blastic transformation in treatment-free remission chronic myeloid leukaemia. Br J Haematol 187(4):543-545, 2019. e-Pub 2019. PMID: 31584727.
Yalniz F, Abou Dalle I, Kantarjian H, Borthakur G, Kadia T, Patel K, Loghavi S, Garcia-Manero G, Sasaki K, Daver N, DiNardo C, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce S, Nogueras González GM, Konopleva M, Andreeff M, Cortes J, Ravandi F. Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. Am J Hematol 94(9):984-991, 2019. e-Pub 2019. PMID: 31237017.
Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Cortes J, Issa GC, Jacob J, Kwari M, Thompson P, Garris R, Pemmaraju N, Yilmaz M, O'Brien SM, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis. Cancer 125(15):2579-2586, 2019. e-Pub 2019. PMID: 30985931.
Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso Pierola A, Yilmaz M, Short N, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Kanagal-Shamanna R, Patel K, Soltysiak KA, Kantarjian HM, Garcia-Manero G. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome. Cancer 125(13):2233-2241, 2019. e-Pub 2019. PMID: 30861111.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med 380(22):2095-2103, 2019. e-Pub 2019. PMID: 31141631.
Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce SA, Jabbour EJ, Cortes JE. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol 109(5):545-552, 2019. e-Pub 2019. PMID: 30830579.
Jain P, Kantarjian H, Boddu PC, Nogueras-González GM, Verstovsek S, Garcia-Manero G, Borthakur G, Sasaki K, Kadia TM, Sam P, Ahaneku H, O'Brien S, Estrov Z, Ravandi F, Jabbour E, Cortes JE. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv 3(6):851-861, 2019. e-Pub 2019. PMID: 30885996.
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv 3(6):922-933, 2019. e-Pub 2019. PMID: 30902805.
Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma 60(2):442-452, 2019. e-Pub 2019. PMID: 30032678.
Short NJ, Jabbour E, Naqvi K, Patel A, Ning J, Sasaki K, Nogueras-Gonzalez GM, Bose P, Kornblau SM, Takahashi K, Andreeff M, Sanchez-Petitto G, Estrov Z, Dinardo CD, Montalban-Bravo G, Konopleva M, Alvarado Y, Bhalla KN, Fiskus W, Khouri M, Islam R, Kantarjian H, Garcia-Manero G. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol 94(1):74-79, 2019. e-Pub 2019. PMID: 30328139.
Jabbour E, Short NJ, Ravandi F, Huang X, Daver N, DiNardo CD, Konopleva M, Pemmaraju N, Wierda W, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Khoury JD, Jorgensen J, Jain N, Alvarez J, O'Brien S, Kantarjian H. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematol 5(12):e618-e627, 2018. e-Pub 2018. PMID: 30501869.
Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer 124(20):4044-4055, 2018. e-Pub 2018. PMID: 30307611.
Kadia TM, Cortes J, Ravandi F, Jabbour E, Konopleva M, Benton CB, Burger J, Sasaki K, Borthakur G, DiNardo CD, Pemmaraju N, Daver N, Ferrajoli A, Wang X, Patel K, Jorgensen JL, Wang S, O'Brien S, Pierce S, Tuttle C, Estrov Z, Verstovsek S, Garcia-Manero G, Kantarjian H. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematol 5(9):e411-e421, 2018. e-Pub 2018. PMID: 30115541.
Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36(18):1788-1797, 2018. e-Pub 2018. PMID: 29702001.
Sasaki K, Kantarjian H, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour E, Cortes JE. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer 124(6):1160-1168, 2018. e-Pub 2018. PMID: 29266206.
Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol 4(2):230-234, 2018. e-Pub 2018. PMID: 28859185.
Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol 19(2):240-248, 2018. e-Pub 2018. PMID: 29352703.
Issa GC, Kantarjian HM, Gonzalez GN, Borthakur G, Tang G, Wierda W, Sasaki K, Short NJ, Ravandi F, Kadia T, Patel K, Luthra R, Ferrajoli A, Garcia-Manero G, Rios MB, Dellasala S, Jabbour E, Cortes JE. Clonal chromosomal abnormalities appearing in Philadelphia negative metaphases during CML treatment. Blood 130(19):2084-2091, 2017. e-Pub 2017. PMID: 28835440.
Jabbour E, Short NJ, Montalban-Bravo G, Huang X, Bueso-Ramos C, Qiao W, Yang H, Zhao C, Kadia T, Borthakur G, Pemmaraju N, Sasaki K, Estrov Z, Cortes J, Ravandi F, Alvarado Y, Komrokji R, Sekeres MA, Steensma DP, DeZern A, Roboz G, Kantarjian H, Garcia-Manero G. A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN. Blood 130(13):1514-1522. e-Pub 2017. PMID: 28774880.
Jain P, Kantarjian HM, Ghorab A, Sasaki K, Jabbour EJ, Nogueras Gonzalez G, Kanagal-Shamanna R, Issa GC, Garcia-Manero G, Kc D, Dellasala S, Pierce S, Konopleva M, Wierda WG, Verstovsek S, Daver NG, Kadia TM, Borthakur G, O'Brien S, Estrov Z, Ravandi F, Cortes JE. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients. Cancer 123(22):4391-4402. e-Pub 2017. PMID: 28743165.
Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 59(4):813-820, 2017. e-Pub 2017. PMID: 28718728.
Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer 123(22):4430-4439, 2017. e-Pub 2017. PMID: 28708931.
Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian H, Jabbour E. TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer 123(19):3717-3724, 2017. e-Pub 2017. PMID: 28608976.
Jain P, Kantarjian H, Jain N, Short NJ, Yin CC, Kanagal-Shamanna R, Khoury J, Konopleva M, Sasaki K, Kadia TM, Garris R, Pierce S, Estrov Z, Wierda W, Cortes J, O'Brien S, Ravandi F, Jabbour E. Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens. Am J Hematol 92(10):E595-E597. e-Pub 2017. PMID: 28646517.
Gettys SC, Gulbis A, Wilhelm K, Sasaki K, Dinh Y, Rondon G, Qazilbash MH. Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma. Eur J Haematol 98(4):388-392, 2017. e-Pub 2017. PMID: 28009447.
Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Ko H, Cameron Yin C, Garcia-Manero G, Cortes JE, Garris R, O'Brien SM, Patel K, Khouri M, Thomas D, Jain N, Kadia TM, Daver NG, Benton CB, Issa GC, Konopleva M, Jabbour E. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor. Am J Hematol 92(3):238-243, 2017. e-Pub 2017. PMID: 28006851.
Jabbour E, Faderl S, Sasaki K, Kadia T, Daver N, Pemmaraju N, Patel K, Khoury JD, Bueso-Ramos C, Bohannan Z, Ravandi F, Borthakur G, Verstovsek S, Miller D, Maduike R, Hosing C, Kantarjian HM, Garcia-Manero G. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer 123(4):629-637, 2017. e-Pub 2017. PMID: 27741352.
Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer 123(3):459-467, 2017. e-Pub 2017. PMID: 27696391.
Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer 123(2):294-302, 2017. e-Pub 2017. PMID: 27602508.
Sasaki K, Jabbour EJ, Ravandi F, Short NJ, Thomas DA, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jeanis V, Moore HG, Garris RS, Pemmaraju N, Cortes JE, O'Brien SM, Kantarjian HM. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis. Cancer 122(23):3650-3656, 2016. e-Pub 2016. PMID: 27479888.
Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 122(24):3812-3820, 2016. e-Pub 2016. PMID: 27508525.
Takahashi K, Kantarjian HM, Yang Y, Sasaki K, Jain P, DellaSala S, Ravandi F, Kadia T, Pemmaraju N, Daver N, Borthakur G, Garcia-Manero G, Jabbour E, Cortes JE. A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase. Cancer 122(21):3336-3343, 2016. e-Pub 2016. PMID: 27509035.
Sasaki K, Jabbour E, Cortes J, Kadia T, Garcia-Manero G, Borthakur G, Jain P, Pierce S, Daver N, Takahashi K, O'Brien S, Kantarjian H, Ravandi F. Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia. Clin Lymphoma Myeloma Leuk 16(11):616-624, 2016. e-Pub 2016. PMID: 27601000.
Tamamyan GN, Kantarjian HM, Ning J, Jain P, Sasaki K, McClain KL, Allen CE, Pierce SA, Cortes JE, Ravandi F, Konopleva MY, Garcia-Manero G, Benton CB, Chihara D, Rytting ME, Wang S, Abdelall W, Konoplev SN, Daver NG. Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes. Cancer 122(18):2857-66, 2016. e-Pub 2016. PMID: 27244347.
Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Jain P, Satta T, Pierce S, Rios MB, Cortes JE. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis. Haematologica 101(8):e324-7, 2016. e-Pub 2016. PMID: 27175025.
Sasaki K, Popat U, Jain P, Kadia T, Patel K, Patel K, Jain N, Takahashi K, Young K, Miranda RN, Oo TH, Lu H, Pemmaraju N. Successful treatment of aplastic anemia-paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. Clin Case Rep 4(8):765-7, 2016. e-Pub 2016. PMID: 27525080.
Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 128(4):504-7, 2016. e-Pub 2016. PMID: 27235138.
Jain P, Kantarjian H, Sasaki K, Jabbour E, Dasarathula J, Nogueras Gonzalez G, Verstovsek S, Borthakur G, Wierda W, Kadia T, Dellasala S, Pierce S, Ravandi F, O'Brien S, Cortes J. Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes. Br J Haematol 173(1):114-26, 2016. e-Pub 2016. PMID: 26846160.
Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes J. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood 127(10):1269-75, 2016. e-Pub 2016. PMID: 26729897.
Sasaki K, Lahoti A, Jabbour E, Jain P, Pierce S, Borthakur G, Daver N, Kadia T, Pemmaraju N, Ferrajoli A, O'Brien S, Kantarjian H, Cortes J. Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction. Clin Lymphoma Myeloma Leuk 16(3):152-62, 2016. e-Pub 2016. PMID: 26796981.
Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 16(1):36-42, 2016. e-Pub 2016. PMID: 26702475.
Sasaki K, Kantarjian HM, Jain P, Jabbour EJ, Ravandi F, Konopleva M, Borthakur G, Takahashi K, Pemmaraju N, Daver N, Pierce SA, O'Brien SM, Cortes JE. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors. Cancer 122(2):238-48, 2016. e-Pub 2016. PMID: 26479889.
Jabbour E, Kantarjian H, Ravandi F, Thomas D, Huang X, Faderl S, Pemmaraju N, Daver N, Garcia-Manero G, Sasaki K, Cortes J, Garris R, Yin CC, Khoury JD, Jorgensen J, Estrov Z, Bohannan Z, Konopleva M, Kadia T, Jain N, DiNardo C, Wierda W, Jeanis V, O'Brien S. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol 16(15):1547-55, 2015. e-Pub 2015. PMID: 26432046.
Daver N, Cortes J, Newberry K, Jabbour E, Zhou L, Wang X, Pierce S, Kadia T, Sasaki K, Borthakur G, Ravandi F, Pemmaraju N, Kantarjian H, Verstovsek S. Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis. Haematologica 100(8):1058-63, 2015. e-Pub 2015. PMID: 26088933.
Sasaki K, Gotlib JR, Mesa RA, Newberry KJ, Ravandi F, Cortes JE, Kelly P, Kutok JL, Kantarjian HM, Verstovsek S. Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis. Leuk Lymphoma 56(7):2092-7, 2015. e-Pub 2015. PMID: 25641433.
Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Jain P, Pierce S, Kantarjian H, Cortes JE. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2(5):e186-93, 2015. e-Pub 2015. PMID: 26688093.
Jain P, Kantarjian H, Alattar ML, Jabbour E, Sasaki K, Nogueras Gonzalez G, Dellasala S, Pierce S, Verstovsek S, Wierda W, Borthakur G, Ravandi F, O'Brien S, Cortes J. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Lancet Haematol 2(3):e118-28, 2015. e-Pub 2015. PMID: 26687797.
Jabbour E, O'Brien S, Huang X, Thomas D, Rytting M, Sasaki K, Cortes J, Garcia-Manero G, Kadia T, Ravandi F, Pierce S, Kantarjian H. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Am J Hematol 90(3):193-6, 2015. e-Pub 2015. PMID: 25407953.
Satta T, Sasaki K, Tsuura Y, Shioi K. High-grade neuroendocrine carcinoma of the bladder (large cell and small cell mixed): a literature review and case report of a rare bladder tumor. International Cancer Conference Journal 4(4):249-253, 2015. e-Pub 2015.
Pemmaraju N, Sasaki K, Johnson D, Daver N, Afshar-Kharghan V, Chen M, Ahmed S, Colen RR, Kwon M, Huh Y, Borthakur G. Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Review of the Literature. Front Oncol 5:29, 2015. e-Pub 2015. PMID: 25717439.
Sasaki K, Pemmaraju N, Westin JR, Wang WL, Khoury JD, Podoloff DA, Moon B, Daver N, Borthakur G. A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine. Front Oncol 4:297, 2014. e-Pub 2014. PMID: 25401088.
Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 19(8):1227-32, 2013. e-Pub 2013. PMID: 23733001.
Yamamoto M, Kumekawa H, Sasaki K, Murata Y, Ohki M, Kurosu T, Fukuda T, Arai A, Murakami N, Miura O. [Marked reactive plasmacytosis accompanied by drug eruption in a patient with aplastic anemia]. Rinsho Ketsueki 53(5):526-30, 2012. e-Pub 2012. PMID: 22728555.
Ishigaki T, Sasaki K, Watanabe K, Nakamura N, Toyota S, Kobayashi H, Tohda S. Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case. Cancer Genet Cytogenet 201(1):62-5, 2010. e-Pub 2010. PMID: 20633772.
Sasaki K, Kodama Y, Tsuchida Y, Kanzaki M, Maeda M, Miyoshi S. Acute mesenteric ischemia complicated with severe septic shock. The Medical Journal of Fraternity Memorial Hospital 24(99), 2006. e-Pub 2006.

Invited Articles

Sasaki K. Ponatinib for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Medicine and Drug 54(5):1229-1233, 2018. e-Pub 2018.

Review Articles

Kantarjian, HM, Breccia, M, Haddad, FG, Hehlmann, R, Issa, GC, Malhotra, H, Nicolini, FE, Sasaki, K, Stenke, L, Jabbour, EJ. Management of chronic myeloid leukemia in 2025. Cancer 131(14), 2025. e-Pub 2025. PMID: 40616814.
Kantarjian, HM, Zhai, Y, Oehler, VG, Jamy, O, Koller, PB, Haddad, FG, Sasaki, K, Jabbour, EJ. Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research. Cancer 131(8), 2025. e-Pub 2025. PMID: 40197896.
Kantarjian, H, Borthakur, G, Daver, N, DiNardo, CD, Issa, GC, Jabbour, EJ, Kadia, TM, Sasaki, K, Short, NJ, Yilmaz, M, Ravandi, F. Current status and research directions in acute myeloid leukemia. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39300079.
Cuglievan B, Kantarjian H, Rubnitz JE, Cooper TM, Zwaan CM, Pollard JA, DiNardo CD, Kadia TM, Guest E, Short NJ, McCall D, Daver N, Nunez C, Haddad FG, Garcia M, Bhalla KN, Maiti A, Catueno S, Fiskus W, Carter BZ, Gibson A, Roth M, Khazal S, Tewari P, Abbas HA, Bourgeois W, Andreeff M, Shukla NN, Truong DD, Connors J, Ludwig JA, Stutterheim J, Salzer E, Juul-Dam KL, Sasaki K, Mahadeo KM, Tasian SK, Borthakur G, Dickson S, Jain N, Jabbour E, Meshinchi S, Garcia-Manero G, Ravandi F, Stein EM, Kolb EA, Issa GC. Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community. Leukemia 38(10):2073-2084, 2024. e-Pub 2024. PMID: 39179671.
Kantarjian H, Branford S, Breccia M, Cortes J, Haddad FG, Hochhaus A, Hughes T, Issa GC, Jabbour E, Nicolini FE, Sasaki K, Xavier-Mahon F. Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?. Leukemia 38(5):947-950, 2024. e-Pub 2024. PMID: 38531949.
Jen WY, Sasaki K, Rausch CR, DiNardo CD, Kadia TM, Yilmaz M, Borthakur G, Alvarado Y, McCue D, McCue D, Kantarjian HM, Ravandi F. Acute kidney injury in acute promyelocytic leukemia: a possible adverse effect of high dose arsenic trioxide in obese patients. Leuk Lymphoma 65(3):378-382, 2024. e-Pub 2024. PMID: 38054837.
Oshikawa G, Sasaki K. Optimizing Treatment Options for Newly Diagnosed Acute Myeloid Leukemia in Older Patients with Comorbidities. Cancers (Basel) 15(8), 2023. e-Pub 2023. PMID: 37190327.
Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J 13(1):58, 2023. e-Pub 2023. PMID: 37088793.
Kim K, Ong F, Sasaki K. Current Understanding of DDX41 Mutations in Myeloid Neoplasms. Cancers (Basel) 15(2), 2023. e-Pub 2023. PMID: 36672294.
Yoshifuji K, Sasaki K. Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia. Front Oncol 12:1021662, 2022. e-Pub 2022. PMID: 36276124.
Nogami A, Sasaki K. Therapeutic Advances in Immunotherapies for Hematological Malignancies. Int J Mol Sci 23(19), 2022. e-Pub 2022. PMID: 36232824.
Umezawa Y, Sasaki K. Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Int J Hematol 117(1):24-29, 2022. e-Pub 2022. PMID: 36087226.
Senapati J, Sasaki K. Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects. Cancers (Basel) 14(10), 2022. e-Pub 2022. PMID: 35626137.
Morita K, Sasaki K. Current status and novel strategy of CML. Int J Hematol 113(5):624-631, 2021. e-Pub 2021. PMID: 33782818.
Oshikawa G, Arai A, Sasaki K, Ichinohasama R, Miura O. [Primary multifocal osseous Hodgkin lymphoma]. Rinsho Ketsueki 50(2):92-6, 2009. e-Pub 2009. PMID: 19265301.

Editorials

Sasaki, K. Favorable transplantation outcome of patients with de novo chronic myeloid leukemia in blast phase (lymphoid and myeloid). Cancer 131(1), 2025. PMID: 39748506.

Abstracts

Khouri IF, Alzahrani K, Gulbis A, Sasaki K, Jain N, Short NJ, Kadia TM, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Srour SA, Kebriaei P, Shpall EJ, Kantarjian HM, Champlin RE, Jabbour E. Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results. Blood 142, 2023. e-Pub 2023.
Calvete O, Kanagal-Shamanna R, Mestre J, Montalban-Bravo G, DiNardo CD, Sasaki K, Aranda J, Acha P, Xicoy B, Pérez González A, Palomo L, Montoro MJ, Margeli M, Sole F. Role and Prevalence of Risk Factors That Trigger Therapy Related Myeloid Neoplasms (TRMN) in Patients with Previous Treated Breast Cancer. Blood 142, 2023. e-Pub 2023.
Bazinet A, Kantarjian HM, Borthakur G, Yilmaz M, Bose P, Jabbour E, Alvarado Valero Y, Chien KS, Pemmaraju N, Takahashi K, Short NJ, Daver N, Issa GC, Jain N, Hammond DE, Bull-Linderman D, DiNardo CD, Burger JA, Ferrajoli F, Montalban-Bravo G, Sasaki K, Garcia-Manero G, Ravandi F, Kadia TM. Azacitidine Plus Venetoclax Maintenance in Acute Myeloid Leukemia Produces Sustained Remissions with Low Toxicity: Results of a Phase 2 Study. Blood 142, 2023. e-Pub 2023.
Chien KS, Urrutia S, Kanagal-Shamanna R, Abdelhakeem A, Abuasab T, Almanza E, Gener-Ricos G, Bataller A, Bazinet A, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Hammond DE, Swaminathan M, Sasaki K, Dong XQ, Sherry Pierce S, Kantarjian H, Garcia-Manero G. Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Hypomethylating Agent-Treated Patients with Myelodysplastic Syndromes. Blood 142, 2023. e-Pub 2023.
Calvete O, Mestre J, Montalban-Bravo G, Sasaki K, DiNardo CD, Manzanares A, Acha P, Xicoy B, Zamora L, Granada I, Diaz-Gonzalez A Such E, Palomo L, Montoro MJ, García S, Arenillas L, Ferreiras DV, Jerez A, Diez-Campelo M, Prosper F, Yang H, Bueso-Ramos CE, Garcia-Manero G, Sole F, Kanagal-Shamanna R. Clinical and Molecular Characterization of Patients with Therapy Related Myeloid Neoplasms (TRMN). Blood 142, 2023. e-Pub 2023.
Gener-Ricos G, Bataller A, Almanza-Huante E, Chien KS, Hammond DE, Sasaki K, DiNardo CD, Kadia TM, Daver N, Borthakur G, Issa GC, Short NJ, Garcia-Manero G, Montalban-Bravo G. NPM1-Mutated Myeloid Neoplasms: Updated Outcomes with High-Intensive Chemotherapy Regardless of the Blast Percentage. Blood 142, 2023. e-Pub 2023.
Senapati J, Loghavi S, Reville PK, Daver N, Borthakur, G DiNardo CD, Jabbour E, Short NJ, Pemmaraju N, Maiti A, Issa GC, Popat UR, Alousi A, Shpall EJ, Sasaki K, Garcia-Manero G, Ravandi F, Kadia TM. Outcomes of Patients (pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) and TP53 mutation/Loss Treated on the Phase 2 Study of Venetoclax (Ven) Added to Alternating Cladribine (Clad) Plus Low-Dose Cytarabine (LDAC) and Azacitidine (Aza): A Subgroup Analysis. Blood 142, 2023. e-Pub 2023.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Senapati J, Burger JA, Borthakur G, Swaminathan G, Takahashi K, Estrov Z, Konopleva MY, Sasaki K, Kadia TM, Pemmaraju N, Daver N, Jabbour E, DiNardo CD, Alvarado Valero Y, Yilmaz M, Bose P, Ohanian M, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Nassar S, Garg N, Hwang H, Wang X, Cruz N, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 5-Year Follow-up Data. Blood 142, 2023. e-Pub 2023.
Masarova L, Kantarjian HM, Pemmaraju N, Abbas HA, Bose P, Swaminathan M, Pierce S, Sasaki K, Yilmaz M, Short NJ, Daver N, Borthakur G, Garcia-Manero G, Ohanian, M, Bhalla KN, DiNardo CD, Kadia TM. Cladribine-Based Chemotherapy for Patients with Secondary Acute Myeloid Leukemia (AML) Arising after Myeloproliferative Neoplasms (MPNs). Blood(142), 2023. e-Pub 2023.
Chien KS, Urrutia S, Li Z, Kanagal-Shamanna R, Abdelhakeem A, Abuasab T, AlmanzaE, Gener-Ricos G, Bataller, A, Bazinet A, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Hammond DE, Swaminathan M, Sasaki K, Dong XQ, Pierce S, Kantarjian HM, Garcia-Manero G. Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes. Blood 142, 2023. e-Pub 2023.
Nasr LF, Short NJ, Senapati J, Alvarado Y, Jain N, Konopleva M, Macaron W, Ravandi F, Dinardo CD, Sasaki K, Ferrajoli A, Nasnas CC, Zoghbi M, Jacob J, Mayor E, Milton A, Loiselle C, Garris R, Kantarjian HM, Jabbour E. Inotuzumab ozogamicin (INO) for the treatment of measurable residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase II study. J Clin Oncol 41 Suppl:e19008, 2023. e-Pub 2023.
Almanza-Huante E, Bataller A, Urrutia S, Gener-Ricos G, Briski R, Kanagal-Shamanna R, Lu KH, Westin SN, Yap TA, Takahashi K, Ravandi F, Alvarado Y, Kadia TM, Sasaki K, Kantarjian HM, Garcia-Manero G. Outcomes of myeloid malignancies in patients previously treated with PARP inhibitors for solid malignancies: A single institution experience. J Clin Oncol 41 Suppl:e19000, 2023. e-Pub 2023.
Atallah EL, Mauro MJ, Sasaki K, Levy MY, Koller PB, Sadek I, Yang D, Ruckel-Kumar J, Khan MH, Cortes JE. ASC2ESCALATE: A US phase 2, single-arm, dose-escalation study of asciminib monotherapy in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously treated with 1 prior tyrosine kinase inhibitor (TKI). J Clin Oncol 41 Suppl:TPS7082, 2023. e-Pub 2023.
Nasnas CC, Jabbour E, Haddad F, Short NJ, Macaron W, Zoghbi M, Nasr LF, Jain N, Almanza E, Sasaki K, Ravandi F, Kebriaei P, Huang X, Garcia-Manero G, Kadia TM, Wang SA, Jacob J, Garris R, O'Brien SM, Kantarjian HM. Phase II trial of mini-hyper-CVD-inotuzumab (InO) followed by blinatumomab (blina) consolidation in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). J Clin Oncol 41 Suppl:e19037, 2023. e-Pub 2023.
Chien KS, Ong F, Kim K, Li Z, Kanagal-Shamanna R, DiNardo CD, Takahashi K, Montalban-Bravo G, Hammond D, Sasaki K, Pierce S, Kantarjian HM, Garcia-Manero G. Outcomes of individuals with clonal hematopoiesis evaluated at a cancer center. J Clin Oncol:7072, 2023. e-Pub 2023.
Senapati J, Ravandi F, DiNardo CD, Issa GC, Sasaki K, Konopleva M, Macaron W, Nasr LF, Zoghbi M, Nasnas CC, Pemmaraju N, Chien KS, Ohanian M, Jabbour E, Maiti A, Kantarjian HM, Short NJ. A phase 2 study of the combination of decitabine (DAC), venetoclax (VEN), and ponatinib in patients (Pts) with chronic myeloid leukemia (CML) in accelerated phase (AP)/myeloid blast phase (MBP) or Philadelphia-chromosome positive (Ph+) acute myeloid leukemia (AML). J Clin Oncol 41 Suppl:e19044, 2023. e-Pub 2023.
Senapati J, Ravandi F, DiNardo CD, Issa GC, Sasaki K, Konopleva M, Pemmaraju N, Chien KS, Ohanian M, Jabbour E, Maiti A, Roy E, Delumpa R, Rivera J, Loiselle C, Banks G, Kantarjian H, Short N. A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML). Blood 140 (Supplement 1):3880-3882, 2022. e-Pub 2022.
Briski RE, Chien KS, Montalban-Bravo G, Kadia TM, Jabbour E, Pemmaraju N, Sasaki K, Hammond D, Short N, Ravandi F, Alvarado Y, Pierce SA, Garcia-Manero G, Kantarjian H. Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients. Blood 140 (Supplement 1):4042-4044, 2022. e-Pub 2022.
Bataller A, Sasaki K, Jabbour E, Issa GC, Haddad F, Skinner J, Dellasala SE, Garcia-Manero G, Pierce SA, Kantarjian H. Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia. Blood 140 (Supplement 1):3895-3896, 2022. e-Pub 2022.
Daver N, Senapati J, Maiti A, Loghavi S, Kadia TM, DiNardo CD, Pemmaraju N, Jabbour E, Montalban-Bravo G, Tang G, Sasaki K, Borthakur G, Yilmaz M, Alvarez J, Pierce SA, González GMN, Ning J, Issa GC, Andreeff M, Abbas HA, Ravandi F, Garcia-Manero G, Kantarjian H. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. Blood 140 (Supplement 1):141-144, 2022. e-Pub 2022.
Haddad F, Jabbour E, Short N, Jain N, Huante EA, Sasaki K, Nasnas P, Ravandi F, Kebriaei P, Huang X, Konopleva M, Garcia-Manero G, Champlin RE, Kadia TM, Takahashi K, Daver N, Khoury JD, Jorgensen JL, Wang SA, Jacob J, Garris R, Kantarjian H. Improved Outcomes with Low-Dose Inotuzumab and Mini-Hyper-CVD Followed By Blinatumomab Consolidation in Relapsed-Refractory Acute Lymphoblastic Leukemia: Results of a Phase II Study. Blood 140 (Supplement 1):11698-11701, 2022. e-Pub 2022.
Short N, Jabbour EJ, Ravandi F, DiNardo CD, Daver N, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Sasaki K, Thompson PA, Burger JA, Maiti A, Alvarado Y, Kwari M, Delumpa R, Thankachan J, Mayor E, Loiselle C, Milton A, Banks G, Kadia TM, Konopleva M, Kantarjian H. The Addition of Inotuzumab Ozogamicin to Hyper-CVAD Plus Blinatumomab Further Improves Outcomes in Patients with Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study. Blood 140 (Supplement 1):8966-8968, 2022. e-Pub 2022.
Bidikian A, Kantarjian H, Issa GC, Ravandi F, Garcia-Manero G, Borthakur G, Kadia TM, Daver N, Jain N, Pemmaraju N, DiNardo CD, Haddad F, Pierce SA, Jabbour E, Sasaki K. Outcomes of Chronic Myeloid Leukemia with No Major Molecular Response within 2 Years of Tyrosine Kinase Inhibitor Therapy. Blood 140 (Supplement 1):9626-9628, 2022. e-Pub 2022.
Sasaki K, Mauro M, Levy MY, Atallah EL, Koller PB, Maegawa R, Damon A, Kumar J, Khan M, Cortes JE. ASC2ESCALATE: A Phase 2, Single-Arm, Dose-Escalation Study of Asciminib Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with 1 Prior Tyrosine Kinase Inhibitor (TKI). Blood 140 (Supplement 1):6784-6786, 2022. e-Pub 2022.
Jabbour E, Sasaki K, Issa GC, Haddad F, Garcia-Manero G, Kadia TM, Wierda WG, Yilmaz M, DiNardo CD, Skinner J, Pemmaraju N, Dellasala SE, Pierce SA, Cortes JE, Kantarjian H. Outcome of Third-Line Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis. Blood 140 (Supplement 1):809-811, 2022. e-Pub 2022.
Bazinet A, Kantarjian H, Borthakur G, Yilmaz M, Bose P, Jabbour E, Alvarado Y, Chien KS, Pemmaraju N, Takahashi K, Short N, Daver N, Issa GC, Jain N, Linderman DB, DiNardo CD, Burger JA, Ferrajoli A, Montalban-Bravo G, Garcia-Manero G, Sasaki K, Ravandi F, Kadia TM. A Phase II Study of Azacitidine Plus Venetoclax As Maintenance Therapy in Acute Myeloid Leukemia: Durable Responses with Longer Term Follow-up. Blood 140 (Supplement 1):9005-9007, 2022. e-Pub 2022.
Senapati J, Kantarjian H, Ravandi F, DiNardo CD, Takahashi K, Hammond D, Sasaki K, Chien KS, Kanagal-Shamanna R, Popat UR, Pierce SA, Jabbour E, Champlin RE, Garcia-Manero G, Kadia TM. Outcomes of Older Patients with Aplastic Anemia Treated with Frontline Anti-Thymocyte Globulin (ATG)-Based Immunosuppressive Therapy. Blood 140 (Supplement 1):8652-8654, 2022. e-Pub 2022.
Gener-Ricos G, Sasaki K, Loghavi S, Maiti A, Short N, Haddad F, Daver N, Borthakur G, Ravandi F, Kantarjian H, Patel KP, Andreeff M, DiNardo CD. A Descriptive Analysis of TP53 Y220C Mutations in Patients with Hematologic Malignancies. Blood 140 (Supplement 1):11830–11832, 2022. e-Pub 2022.
Atluri H, Maiti A, Sasaki K, Daver N, Alvarado Y, Hossain F, Wang X, Pemmaraju N, Takahashi K, Borthakur G, Ferrajoli A, Short N, Abbas HA, Ravandi F, Jabbour E, Andreeff M, Garcia-Manero G, Kantarjian H, Konopleva M, DiNardo CD. Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia. Blood 140 (Supplement 1):6170-6172, 2022. e-Pub 2022.
Urrutia S, Sasaki K, Kanagal-Shamanna R, Bataller A, Montalban-Bravo G, Ganan-Gomez I, Wei Y, Yang H, Chien KS, Hammond D, Bueso-Ramos CE, Pierce SA, Kantarjian H, Garcia-Manero G. Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS). Blood 140 (Supplement 1):6952-6954, 2022. e-Pub 2022.
Mill CP, Fiskus WC, Davis JA, Das K, Birdwell CE, Kadia TM, Sasaki K, Takahashi K, DiNardo CD, Loghavi S, Daver N, Bhalla KN. Efficacy of Novel Non-Chemotherapy Combinations Against AML Cells with Mutant NPM1. Blood 140 (Supplement 1):5860-5861, 2022. e-Pub 2022.
Yang H, Garcia-Manero G, Wei Y, Sasaki K, Chien KS, Tang Z, Montalban-Bravo G, Kalia A, Luthra R, Medeiros LJ, Kanagal-Shamanna R. Combined Structural Variant and Mutation Profiling for Comprehensive Characterization of Chromoanagenesis and TP53 Mutations in Myelodysplastic Syndromes with Complex Karyotype. Blood 140 (Supplement 1):7844-7845, 2022. e-Pub 2022.
Bataller A, Kanagal-Shamanna R, Chien KS, Montalban-Bravo G, Kadia TM, Ravandi F, DiNardo CD, Daver N, Short N, Borthakur G, Jabbour E, Hammond D, Masarova L, Ganan-Gomez I, Adema V, Kantarjian H, Garcia-Manero G, Sasaki K. Myelodysplastic Syndromes without Detectable Mutations: Analysis of Clinical Presentation and Outcome. Blood 140 (Supplement 1):9793-9795, 2022. e-Pub 2022.
Gener-Ricos G, Haddad F, Sasaki K, Issa GC, Skinner J, Takahashi K, Masarova L, Burger JA, Borthakur G, Bose P, Garcia-Manero G, Jabbour E, Kantarjian H. Long-Term Follow-up of Low-Dose Dasatinib (50mg Daily) As Frontline Therapy in Newly Diagnosed Chronic Myeloid Leukemia. Blood 140 (Supplement 1):1493-1494, 2022. e-Pub 2022.
Ong F, Garcia-Manero G, Montalban-Bravo G, Alvarado Y, Ohanian M, Konopleva M, Jabbour E, Jain N, Borthakur G, DiNardo CD, Daver, N Issa GC, Sasaki K, Chien, KS Takahashi K, Andreeff M, Muftuoglu M, Delumpa R, Mayor F, Loiselle C, Waller L, Bank G, Kantarjian H, Cortes JE, Short N. A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure. Blood 140 (Supplement 1):6206-6208, 2022. e-Pub 2022.
Haddad F, Sasaki K, Issa GC, Kim K, Skinner J, Dellasala SE, Alvarado Y, Ferrajoli A, Kadia TM, Yilmaz M, Pemmaraju N, Garcia-Manero G, Pierce SA, Jabbour E, Kantarjian H. More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia. Blood 140 (Supplement 1):3897-3899, 2022. e-Pub 2022.
Jabbour E, Paul S, Nichols DE, Darbaniyan F, Lee J, Sasaki K, Short N, Jain N, Ravandi F, Garcia-Manero G, Kadia TM, Montalban-Bravo G, Borthakur G, Garris R, Konopleva M, Kantarjian H. Incidence of Central Nervous System Toxicity and Cytokine Release Syndrome in Leukemia Patients Treated with Blinatumomab. Blood 140 (Supplement 1):11663-11665, 2022. e-Pub 2022.
Senapati J, Short N, Maiti A, Abbas HA, Daver N, Pemmaraju N, Pierce SA, Chien KS, Sasaki K, Hammond D, Borthakur G, Ravandi F, Kantarjian H, DiNardo CD. Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia. Blood 140 (Supplement 1):1427-1429, 2022. e-Pub 2022.
Venugopal S, Loghavi S, Routbort M, Jelloul FZ, Kanagal-Shamanna R, Pierce SA, Issa GC, Abbas HA, Sasaki K, Takahashi K, Daver N, Ravandi F, Kantarjian H, DiNardo CD. Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies. Blood 140 (Supplement 1):6328-6330, 2022. e-Pub 2022.
Short N, DiNardo CD, Daver N, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Sasaki K, Thompson PA, Burger JA, Maiti A, Alvarado Y, Kwari M, Delumpa R, Thankachan J, Mayor E, Loiselle C, Milton A, Banks G, Kadia TM, Konopleva M, Kantarjian H, Ravandi F. Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia. Blood 140 (Supplement 1):2007-2009, 2022. e-Pub 2022.
Nasnas P, Jabbour E, Short N, Sasaki K, Ravandi F, Jain N, Daver N, Pemmaraju N, Yilmaz M, Kadia TM, Garris R, Garcia-Manero G, DiNardo CD, Konopleva M, Wierda WG, Kwari M, Loiselle C, Milton A, Rivera J, Banks G, Kantarjian H. Frontline Combination of Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-6-Year Follow-up Results. Blood 140 (Supplement 1):3250-3252, 2022. e-Pub 2022.
Nguyen H, Sasaki K, Ravandi F, Luthra R, Patel KR, Loghavi S, Jelloul FZ, Routbort M, Kalia A, Montalban-Bravo G, Chien KS, Hu P, Yilmaz M, Bueso-Ramos CE, Medeiros LJ, Garcia-Manero G, Kanagal-Shamanna R. Homologous Recombination DNA Repair Deficiency Score Is Independent Prognostic Variable in Myelodysplastic Syndrome/ Acute Myeloid Leukemia with Complex Karyotype. Blood 140 (Supplement 1):1353-1354, 2022. e-Pub 2022.
Birdwell CE, Fiskus WC, Kadia TM, Mill CP, Davis JA, Das K, Daver N, DiNardo CD, Takahashi K, Sasaki K, Horrigan S, Bhalla KN. Preclinical Efficacy of Novel Drug Combination Against AML with 3q26 Lesions and EVI1 Overexpression. Blood 140 (Supplement 1):493-494, 2022. e-Pub 2022.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Senapati J, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Konopleva M, Sasaki K, Kadia TM, Pemmaraju N, Daver N, Jabbour E, DiNardo CD, Alvarado Y, Yilmaz M, Bose P, Ohanian M, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Nassar S, Garg N, Hwang H, Wang X, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data. Blood 140 (Supplement 1):234-237, 2022. e-Pub 2022.
Fiskus WC, Das K, Mill CP, Birdwell CE, Davis JA, Philip K, Alhamadani N, Kadia TM, Daver N, Sasaki K, Takahashi K, Loghavi S, DiNardo CD, Vargas J, Bhalla KN. Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53. Blood 140 (Supplement 1):8807-8808, 2022. e-Pub 2022.
Bidikian A, Basu S, Zhong H, Atluri H, Zarka J, Andreeff M, Sasaki K, Jabbour E, Cortes JE, Sharma P, Issa GC. A Suboptimal Response in CML Is Associated with Expression of the Immune Checkpoint VISTA. Blood 140 (Supplement 1):6739-6741, 2022. e-Pub 2022.
Desikan SP, Konopleva M, Takahashi K, Lachowiez CA, Loghavi S, Xiao LC, Kadia TM, Daver N, Short N, Sasaki K, Borthakur G, Issa GC, Maiti A, Chien KS, Alvarado Y, Montalban-Bravo G, Masarova L, Yilmaz M, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau SM, Ravandi F, Kantarjian H, DiNardo CD. Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia. Blood 140 (Supplement 1):534-536, 2022. e-Pub 2022.
Senapati J, Almanza EH, Kadia TM, Montalban-Bravo G, Faderl S, Sasaki K, Short N, Daver N, DiNardo CD, Masarova L, Ferrajoli A, Jabbour E, Borthakur G, Al Azzawi H, Konopleva M, Garcia-Manero G, Andreeff M, Kantarjian H, Ravandi F, Alvarado Y. Updated Results of CPX-351 in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). Blood 140 (Supplement 1):9050-9053, 2022. e-Pub 2022.
Reville PK, Kantarjian H, Borthakur G, Pemmaraju N, Daver N, DiNardo CD, Sasaki K, Short N, Issa GC, Ohanian M, Jabbour E, Montalban-Bravo G, Maiti A, Jain N, Ferrajoli A, Bhalla KN, Takahashi K, Rausch CR, Hammond D, Malla R, Quagliato K, Brandt M, Popat UR, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM. Venetoclax Added to Cladribine (CLAD) + Low Dose AraC (LDAC) Alternating with Azacitidine (AZA) Is Highly Active As Frontline Therapy in Older Patients with Newly Diagnosed Acute Myeloid Leukemia in a Phase 2 Study. Blood 140 (Supplement 1):9041-9043, 2022. e-Pub 2022.
Senapati J, Short N, Alvarado Y, Burger JA, Jain N, Konopleva M, Ravandi F, DiNardo CD, Masarova L, Sasaki K, Thompson PA, Ferrajoli A, Jacob J, Mayor E, Milton A, Loiselle C, Garris R, Kantarjian H, Jabbour E. A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. Blood 140 (Supplement 1):3253-3255, 2022. e-Pub 2022.
Sasaki K, Mauro MJ, Levy MY, Atallah EL, Koller P, Maegawa R, Damon A, Kumar J, Khan M, Cortes JE. CML-433 ASC2ESCALATE Trial in Progress: A Phase 2 Single-Arm Dose Escalation Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated With 1 Prior Tyrosine Kinase Inhibitor (TKI). Clin Lymphoma Myeloma Leuk 22 Suppl 2:S299, 2022. e-Pub 2022. PMID: 36163933.
Réa D, Hochhaus A, Mauro MJ, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Cortes JE, Abdo A, Fogliatto LM, Kim DDH, Coutre PL, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Chee L, García-Gutiérrez V, Sasaki K, Kapoor S, Allepuz A, Quenet S, Bédoucha V, Boquimpani C. CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After =2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S295-S296, 2022. e-Pub 2022. PMID: 36163925.
Bidikian A, Kantarjian H, Jabbour E, Short N, Ravandi F, Issa G, Sasaki K. CML-288 Impact of ASXL1 Mutations on Prognosis of Chronic Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S291, 2022. e-Pub 2022. PMID: 36163917.
Kim K, Ong F, Montalban-Bravo G, Shamanna RK, Kadia T, Jabbour E, Alvarado Y, Sasaki K, Dong XQ, Pierce S, Bueso-Ramos C, Kantarjian H, Kelly C, Garcia-Manero G. MDS-406 Prognostic Implication of the Molecular Profiles of Patients With Hypocellular Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S310, 2022. e-Pub 2022. PMID: 36163955.
Bazinet A, Kantarjian H, Borthakur G, Yilmaz M, Bose P, Jabbour E, Alvarado Y, Chien K, Pemmaraju N, Takahashi K, Short N, Daver N, Issa G, Jain N, Bull-Linderman D, DiNardo C, Montalban-Bravo G, Garcia-Manero G, Sasaki K, Ravandi F, Kadia T. AML-342 A Phase II Study of Azacitidine and Venetoclax as Maintenance Therapy in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S239-S240, 2022. e-Pub 2022. PMID: 36163817.
Ong F, Kadia T, Short NJ, Yilmaz M, Alvarado Y, Sasaki K, Pierce SA, Garcia-Manero G, DiNardo C, Borthakur G, Konopleva M, Daver N, Kantarjian H, Ravandi F. The Role of FLT3 Inhibitors in Patients With Acute Myeloid Leukemia (AML) and T(6;9)(P22;Q34). Clin Lymphoma Myeloma Leuk 22 Suppl 2, 2022. e-Pub 2022.
Abuasab T, Mohamed SF, Hwang H, Wang X, Sasaki K, Yilmaz M, Kadia T, DiNardo C, Daver N, Pemmaraju N, Ravandi F, Kantarjian H, Garcia-Manero G, Takahashi K. Clinical Characteristics of Secondary Myeloid Neoplasms (MNs) in Patients With Inflammatory Bowel Disease (IBD). Clin Lymphoma Myeloma Leuk 22 Suppl 2, 2022. e-Pub 2022.
Hughes TP, Cortes JE, Réa D, Mauro MJ, Hochhaus A, Kim DW, Sasaki K, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen JWM, Talpaz M, le Coutre P, Kapoor S, Cacciatore S, Polydoros F, Agrawal N, Mahon FX. Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S300, 2022. e-Pub 2022.
Haddad FG, Kantarjian H, Short NJ, Konopleva M, Jain N, Huang X, Ravandi F, Wierda W, Borthakur G, Sasaki K, Issa G, Alvarado Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. Updated Results from the Phase II Study of Blinatumomab in Combination With Ponatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S204, 2022. e-Pub 2022.
Sasaki K, Mauro MJ, Levy MY, Atallah EL, Koller P, Maegawa R, Damon A, Kumar J, Khan M, Cortes JE. ASC2ESCALATE Trial in Progress: A Phase 2 Single-Arm Dose Escalation Study of Asciminib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated With 1 Prior Tyrosine Kinase Inhibitor (TKI). Clin Lymphoma Myeloma Leuk 22 Suppl 2:S299, 2022. e-Pub 2022.
Baran N, Babakhanlou R, Sasaki K, Takahashi K, Short N, Ravandi F, Garcia-Manero G, Jabbour EJ, Kantarjian HM, Jain N. Acute Lymphoblastic Leukemia Following Multiple Myeloma Therapy: A Single-Center Experience With 9 Patients. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S201-S202, 2022. e-Pub 2022.
Bidikian A, Kantarjian H, Dabaja B, Ravandi F, Jabbour E, DiNardo C, Borthakur G, Daver N, Garcia-Manero G, Kadia T, Sasaki K, Issa G. Association Between Myeloid Malignancies With MECOM Rearrangement and Ocular Adnexal Leukemic Infiltration. Clin Lymphoma Myeloma Leuk 22 Suppl 2:S233-S234, 2022. e-Pub 2022.
Macaron W, Jabbour E, Konopleva M, Ravandi F, Jain N, Issa G, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson P, Takahashi K, Abbas H, Wierda W, Garris R, Kantarjian H, Short N. DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB. European Hematology Association 6, 2022. e-Pub 2022.
Short N, Kantarjian H, Ravandi F, Yilmaz M, Kadia T, Thompson P, Huang X, Konopleva M, Ferrajoli A, Jain N, Sasaki K, Alvarado Y, Borthakur G, DiNardo C, Ohanian M, Macaron W, Kornblau S, Zhao M, Kwari M, Loiselle C, Delumpa R, Milton A, Rivera J, Lewis S, Garris R, Jabbour E. HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITHOUT INOTUZUMAB OZOGAMICIN, IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. European Hematology Association 6, 2022. e-Pub 2022.
Kim K, Chien K, Ong F, Montalban-Bravo G, Kanagal-Shamanna R, Kadia T, Jabbour E, Alvarado Y, Sasaki K, Dong XQ, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. MUTATION PROFILES AND RISK STRATIFICATION IN HYPOCELLULAR MYELODYSPLASTIC SYNDROME. European Hematology Association 6:P769, 2022. e-Pub 2022.
Nguyen D, Ning J, Qiao W, Sasaki K, Kantarjian HM, Short NJ, Cuglievan B, Daver NG, DiNardo CD, Jabbour E, Kadia TM, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Ravandi F, Issa GC. Acute myeloid leukemia with KMT2Ar and association with risk of bleeding and early mortality. J Clin Oncol 40 Suppl:7026, 2022. e-Pub 2022.
Short N, Kantarjian H, KonoplevaM, Jain N, Ravandi F, Huang X, Macaron W, Wierda W, Borthakur G, Kadia T, Sasaki K, Issa G, Montalban-Bravo G, Alvarado Y, Garcia-Manero G, Dinardo C, Thankachan J, Delumpa R, Mayor E, Deen W, Milton A, Rivera J, Waller L, Loiselle C, Garris R, Jabbour E. Ponatinib And Blinatumomab For Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results From A Phase Ii Study. European Hematology Association 6:15-16, 2022. e-Pub 2022.
Abuasab T, Mohadam SF, Hwang H, Wang X, Sasaki K, Yilmaz M, Kadia T, DiNardo C, Daver N, Pemmaraju N, Borthakur G, Ravandi F, Garcia-Manero G, Takahashi K. CLINICAL CHARACTERISTICS OF SECONDARY MYELOID NEOPLASMS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. European Hematology Association 6:P476, 2022. e-Pub 2022.
Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Wang S, Jorgensen J, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda W. Long Term Outcomes Of Ifcg Regimen For Firstline Treatment Of Patients With Cll With Mutated Ighv And Without Del(17p)/Tp53 Mutation. European Hematology Association 6:50-51, 2022. e-Pub 2022.
Senapati J, Kantarjian H, Short N, Alvarado Y, Burger Y, Jain N, Konopleva M, Ravandi F, DiNardo C, Masarova L, Sasaki K, Thompson PA, Ferrajoli A, Jacob JO, Mayor ED, Milton AM, Loiselle C, Garris RS, Jabbour EJ. A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. European Hematology Association 6, 2022. e-Pub 2022.
Haddad F, Kantarjian H, Jabbour E, Short N, Bidikian A, Ning J, Xiao L, Pemmaraju N, Marx K, Ravandi F, Sasaki K, Issa G. ASSOCIATION BETWEEN BARIATRIC SURGERY AND OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH ORAL TYROSINE KINASE INHIBITORS. European Hematology Association 6:P703, 2022. e-Pub 2022.
Haddad F, Jabbour E, Issa GC, Garcia-Manero G, Ravandi F, Kadia TM, Cortes JE, Konopleva M, Pemmaraju N, Alvarado Y, Yilmaz M, Borthakur G, DiNardo CD, Jain N, Daver NG, Short NJ, Kantarjian HM, Sasaki K. Treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) following the discontinuation of tyrosine kinase inhibitors. J Clin Oncol 40 Suppl:7050, 2022. e-Pub 2022.
Hughes T, Cortes JE, Rea D, Mauro MJ, Hochhaus A, Kim DW, Sasaki K, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen JWM, Talpaz M, de Soria VGG, le Coutre P, Kapoor S, Cacciatore S, Polydoros F, Agrawal N, Mahon FX. ASCIMINIB PROVIDES DURABLE MOLECULAR RESPONSES IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) WITH THE T315I MUTATION: UPDATED EFFICACY AND SAFETY DATA FROM A PHASE I TRIAL. European Hematology Association 6:P704, 2022. e-Pub 2022.
Short NJ, Kantarjian HM, Konopleva M, Montalban-Bravo G, Ravandi F, Jain N, Kadia TM, Alvarado Y, Chien KS, Daver NG, Macaron W, Sasaki K, Thankachan J, Delumpa R, Mayor E, Deen W, Loiselle C, Kwari M, Garris R, Jabbour E. A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). J Clin Oncol 40 Suppl:7009, 2022. e-Pub 2022.
Kim K, Ahaneku H, Deborah M, Sasaki K, Hammond D, Chien K, Adachi J, Ferrajoli A. OUTCOME OF HYPERBARIC OXYGEN THERAPY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES -TERTIARY CANCER CENTER. European Hematology Association 6:P1590, 2022. e-Pub 2022.
Bidikian A, Kantarjian H, Jabbour E, Short N, Ravandi F, Issa G, Sasaki K. PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN CHRONIC PHASE CML. European Hematology Association 6:P695, 2022. e-Pub 2022.
Short NJ, Kantarjian HM, Ravandi F, Yilmaz M, Kadia TM, Thompson PA, Konopleva M, Ferrajoli A, Jain N, Sasaki K, Alvarado Y, Borthakur G, Dinardo CD, Ohanian M, Macaron W, Garris R, Zhao M, Kwari M, Loiselle C, Jabbour E. A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL). J Clin Oncol 40 Suppl:7034, 2022. e-Pub 2022.
Haddad F, Sasaki K, Abuasab T, Venugopal S, Rivera D, Bazinet A, Babakhanlou R, Kim K, Senapati J, Ong F, Desikan SP, Short NJ, Pemmaraju N, Borthakur G, DiNardo CD, Daver NG, Jabbour E, Garcia-Manero G, Ravandi F, Kadia TM. Outcomes of patients with newly diagnosed acute myeloid leukemia (AML) and hyperleukocytosis. J Clin Oncol 40 Suppl:e19029, 2022. e-Pub 2022.
Darbaniyan F, Montalban-Bravo G, Chien KS, Kanagal-Shamanna R, Sasaki K, Yang H, Soltysiak KA, Li Z, Do KA, Garcia-Manero G. NONLINIEAR IMPACT OF CLINICAL FEATURES ON THE SURVIVAL OUTCOME OF MYELODYSPLASTIC SYNDROMES PATIENTS. European Hematology Association:P762, 2022. e-Pub 2022.
Bazinet A, Kantarjian HM, Borthakur G, Yilmaz M, Bose P, Jabbour E, Alvarado Y, Chien KS, Pemmaraju N, Takahashi K, Short NJ, Daver NG, Issa GC, Jain N, Bull-Linderman D, DiNardo CD, Garcia-Manero G, Sasaki K, Ravandi F, Kadia TM. Phase 2 study of azacitidine (AZA) and venetoclax (VEN) as maintenance therapy for acute myeloid leukemia (AML) patients in remission. J Clin Oncol 40 Suppl:e19018, 2022. e-Pub 2022.
Rea D, Hochhaus A, Mauro MJ, Minami Y, Lomaia E, Voloshin S, Turkina A, D-W K, Apperley JF, Cortes JE, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Chee L, Garcia-Gutierez V, Sasaki K, Kapoor S, Allepuz A, Quenet S, Bedoucha V, Boquimpani C. Efficacy and safety results from ascembl, a phase 3 study of asciminib vs bosutinib in patients with chronic myeloid leukemia in chronic phase after .2 prior tyrosine kinase inhibitors: wk 96 update. European Hematology Association 6:56-57, 2022. e-Pub 2022.
Haddad F, Sasaki K, Abuasab T, Venugopal S, Delgado DR, Bazinet A, Babakhanlou R, Kim K, Senapati J, Ong F, Desikan S, Short N, Pemmaraju N, Borthakur G, DiNardo C, Daver N, Jabbour E, Garcia-Manero G, Ravandi F, Kadia T. OUTCOMES AND MANAGEMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PRESENTING WITH HYPERLEUKOCYTOSIS. European Hematology Association 6:P541, 2022. e-Pub 2022.
Yang H, Garcia-Manero G, Sasaki K, Montalban-Bravo G, Tang Z, Wei Y, Kadia T, Chien K, Rush D, Nguyen H, Kalia A, Nimmakayalu M, Bueso-Ramos C, Kantarjian H, Medeiros LJ, Luthra R, Kanagal-Shamanna R. CLINICAL SIGNIFICANCE OF ROUTINE HIGH-RESOLUTION STRUCURAL VARIANT PROFILING IN MYELODYSPLASTIC SYNDROMES. European Hematology Association 6:P767, 2022. e-Pub 2022.
Rea D, Mauro MJ, Hochhaus A, Boquimpani C, Lomaia E, Voloshin S, Turkina AG, D-W K, Apperley J, Cortes JE, Sasaki K, Kapoor S, Allepuz A, Quenet S, Bédoucha V, Minami Y. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib versus bosutinib (BOS) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) after ≥2 prior tyrosine kinase inhibitors (TKIs): Week 96 update. J Clin Oncol 40(Suppl 16), 2022. e-Pub 2022.
Sasaki K, Kantarjian HM, Konopleva M, Jain N, Huang X, Ravandi F, Wierda WG, Borthakur G, Short NJ, Issa G, Alvarado Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. Phase II Study of Ponatinib and Blinatumomab in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. Japanese Society of Medical Oncology, 2022. e-Pub 2022.
Short NJ, Kantarjian H, Konopleva M, Desikan SP, Jain N, Ravandi F, Huang X, Wierda WG, Borthakur G, Sasaki K, Issa GC, Alvarado Y, Pemmaraju N, Garcia-Manero G, DiNardo CD, Thankachan J, Delumpa R, Milton A, Rivera J, Waller L, Garris R, Jabbour EJ. Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood 138 (Supplement 1):2298, 2021. e-Pub 2021.
Yilmaz M, Kantarjian H, Short NJ, Konopleva M, Kadia TM, DiNardo CD, Borthakur G, Pemmaraju N, Maiti A, Jabbour EJ, Issa GC, Jain N, Takahashi K, Sasaki K, Ohanian M, Tang G, Loghavi S, Patel K, Garcia-Manero G, Andreeff M, Ravandi F, Daver N. Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor “Triplet” Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML. Blood 138 (Supplement 1):798, 2021. e-Pub 2021.
Kim K, Kantarjian H, Jabbour EJ, Issa GC, Ravandi F, DiNardo CD, Konopleva M, Jain N, Pemmaraju N, Borthakur G, Kadia TM, Garcia-Manero G, Morita K, Pierce SA, Cortes JE, Sasaki K. The Prognostic Implication of Adult Comorbidity Evaluation 27 Score in CML Patients on Tyrosine-Kinase Inhibitors. Blood 138 (Supplement 1):2554, 2021. e-Pub 2021.
Sasaki K, Jabbour EJ, Issa GC, Naqvi K, Skinner J, Anderson K, Dellasala SE, Yilmaz M, Ferrajoli A, Bose P, Thompson PA, Alvarado Y, Jain N, Garcia-Manero G, Takahashi K, Burger JA, Borthakur G, Pemmaraju N, Haddad F, Khouri MR, Paul S, Pierce SA, Cortes JE, Kantarjian H. Low-Dose Dasatinib 50 Mg/Day Versus Standard-Dose Dasatinib 100 Mg/Day As Frontline Therapy in Chronic Myeloid Leukemia in Chronic Phase: A Propensity Score Analysis. Blood 138 (Supplement 1):631, 2021. e-Pub 2021.
Haddad F, Kantarjian H, Jabbour EJ, Short NJ, Pemmaraju N, Marx K, Ravandi F, Sasaki K, Issa GC. Association between Bariatric Surgery and Outcomes in Patients with Chronic Myeloid Leukemia Treated with Oral Tyrosine Kinase Inhibitors. Blood 138 (Supplement 1):2560, 2021. e-Pub 2021.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Sasaki K, Kadia TM, Konopleva M, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour EJ, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen JL, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Focus on Long-Term MRD Results. Blood 138 (Supplement 1):3720, 2021. e-Pub 2021.
Siddiqui M, Issa GC, Sasaki K, Montalban-Bravo G, Chien KS, Jabbour EJ, Bueso-Ramos CE, Kanagal-Shamanna R, Kantarjian H, Garcia-Manero G. Clinical Outcomes of Patients with Newly Diagnosed Myelodysplastic Syndrome with MLL Aberrations. Blood 138 (Supplement 1):4673, 2021. e-Pub 2021.
Maiti A, DiNardo CD, Rausch CR, Pemmaraju N, Garcia-Manero G, Ohanian M, Daver N, Issa GC, Borthakur G, Ravandi F, Alvarado Y, Kadia TM, Short NJ, Jabbour EJ, Montalban-Bravo G, Jain N, Kornblau SM, Masarova L, Wierda WG, Sasaki K, Takahashi K, Yilmaz M, Burger JA, Estrov ZE, Verstovsek S, Andreeff M, Bose P, Ferrajoli A, Thompson PA, Montalbano K, Vaughan K, Bivins CA, Pierce SA, Qiao W, Ning J, Welch J, Kantarjian H, Konopleva M. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. Blood 138 (Supplement 1):1270, 2021. e-Pub 2021.
Haddad F, Kantarjian H, Short NJ, Sasaki K, Ravandi F, Kebriaei P, Huang X, Jain N, Konopleva M, Garcia-Manero G, Champlin RE, Kadia TM, Takahashi K, Daver N, Khoury JD, Jorgensen JL, Wang SA, Jacob J, Garris, O'Brien SM, Jabbour EJ. Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. Blood 138 (Supplement 1):3383, 2021. e-Pub 2021.
Rivera D, Kadia TM, Montalban-Bravo G, Faderl S, Sasaki K, Short NJ, Daver N, DiNardo CD, Masarova L, Ferrajoli A, Jabbour EJ, Borthakur G, Al Azzawi H, Konopleva M, Garcia-Manero G, Andreeff M, Kantarjian H, Ravandi F, Alvarado Y. Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). Blood 138 (Supplement 1):2323, 2021. e-Pub 2021.
Darbaniyan F, Class C, Montalban-Bravo G, Kanagal-Shamanna R, Estecio M, Lu Y, Soltysiak KA, Chien KS, Yang H, Sasaki K, Ganan-Gomez I, Colla S, Do KA, Garcia-Manero G, Wei Y. Transcriptomic Signitures of Azacitidine (AZA) and Decitabine (DAC) Resistance in MDS and CMML. Blood 138 (Supplement 1):4652, 2021. e-Pub 2021.
Venugopal S, Chien KS, Hammond D, Kanagal-Shamanna R, Sasaki K, Kadia TM, DiNardo CD, Konopleva M, Daver N, Ravandi F, Pemmaraju N, Short NJ, Issa GC, Takahashi K, Estrov ZE, Pierce SA, Kantarjian H, Garcia-Manero G, Montalban-Bravo G. Outcomes of Patients with Chronic Myelomonocytic Leukemia (CMML) Treated with Hypomethylating Agents. Blood 138 (Supplement 1):2613, 2021. e-Pub 2021.
Lachowiez C, DiNardo CD, Takahashi K, Loghavi S, L-C X, Kadia TM, Daver N, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa GC, Maiti A, Alvarado Y, Pemmaraju N, Montalban-Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau SM, Ravandi F, Jabbour EJ, Konopleva M, Kantarjian H. Venetoclax Combined with FLAG-IDA Induction and Consolidation in Newly Diagnosed Acute Myeloid Leukemia. Blood 138 (Supplement 1):701, 2021. e-Pub 2021.
Mohamed SF, Pemmaraju N, Sasaki K, Borthakur G, Abuasba T, Khan M, Hwang H, Wang X, Verstovsek S, Busaidy N. General Characteristics and Association of Myeloid Neoplasm with Thyroid Cancer. Blood 138 (Supplement 1):4634, 2021. e-Pub 2021.
Pemmaraju N, Wilson NR, Garcia-Manero G, Sasaki K, Khoury JD, Jain N, Borthakur G, Ravandi F, Daver N, Kadia TM, DiNardo CD, Jabbour EJ, Pierce SA, Villarreal J, Qazilbash MH, Konopleva M, Kantarjian H. Outcomes for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated with Frontline HCVAD-Based Chemotherapy. Blood 138 (Supplement 1):2319, 2021. e-Pub 2021.
Short NJ, DiNardo CD, Daver N, Nguyen D, Yilmaz M, Kadia TM, Garcia-Manero G, Issa GC, Huang X, Qiao W, Sasaki K, Montalban-Bravo G, Chien KS, Borthakur G, Delumpa R, Milton A, Pierce SA, Jabbour EJ, Konopleva M, Kantarjian H, Ravandi F. A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study. Blood 138 (Supplement 1):696, 2021. e-Pub 2021.
Maiti A, DiNardo CD, Rausch CR, Pemmaraju N, Garcia-Manero G, Ohanian M, Daver N, Issa, GC, Borthakur G, Ravandi F, Alvarado Y, Kadia TM, Jabbour EJ, Short NJ, Montalban-Bravo G, Jain N, Kornblau SM, Masarova L, Wierda WG, Sasaki K, Takahashi K, Yilmaz M, Burger JA, Estrov ZE, Verstovsek S, Andreeff M, Bose P, Ferrajoli A, Thompson PA, Montalbano K, Vaughan K, Bivins CA, Pierce SA, Qiao W, Ning J, Welch JS, Kantarjian H, Konopleva M. Outcomes of Relapsed or Refractory Acute Myeloid Leukemia After Frontline Hypomethylating Agent and Venetoclax Regimens. Blood 138, 2021. e-Pub 2021.
Daver N, Konopleva M, Maiti A, Kadia TM, DiNardo CD, Loghavi S, Pemmaraju N, Jabbour EJ, Montalban-Bravo G, Tang G, Sasaki K, Borthakur G, Yilmaz M, Alvarez J, Golez M, Pierce SA, Nogueras González GM, Ning J, Abbas HA, Ravandi F, Garcia-Manero G, Kantarjian H. Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML. Blood 138 (Supplement 1):371, 2021. e-Pub 2021.
Cherng H-J H, Khwaja R, Kanagal-Shamanna R, Burger JA, Thompson PA, Ferrajoli A, Estrov ZE, Sasaki K, Sampath D, Tang G, Wang X, Kantarjian H, Keating MJ, Wierda WG, Jain N. Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton’s Tyrosine Kinase Inhibitor-Based Therapy. Blood 138 (Supplement 1):394, 2021. e-Pub 2021.
Maiti A, DiNardo CD, Rausch CR, Pemmaraju N, Garcia-Manero G, Ohanian M, Daver N, Issa GC, Borthakur G, Ravandi F, Alvarado Y, Kadia TM, Jabbour EJ, Short NJ, Montalban-Bravo G, Jain N, Kornblau SM, Masarova L, Wierda WG, Sasaki K, Takahashi K, Yilmaz M, Burger JA, Estrov ZE, Verstovsek S, Andreeff M, Bose P, Ferrajoli A, Thompson PA, Montalbano K, Vaughan K, Bivins CA, Pierce SA, Qiao W, Ning J, Welch JS, Kantarjian H, Konopleva M. Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups. Blood 138 (Supplement 1):694, 2021. e-Pub 2021.
Short NJ, Kantarjian H, Alvarado Y, Burger JA, Jain N, Konopleva M, Ravandi F, DiNardo CD, Masarova L, Sasaki K, Thompson PA, Ferrajoli A, Jacob J, Milton A, Garris R, Jabbour EJ. A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia. Blood 138 (Supplement 1):2299, 2021. e-Pub 2021.
Reville PK, Kantarjian H, Borthakur G, Pemmaraju N, DiNardo CD, Sasaki K, Daver N, Issa GC, Ohanian M, Montalban-Bravo G, Short NJ, Jain N, Bhalla KN, Jabbour EJ, Ferrajoli A, Takahashi K, Rausch CR, Malla R, Marek K, Brandt M, Popat UR, Andreeff M, Garcia-Manero G, Konopleva M, Ravandi F, Kadia TM. Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 138 (Supplement 1):367, 2021. e-Pub 2021.
Venugopal S, Issa GC, Konopleva M, DiNardo CD, Borthakur G, Jabbour EJ, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce SA, Takahashi K, Tang G, Loghavi S, Andreeff M, Bhalla KN, Garcia-Manero G, Ravandi F, Kantarjian H, Daver N. NPM1 Mutations Do Not Retain a Favorable Prognostic Impact in Adults with Advanced Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML). Blood 138 (Supplement 1):2287, 2021. e-Pub 2021.
Kim K, Chien KS, Ong F, Kadia TM, Jabbour EJ, Alvarado Y, Sasaki K, Bueso-Ramos CE, Kanagal-Shamanna R, Montalban-Bravo G, Dong XQ, Pierce SA, Kantarjian H, Garcia-Manero G. Clinical and Pathological Characteristics of Hypocellular Myelodysplastic Syndrome: A Single-Center Retrospective Study. Blood 138 (Supplement 1):1527, 2021. e-Pub 2021.
Short NJ, Montalban-Bravo G, Alvarado Y, Konopleva M, Jabbour EJ, Garcia-Manero G, Yilmaz M, Jain N, Borthakur G, DiNardo CD, Daver N, Issa GC, Ohanian M, Pemmaraju N, Sasaki K, Maiti A, Chien KS, Ravandi F, Kadia TM, Andreeff M, Muftuoglu M, Delumpa R, Bose P, Pierce SA, Waller L, Banks G, Kantarjian H, Cortes JE. Azacitidine, Venetoclax and Pevonedistat As Frontline Therapy for Patients with Secondary Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Results from a Phase I/II Study. Blood 138 (Supplement 1):2349, 2021. e-Pub 2021.
Haddad F, Kantarjian H, Jabbour EJ, Issa GC, Garcia-Manero G, Ravandi F, Konopleva M, Ferrajoli A, Kadia TM, Pemmaraju N, Takahashi K, Alvarado Y, Yilmaz M, Borthakur G, DiNardo CD, Jain N, Daver N, Short NJ, Pierce SA, Cortes JE, Sasaki K. Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Following the Discontinuation of Tyrosine Kinase Inhibitors. Blood 138 (Supplement 1):1480, 2021. e-Pub 2021.
Mauro MJ, Minami Y, Rea D, Hochhaus A, Lomaia E, Voloshin S, Turkina AG, D-W K, Apperley JF, Cortes JE, Abdo ANR, Fogliatto L, DDH, Kim H, le Coutre PD, Saussele S, Annunziata M, Hughes TP, Chaudhri NA, Chee LCY, Gutierrez VG, Sasaki K, Kapoor S, Allepuz A, Quenet S, Bédoucha V, Boquimpani C. Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks. Blood 138 (Supplement 1):310, 2021. e-Pub 2021.
Bazinet A, Kantarjian H, Borthakur G, Yilmaz M, Bose P, Jabbour EJ, Alvarado Y, Chien KS, Pemmaraju N, Takahashi K, Short NJ, Issa GC, Jain N, Ferrajoli A, Burger JA, Linderman DB, Daver N, DiNardo CD, Konopleva M, Garcia-Manero G, Sasaki K, Ravandi F, Kadia TM. A Phase II Study of 5-Azacytidine (AZA) and Venetoclax As Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission. Blood 138 (Supplement 1):2326, 2021. e-Pub 2021.
Mohamed SF, Khan M, Quesada A, Ma J, Lin P, Yin CC, Sasaki K, Borthakur G, Pemmaraju N, Bashir Q, Qazilbash MH, Kaufman GR, Becnel MR. Disease Characteristics of Multiple Myeloma Involving BRAF Mutations. Blood 138 (Supplement 1):4755, 2021. e-Pub 2021.
Sasaki K, Jabbour E, Issa G, Garcia-Manero G, Kadia T, Wierda W, Yilmaz M, DiNardo CD, Skinner J, Khouri M, Pemmaraju N, Nasnas PE, Pierce S, Cortes J, Kantarjian H. Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-line Tyrosine Kinase Inhibitors. The Japanese Society of Hematology Annual Meeting, 2021. e-Pub 2021.
Smith BD, Cortes JE, Rea D, Mauro MJ, Patwardhan P, Maegawa R, Zacker C, Corbin R, Keeping S, Sasaki K. Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial. Clin Lymphoma Myeloma Leuk 21 Suppl 2, 2021. e-Pub 2021.
Venugopal S, DiNardo C, Takahashi K, Konopleva M, Loghavi S, Borthakur G, DeZern A, Masarova L, Daver N, Short NJ, Alvarado Y, Ravandi F, Montalban-Bravo G, Sasaki K, Delumpa R, Sekeres MA, Patel B, Roboz GJ, Kantarjian H, Garcia-Manero G. Phase Ii Study Of The Idh2-Inhibitor Enasidenib In Patients With High-Risk Idh2-Mutated Myelodysplastic Syndromes (MDS). European Hematology Association Annual Meeting, 2021. e-Pub 2021.
Venugopal S, DiNardo CD, Takahashi K, Konopleva M, Loghavi S, Borthakur G, Dezern AE, Masarova L, Daver NG, Short NJ, Alvarado Y, Ravandi F, Montalban-Bravo G, Sasaki K, Delumpa R, Sekeres MA, Patel BJ, Roboz GJ, Kantarjian HM, Garcia-Manero G. Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS). J Clin Oncol 39 Suppl:7010, 2021. e-Pub 2021.
Hammond D, Sasaki K, Geppner A, Haddad F, Mohamed S, Rivera D, Siddiqui M, Alwash Y, Perez JR, Morita K, Kim K, Pierce S, Gutierrez C, Pemmaraju N, Borthakur G, DiNardo CD, Ravandi F, Garcia-Manero G, Kantarjian HM, Kadia TM. Contemporary outcomes for adults with AML requiring ICU admission. J Clin Oncol 39 Suppl:7025, 2021. e-Pub 2021.
Short NJ, Kantarjian HM, Konopleva M, Jain N, Huang X, Ravandi F, Wierda WG, Borthakur G, Sasaki K, Issa GC, Alvarado Y, Pemmaraju N, Garcia-Manero G, Thankachan J, Garris R, Jabbour E. Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study. J Clin Oncol 39(Suppl 15), 2021. e-Pub 2021.
Short NJ, Kanagal Shamanna R, Sasaki K, Ravandi F, Cortes J, Konopleva M, Issa GC, Kornblau SM, Garcia-Manero G, Garris RS, Higgins J, Pratt G, Williams L, Valentine C, Rivera V, Salk J, Radich J, Kantarjian HM, Jabbour EJ. Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia. Blood 136 (Supplement 1):21-23, 2020. e-Pub 2020.
Morita K, Kantarjian HM, Montalban Bravo G, Sasaki K, Bodden KR, Wang F, Bose P, Alvarado Y, Daver N, Borthakur G, Ravandi F, Takahashi K, Jabbour E, DiNardo CD, Pemmaraju N, Kadia TM, Ohanian M, Pierce SA, Azab M, Garcia-Manero G. Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression. Blood 136 (Supplement 1):38-40, 2020. e-Pub 2020.
Montalban Bravo G, Darbanien F, Kanagal-Shamanna R, Guerra VA, Ramos Perez JM, Hammond D, Paul S, Naqvi K, Sasaki K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov ZE, Khoury JD, Loghavi S, Pierce SA, Bueso-Ramos CE, Patel K, Kantarjian HM, Garcia-Manero G. Transcriptomic Features and Deregulation of Genes Involved in Monopoiesis Influence Outcomes of Patients with Chronic Myelomonocytic Leukemia. Blood 136 (Supplement 1):50-51, 2020. e-Pub 2020.
Sasaki K, Jabbour E, Montalban Bravo G, Short NJ, Kanagal-Shamanna R, Kadia TM, Borthakur G, Pemmaraju N, Cortes JE, Ravandi F, Alvarado Y, Chien KS, Yang H, Kantarjian HM, Garcia-Manero G. The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score AnalysisClinically Relevant Abstract. Blood 136 (Supplement 1):3-5, 2020. e-Pub 2020.
Morita K, Montalban Bravo G, Sasaki K, Bodden KR, Wang F, Bose P, Alvarado Y, Daver N, Borthakur G, Ravandi F, Takahashi K, Jabbour E, DiNardo CD, Pemmaraju N, Kadia TM, Ohanian M, Pierce SA, Azab M, Kantarjian HM, Garcia-Manero G. A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). Blood 136 (Supplement 1):7-9, 2020. e-Pub 2020.
Darbaniyan F, Montalban Bravo G, Wei Y, Kanagal-Shamanna R, Sasaki K, Yang H, Soltysiak KA, Chien KS, K-A D, Garcia-Manero G. Impact of Hemoglobin Level As a Continuous Variable in Calculating Prognosis in MDS: Incorporation into LSC4 and IPSS-R. Blood 136 (Supplement 1):36-37, 2020. e-Pub 2020.
Reville PK, Nogueras González GM, Ravandi F, Sasaki K, Borthakur G, Garcia-Manero G, Daver N, DiNardo CD, Jabbour E, Pemmaraju N, Andreeff M, Verstovsek S, Ferrajoli A, Jain N, Ohanian M, Pierce SA, Estrov ZE, Konopleva M, Kantarjian HM, Kadia TM. Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort. Blood 136 (Supplement 1):44-45, 2020. e-Pub 2020.
Rafei H, Kantarjian HM, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Wang SA, Jorgensen JL, Khouri IF, Kebriaei P, Jain N, Dabaja BS, Alvarado Y, Kadia TM, Paul S, Chew S, Garcia-Manero G, Burger JA, DiNardo CD, Daver N, Montalban-Bravo G, Yilmaz M, Ohanian M, Khouri M, Thompson PA, Jacob J, Rostykus M, Garris R, Konopleva M, O'Brien SM, Jabbour E. Role of Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 Study. Blood 136 (Supplement 1):39-41, 2020. e-Pub 2020.
H-JJ C, Jammal N, Paul S, Wang X, Sasaki K, Thompson PA, Burger JA, Ferrajoli A, Estrov ZE, O'Brien SM, Keating MJ, Wierda WG, Jain N. Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia. Blood 136 (Supplement 1):5-6, 2020. e-Pub 2020.
Kanagal-Shamanna R, Montalban Bravo G, Katsonis P, Sasaki K, Class C, Benton CB, Jabbour E, Chien KS, Luthra R, Bueso-Ramos CE, Kadia TM, Andreeff M, Short NJ, Daver N, Routbort M, Khoury JD, Patel K, Ganan-Gomez I, Wei Y, Borthakur G, Ravandi F, K-A D, Soltysiak KA, Lichtarge O, Medeiros LJ, Kantarjian HM, Garcia-Manero G. Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable Prognosis. Blood 136 (Supplement 1):4-5, 2020. e-Pub 2020.
Hammond D, DiNardo CD, Konopleva M, Borthakur G, Ramos Perez JM, Guerra VAS, Kanagal-Shamanna R, Paul S, Naqvi K, Sasaki K, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Estrov ZE, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Activity of Venetoclax-Based Therapy in CMML and CMML with Blast Transformation. Blood 136 (Supplement 1):36-37, 2020. e-Pub 2020.
Montalban Bravo G, Kanagal-Shamanna R, Guerra VA, Ramos Perez JM, Hammond D, Paul S, Naqvi K, Sasaki K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov ZE, Khoury JD, Loghavi S, Pierce SA, Bueso-Ramos CE, Patel K, Kantarjian HM, Garcia-Manero G. Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia. Blood 136 (Supplement 1):28-29, 2020. e-Pub 2020.
Guerra VA, Alwash Y, Yuanqing Y, Ramos Perez JM, Richard-Carpentier G, Alotaibi AS, Ahaneku HO, Samra B, Raghunath A, Jain N, Short NJ, Ravandi F, Borthakur G, Ferrajoli A, Sasaki K, Kornblau SM, Estrov ZE, Cortes JE, Kantarjian HM, Garcia-Manero G, Jabbour E, Kadia TM. Risk Factors Associated with 30-Day Unplanned Readmissions for Adult Acute Lymphoblastic Leukemia (ALL). Blood 136 (Supplement 1):3-4, 2020. e-Pub 2020.
Siddiqui MT, Kanagal-Shamanna R, Naqvi K, Sasaki K, Masarova L, Jabbour E, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Pierce SA, Verstovsek S, Bose P, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series. Blood 136 (Supplement 1):18-19, 2020. e-Pub 2020.
Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Bueso-Ramos CE, Jabbour E, Wei Y, Darbaniyan F, Routbort M, Pierce SA, Soltysiak KA, Patel K, Medeiros LJ, Kantarjian HM, Garcia-Manero G. Only Hotspot SF3B1 K700E Mutation Is an Independent Predictor of Overall Survival in Myelodysplastic Syndromes. Blood 136 (Supplement 1):24-25, 2020. e-Pub 2020.
Ramos Perez JM, Kadia TM, Montalban-Bravo G, Faderl S, Sasaki K, Daver N, DiNardo CD, Masarova L, Ferrajoli A, Jabbour E, Borthakur G, Al Azzaw H, Pemmaraju N, Konopleva M, Pierce SA, Garcia-Manero G, Andreeff M, Kantarjian HM, Ravandi F, Alvarado Y. Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). Blood 136 (Supplement 1):32-34, 2020. e-Pub 2020.
Lachowiez C, Konopleva M, Kadia TM, Daver N, Loghavi S, Wang SA, Adeoti M, Pierce SA, Takahashi K, Short NJ, MD, Sasaki K, Borthakur G, Issa GC, Wierda WG, Pemmaraju N, Montalban Bravo G, Ferrajoli A, Jain N, Masarova L, Yilmaz M, Jabbour E, Garcia-Manero G, Kornblau SM, Ravandi F, Kantarjian HM, Dinardo CD. Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AM. Blood 136 (Supplement 1):18-20, 2020. e-Pub 2020.
Montalban Bravo G, Kanagal-Shamanna R, Guerra VA, Ramos Perez JM, Hammond D, Paul S, Naqvi K, Sasaki K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov ZE, Khoury JD, Loghavi S, Pierce SA, Bueso-Ramos CE, Patel K, Kantarjian HM, Garcia-Manero G. Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS). Blood 136 (Supplement 1):18-19, 2020. e-Pub 2020.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Sasaki K, Fowler NH, Kadia TM, Konopleva M, Alvarado Y, Yilmaz Y, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen JL, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala, A Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. Blood 136 (Supplement 1):42-43, 2020. e-Pub 2020.
Sasaki Y, Kantarjian HM, Short NJ, Jain N, Sasaki K, Ravandi F, Konopleva M, Guillermo Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Wang F, Furudate K, Garris R, Takahashi K, Jabbour E. Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib. Blood 136 (Supplement 1):40-41, 2020. e-Pub 2020.
Rafei H, Kantarjian HM, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Wang SA, Jorgensen JL, Khouri IF, Kebriaei P, Jain N, Dabaja BS, Alvarado Y, Kadia TM, Paul S, Chew S, Garcia-Manero G, Burger JA, DiNardo CD, Daver N, Montalban-Bravo G, Yilmaz M, Ohanian M, Khouri M, Thompson PA, Jacob J, Rostykus M, Garris R, Konopleva M, O'Brien SM, Jabbour E. Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse. Blood 136 (Supplement 1):36-38, 2020. e-Pub 2020.
Perez JMR, Guerra VA, Hammond D, Chien KS, Kanagal-Shamanna R, Naqvi K, Sasaki K, Paul S, Kadia TM, DiNardo CD, Konopleva M, Daver N, Ravandi F, Pemmaraju N, Short NJ, Takahashi K, Estrov ZE, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Response and Survival Outcomes with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia Based on Disease Phenotype and Risk Categories. Blood 136 (Supplement 1):8-9, 2020. e-Pub 2020.
Issa GC, Zarka J, Sasaki K, Pak D, Ning J, Short NJ, Jabbour E, Kadia TM, Borthakur G, Garcia-Manero G, Andreeff M, Kantarjian HM, Ravandi F. Predictors of Outcomes in Adult AML with MLL Rearrangements. Blood 136 (Supplement 1), 2020. e-Pub 2020.
Morita K, Sasaki K, Richard-Carpentier G, Konopleva M, Huang X, Short NJ, Jain N, Ravandi F, Dabaja BS, Daver N, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang SA, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Takahashi K, O'Brien SM, Kantarjian HM, Jabbour EJ. Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis. Blood 136 (Supplement 1):42-43, 2020. e-Pub 2020.
Sasaki K, Kantarjian HM, Ravandi F, Short NJ, Jain N, Konopleva M, Guillermo Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Wang F, Furudate K, Garris R, Takahashi K, Jabbour E. Long-Term Follow-up of the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed-Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Trial. Blood 136 (Supplement 1):40-42, 2020. e-Pub 2020.
Rafei H, Kantarjian HM, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Wang SA, Jorgensen JL, Khouri IF, Kebriaei P, Jain N, Dabaja BS, Alvarado Y, Kadia TM, Paul S, Chew S, Garcia-Manero G, Burger JA, DiNardo CD, Daver N, Montalban-Bravo G, Yilmaz M, Ohanian M, Khouri M, Thompson PA, Jacob J, Rostykus M, Garris R, Konopleva M, O'Brien SM, Jabbour E. Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. Blood 136 (Supplement 1):45-47, 2020. e-Pub 2020.
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Short NJ, Issa GC, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov ZE, Khoury JD, Loghavi S, Pierce SA, Bueso-Ramos CE, Patel K, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero G. Clinicopathologic Correlates and Natural History of Atypical Chronic Myeloid Leukemia. Blood 136 (Supplement 1):54-56, 2020. e-Pub 2020.
Montalban-Bravo G, Jabbour E, Kadia TM, Ravandi F, Estrov ZE, Naqvi K, Sasaki K, Chien KS, González GMN, Dong XQ, Faderl S, Schneider H, John RB, Kantarjian HM, Garcia-Manero G. Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents. Blood 136 (Supplement 1):1-3, 2020. e-Pub 2020.
Morita K, Montalban Bravo G, Sasaki K, Bodden KR, Wang F, Bose P, Alvarado Y, Daver N, Borthakur G, Ravandi F, Takahashi K, Jabbour E, DiNardo CD, Pemmaraju N, Kadia TM, Ohanian M, Pierce SA, Azab M, Kantarjian HM, Garcia-Manero G. Long-Term Follow up of a Phase II Study of Guadecitabine (SGI-110) in Patients with Higher-Risk Myelodysplastic Syndrome (MDS). Blood 136 (Supplement 1):21-22, 2020. e-Pub 2020.
Morita K, Kantarjian HM, Montalban Bravo G, Sasaki K, Bodden KR, Wang F, Bose P, Alvarado Y, Daver N, Borthakur G, Ravandi F, Takahashi K, Jabbour E, DiNardo CD, Pemmaraju N, Kadia TM, Ohanian M, Pierce SA, Azab M, Garcia-Manero G. Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and Dasatinib. Blood 136 (Supplement 1):46-48, 2020. e-Pub 2020.
Kadia TP, Borthakur G, Pemmaraju N, Daver N, DiNardo CD, Sasaki K, Issa GC, Ohanian M, Montalban Bravo G, Short NJ, Jain N, Ferrajoli A, Bhalla KN, Jabbour E, Kanagal-Shamanna R, Takahashi K, Malla R, Kelly M, Brandt M, Popat UR, Andreeff M, Cortes JE, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian HM. Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 136 (Supplement 1):17-19, 2020. e-Pub 2020.
Maiti A, Jabbour E, Jain N, Borthakur G, Kadia TM, Burger JA, Wierda WG, Konopleva M, Alvarado Y, Short NJ, Faderl S, O'Brien SM, Ferrajoli A, Kornblau SM, Daver N, Pemmaraju N, Bose P, Thompson PA, Khoury JD, Balkin H, Kelly M, Azzawi H, Garris R, Garcia-Manero G, Kantarjian HM, Ravand F. Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia. Blood 136 (Supplement 1):22-25, 2020. e-Pub 2020.
Rafei H, Kantarjian HM, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Wang SA, Jorgensen JL, Khouri IF, Kebriaei P, Jain N, Dabaja BS, Alvarado Y, Kadia TM, Paul S, Chew S, Garcia-Manero G, Burger JA, DiNardo CD, Daver N, Montalban-Bravo G, Yilmaz M, Ohanian M, Khouri M, Thompson PA, Jacob J, Rostykus M, Garris R, Konopleva M, O'Brien SM, Jabbour E. CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. Blood 136 (Supplement 1):23-25, 2020. e-Pub 2020.
Guerra VA, Ramos Perez JM, Hammond D, Chien KS, Kanagal-Shamanna R, Naqvi K, Sasaki K, Paul S, Kadia TM, DiNardo CD, Konopleva M, Daver N, Ravandi F, Pemmaraju, P Short NJ, Issa GC, Takahashi K, Estrov ZE, Pierce SA, Kantarjian HM, Garcia-Manero G, Montalban Bravo G. Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure. Blood 136 (Supplement 1):22-23, 2020. e-Pub 2020.
Sasaki K, Jabbour E, Montalban Bravo G, Short NJ, Kanagal-Shamanna R, Kadia TM, Borthakur G, Pemmaraju N, Cortes JE, Ravandi F, Alvarado Y, Chien KS, Yang H, Kantarjian HM, Garcia-Manero G. Long-Term Outcome of Low-Dose Hypomethylating Agents in Lower-Risk Myelodysplastic Syndromes: A Randomized Phase 2 Study. Blood 136 (Supplement 1):46-47, 2020. e-Pub 2020.
Sasaki K, Kantarjian HM, Ravandi F, Short NJ, Jain N, Konopleva M, Guillermo Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Wang F, Furudate K, Garris R, Takahashi K, Jabbour E. A Prognostic Model for Survival in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia on the Combination of Low-Intensity Chemotherapy Plus Inotuzumab Ozogamicin with or without Blinatumomab. Blood 136 (Supplement 1):2-4, 2020. e-Pub 2020.
Hochhaus A, Boquimpani C, Rea D, Minami Y, Lomaia E, Voloshin S, Turkina AG, D-W K, Apperley J, Cortes JE, Abdo A, Fogliatto LM, Kim DDH, le Coutre PD, Saussele S, Annunziata M, Hughes TP, Chaudhri NA, Chee LCY, García Gutiérrez V, Sasaki K, Aimone P, Allepuz A, Quenet S, Bédoucha V, Mauro MJ. Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs. Blood 136 (Supplement 2):LBA-4, 2020. e-Pub 2020.
Daver N, Basu S, Garcia-Manero G, Abbas HA, Konopleva M, Kadia TM, DiNardo CD, Borthakur G, Alotaibi AS, Pemmaraju N, Jabbour E, Pierce SA, Brandt M, Takahashi K, Ning J, Kornblau SM, Sasaki K, Yilmaz M, Issa GC, Short NJ, Matthews JA, Flores W, Andreeff M, Cortes JE, Ravandi F, Allison JP, Kantarjian HM, Sharma P. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response. Blood 136 (Supplement 1):43-45, 2020. e-Pub 2020.
Sasaki K, Kantarjian HM, Issa GC, Garcia-Manero G, Kadia TM, Wierda WG, Yilmaz M, DiNardo CD, Skinner J, Khouri R, Pemmaraju N, Nasnas P, Dellasala SE, Pierce SA, Cortes JE, Jabbour E. Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors. Blood 136 (Supplement 1):42-44, 2020. e-Pub 2020.
Sasaki K, Jabbour E, Montalban Bravo G, Short NJ, Kanagal-Shamanna R, Kadia TM, Borthakur G, Pemmaraju N, Cortes JE, Ravandi F, Alvarado Y, Chien KS, Yang H, Kantarjian HM, Garcia-Manero G. Outcomes of Patients with Chronic Myeloid Leukemia Treated with Third-Line Tyrosine Kinase Inhibitors. Blood 136 (Supplement 1):25-26, 2020. e-Pub 2020.
Abbas HA, Reville PK, Geppner A, Ohanian M, Sasaki K, Borthakur G, Daver N, DiNardo CD, Bueso-Ramos CE, Andreeff M, Short NJ, Pierce SA, Jabbour E, Garcia-Manero G, Konopleva M, Ravandi F, Kantarjian HM, Kadia TM. Clinical Course, Outcomes and Genetic Characterization of Patients with Isolated Myeloid Sarcoma. Blood 136 (Supplement 1):25-26, 2020. e-Pub 2020.
Sasaki Y, Short N, Kantarjian H, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva M, Rytting M, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal A, Wang F, Takahashi K, Jabbour E. Novel prognostic factor IKZF1 add for Ph+ B-ALL treated with hyper-CVAD plus dasatinib or ponatinib. The Japanese Society of Hematology, Annual Meeting, 2020. e-Pub 2020.
Sasaki K, Kantarjian H, Ravandi F, Short N, Daver N, Pemmaraju N, Thomas D, Yilmaz M, Kadia T, Garris R, Garcia-Manero G, DiNardo C, Konopleva M, Estrov Z, Jain N, Wierda W, Jeanis V, Cortes J, Obrien S, Jabbour E. The combination of intensive therapy with ponatinib for newly diagnosed Ph+ ALL. The Japanese Society of Hematology, Annual Meeting, 2020. e-Pub 2020.
Sasaki K, Jabbour E, Naqvi K, Skinner J, Anderson K, Dellasala S, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Pierce S, Cortes J, Kantarjian H. Low-dose Dasatinib 50 mg Daily versus Standard-dose Dasatinib 100 mg Daily in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score Analysis. Clin Lymphoma Myeloma Leuk 20 Suppl 2, 2020. e-Pub 2020.
Sasaki K, Kantarjian H, Samra B, Short N, Khoury J, Kanagal R, Konopleva M, Jain N, DiNardo C, Khouri R, Garcia-Manero G, Kadia T, Wierda W, Tippett N, Garris R, Jeanis V, Daver N, Thompson P, Yilmaz M, Cortes J, O’Brien S, Ravandi F, Jabbour E. Outcomes of Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Molecular Response at Three Months of Therapy. Clin Lymphoma Myeloma Leuk 20 Suppl 2, 2020. e-Pub 2020.
Sakurai K, Kantarjian HM, Sasaki K, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Wierda WG, Daver NG, Takahashi K, Naqvi K, DiNardo CD, Montalban-Bravo G, Issa GC, Jain P, Pierce SA, Soltysiak KA, Garcia-Manero G, Tingen MS, Cortes JE. Geographic disparity of outcome in patients with cancer over decades: The surveillance, epidemiology, and end results. J Clin Oncol 38 Suppl:1574, 2020. e-Pub 2020.
Zarka J, Issa GC, Sasaki K, Short NJ, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Kantarjian H, Ravandi F. CHARACTERISTICS AND CLINICAL OUTCOMES OF MLL REARRANGEMENTS IN ADULTS WITH AML. European Hematology Association:EP549, 2020. e-Pub 2020.
Maiti A, DiNardo C, Kadia T, Rausch C, Pemmaraju N, Daver N, Borthakur G, Naqvi K, Ohanian M, Short N, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau S, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa G, Jabbour E, Masarova L, Thompson P, Pierce S, Garcia-Manero G, Ravandi F, Welch J, Qiao W, Ning J, Kantarjian H, Konopleva M. 10-DAY DECITABINE AND VENETOCLAX (DEC10-VEN) VS. INTENSIVE CHEMOTHERAPY (IC) IN ACUTE MYELOID LEUKEMIA (AML): A PROPENSITY SCORE MATCHED ANALYSIS STRATIFIED BY RISK OF TREATMENT-RELATED MORTALITY. European Hematology Association Annual Meeting, 2020. e-Pub 2020.
Kanagal-Shamanna R, Montalban-Bravo G, Sasaki K, Class C, Benton C, Jabbour E, Kadia T, Routbort M, Bueso-Ramos C, Khoury J, Patel K, Do KA, Soltysiak K, Medeiros LJ, Kantarjian H, Garcia-Manero G. EVOLUTIONARY ACTION SCORE OF MISSENSE TP53 MUTATIONS (EAP53) IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN MYELODYSPLASTIC SYNDROMES. European Hematology Association, 2020. e-Pub 2020.
Sasaki K, Kantarjian HM, Jabbour E, Ravandi F, Borthakur G, Wierda W, Takahashi K, Naqvi K, Montalban-bravo G, Kanagal-Shamanna R, Pemmaraju N, Issa GC, Jain P, Skinner J, Rios MB, Pierce SA, Soltysiak K, Sato J, Garcia-Manero G, Cortes JE. Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur GM, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Benton CB, Kadia TM, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour E, Masarova L, Rytting ME, Thompson PA, Wang SA, Konoplev S, Chen Z, Goswami M, Maduike R, Guerrero JA, Zhang Q, Cavazos A, Ma H, Bivins CA, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Patel KP, Kantarjian HM, Konopleva MY, DiNardo CD. Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Chien KS, Kanagal-Shamanna R, Naqvi K, Koji Sasaki K, Alvarado Y, Takahashi K, Kadia TM, Borthakur GM, Jabbour E, Routbort M, Pierce SA, Soltysiak K, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. The Impact of PHF6 Mutations in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Jabbour E, Roberts KG, Sasaki K, Zhao Y, Qu C, Gu Z, Jain N, Patel KP, Ravandi F, Short NJ, Garcia-Manero G, Garris R, Kornblau S, Konopleva MY, Mullighan CG, Kantarjian HM. Inotuzumab Ozogamicin (Ino) May Overcome the Impact of Philadelphia Chromosome (Ph)-like Phenotype in Adult Patients (pts) with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Sasaki Y, Short NJ, Kantarjian HM, Garris R, Jain N, Sasaki K, Ravandi F, Konopleva MY, Rytting ME, Garcia-Manero G, Little L, Gumbs C, Zhao L, Futreal PA, Wang F, Takahashi K, Jabbour E. Prognostic Significance of IKZF1, PAX5, and CDKN2A Deletions in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD/MA with Dasatinib or Ponatinib. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Masarova L, Verstovsek S, Bose P, Pemmaraju N, Cortes JE, Jabbour E, Ohanian M, Zhou L, Pierce SA, Gergis R, Borthakur GM, Kadia TM, DiNardo CD, Ravandi F, Konopleva MY, Naqvi K, Sasaki K, Estrov ZE, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver NG. Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Kadia TM, Cortes JE, Konopleva MY, Borthakur GM, Pemmaraju N, Daver NG, Montalban Bravo G, Issa GC, Naqvi K, Short NJ, DiNardo CD, Bhalla KN, Jabbour E, Takahashi K, Sasaki K, Kornblau SM, Malla B, Pierce SA, Wang X, Estrov ZE, Andreeff M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Guerra VA, Kantarjian HM, Cortes JE, Garcia-Manero G, Masarova L, Pemmaraju N, Jabbour E, Kadia TM, DiNardo CD, Zhou L, Pierce SA, Borthakur GM, Wierda WG, Ferrajoli A, Sasaki K, Takahashi K, Naqvi K, Alvarado Y, Ohanian MN, Jain N, Bose P, Ravandi F, Konopleva MY, Estrov ZE, Verstovsek S, Daver NG. A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes JE, Daver NG, Takahashi K, DiNardo CD, Jabbour E, Borthakur GM, Naqvi K, Konopleva MY, Pierce SA, Bueso-Ramos CE, Patel KP, Kantarjian HM, Garcia-Manero G, Kadia TM. Outcomes of Patients with Acute Myeloid Leukemia with Myelodysplastic Are Dependent on Diagnostic Criteria and Therapy. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Kantarjian HM, Richard-Carpentier G, Borthakur GM, Ravandi F, Naqvi K, Sasaki K, Kadia TM, Verstovsek S, Garcia-Manero G, DiNardo CD, Pemmaraju N, Daver NG, Bose P, Pierce SA, Dara S, Jabbour E, Shoukier M, Cortes JE. Effectiveness of Bosutinib in Chronic Myeloid Leukemia (CML) Who Have Received Multi Tyrosine Kinase Inhibitors (TKIs). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Sasaki K, J-M R, Figueroa M, Ravandi F, Short NJ, Garcia-Manero G, Kadia TM, Konopleva MY, Jain N, Issa GC, Estrov ZE, Garris R, Khouri R, Nasnas P, DiNardo CD, Naqvi K, Kornblau SM, Montalban-Bravo G, Pemmaraju N, Cortes JE, O'Brien SM, Chandra J, Kantarjian HM, Jabbour E. The Impact of Smoking on Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Richard-Carpentier G, Kantarjian HM, Konopleva MY, Patel KP, Roberts KG, Gu Z, Ravandi F, Jain N, Short NJ, Garcia-Manero G, Schroeder HM, Kwari M, Garris R, Khouri R, Jones M, Loiselle C, Cortes JE, Sasaki K, Issa GC, Kadia TM, DiNardo CD, Verstovsek S, Daver NG, Mullighan CG, O'Brien SM, Jabbour E. Phase II Study of the Hyper-CVAD Regimen in Combination with Ofatumumab (HCVAD-O) As Frontline Therapy for Adult Patients (pts) with CD20-Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Samra B, Kantarjian HM, Sasaki K, Short NJ, Khouri R, Khoury JD, Champlin RE, Kebriaei P, Cortes JE, Jorgensen JL, Wang SA, Garcia-Manero G, Kadia TM, Borthakur GM, Verstovsek S, Daver NG, Montalban-Bravo G, Jain N, Konopleva MY, Yilmaz ME, Naqvi K, O'Brien SM, Ravandi F, Jabbour E. Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Paul S, Sasaki K, Savoy JM, Dipippo A, Jammal N, Marx K, Kidia TM, Garcia-Manero G, Ravandi F, Kantarjian HM, Jabbour E. 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes JE, Daver NG, Takahashi K, DiNardo CD, Jabbour E, Borthakur GM, Naqvi K, Konopleva MY, Pierce SA, Bueso-Ramos CE, Patel KP, Kantarjian HM, Garcia-Manero G, Kadia TM. Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Short NJ, Kantarjian HM, Ravandi F, Huang X, Jain N, Daver N, Thomas DA, Pemmaraju N, Khouri R, Dhoury JD, Lorgensen JL, Alvarado Y, Sasaki K, Konopleva M, Garcia-Manero G, Kadia T, Cortes JE, Benton CB, Borthakur G, Burger JA, Ohanian M, Wierda WC, Estrov Z, Kornblau SM, DiNardo CD, Ferrajoli A, Bacob J, Manzoor A, Garris R, OBrien SM, Jabbour EJ. Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood 134, 2019. e-Pub 2019.
Cortes J, Alfayez M, Kadia TM, Konopleva MY, Ravandi F, Cortes JE, Jabbour E, Garcia-Manero G, Pierce SA, Yilmaz ME, Short NJ, Sasaki K, Masarova L, Pemmaraju N, Borthakur GM, Kantarjian HM, DiNardo CD, Daver NG. Activity of Multiple Targetable Therapies in FLT3-Mutated (mu) Acute Myeloid Leukemia (AML) Patients (pts) with Concurrent Isocitrate Dehydrogenase Mutation (IDHm). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL). Blood 134 (Supplement 1):34, 2019. e-Pub 2019. PMID: 31724006.
Daver NG, Garcia-Manero G, Konopleva MY, Alfayez M, Pemmaraju N, Kadia TM, DiNardo CD, Cortes JE, Ravandi F, Abbas H, Basu S, Jabbour E, Pierce SA, Estrov ZE, Takahashi K, Ning J, Kornblau SM, Sasaki K, Masarova L, Flores W, Allison JP, Sharma P, Kantarjian HM. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Short NJ, Garcia-Manero G, Naqvi K, Kornblau SM, Maiti A, Konopleva M, DiNardo CD, Takahashi K, Alvarado Y, Ohanian M, Estrov Z, Bose P, Andreeff M, Islam R, Dong X, Cortes JE, Kantarjian HM, Jabbour EJ. Updated Results of a Phase II Study of Reduced-Intensity Chemotherapy with Mini-Hyper-CVD in Combination with Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Maiti A, DiNardo CD, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur GM, Naqvi K, Ohanian MN, Short NJ, Alvarado Y, Benton CB, Kadia TM, Takahashi K, Yilmaz ME, Jain N, Kornblau SM, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour E, Masarova L, Rytting ME, Thompson PA, Wang SA, Konoplev S, ChenZ, Goswami M, Maduike R, Guerrero JA, Zhang Q, Cavazos A, Ma H, Bivins CA, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, Konopleva MY. Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Rausch CR, DiNardo CD, Maiti A, Jammal N, Kadia TM, Marx K, Borthakur GM, Savoy JM, Pemmaraju N, Dipippo A, Daver NG, Chew S, Sasaki K, Issa GC, Naqvi K, Ravandi F, Kantarjian HM, Konopleva MY. Venetoclax Dosing in Combination with Antifungal Agents: Real World Experience in Patients with Acute Myeloid Leukemia. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Garcia-Manero G, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Shoukier M, Cortes JE, Daver NG, Takahashi K, Jabbour E, Borthakur GM, Pemmaraju N, Konopleva MY, Pierce SA, Bueso-Ramos CE, Patel KP, Kantarjian HM, Montalban Bravo G. Activity of Venetoclax-Based Therapy in Myelodysplastic Syndrome (MDS). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Richard-Carpentier G, DeZern AE, Takahashi K, Konopleva MY, Loghavi S, Masarova L, Alvardo Y, Ravandi F, Montalban Bravo G, Naqvi K, Sasaki K, Delumpa R, Swari M, Sekeres MA, Zazha A, Roboz GJ, Kantarjain HM, Grcia-Manero G, DiNardo CD. Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS). Blood 134 (Supplement 1), 2019. e-Pub 2019.
k S, Kantarjian HM, Samra B, Short NJ, Khoury D, Kanagal-Shamanna R, Konopleva MY, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda W, Tipett N, Garris R, Jeanis V, Daver NG, Thompson PA, Yilmaz M, Cortes JE, O'Brien SM, Ravandi F, Jabbour E. Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) within 3 Months of Therapy with Tyrosine Kinase Inhibitors (TKIs). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Sasaki K, Kantarjian HM, Jabbour E, Ravandi F, Borthakur G, Wierda W, Takahashi K, Naqvi K, Montalban-bravo G, Kanagal-Shamanna R, Pemmaraju N, Issa GC, Jain P, Skinner J, Rios MB, Pierce SA, Soltysiak K, Sato J, Garcia-Manero G, Cortes JE. The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Richard-Carpentier G, Kantarjian HM, Short NJ, Ravandi F, Ferrajoli A, Schroeder HM, Garcia-Manero G, Montalban Bravo G, Cortes JE, Kwari M, Loiselle C, Garris R, Volter N, Jain N, Konopleva MY, Takahashi K, Sasaki K, Wierda WG, Jabbour E. Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Ramos-Perez JM, Kadia TM, Montalban-Bravo G, Benton CB, Faderl S, Sasaki K, Naqvi K, Cortes JE, Daver NG, DiNardo CD, Jabbour E, Borthakur GM, Al Azzawi H, Pemmaraju N, Konopleva MY, Pierce SA, Jain N, Ohanian M, Garcia-Manero G, Andreeff M, Kantarjian HM, Ravandi F, Alvarado Y. Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Short NJ, Kantarjian HM, Kanagal-Shamanna R, Sasaki K, Ravandi F, Cortes JE, Konopleva MY, Issa GC, Kornblau SM, Garcia-Manero G, Rivera V, Garris R, Higgins J, Pratt G, Williams LN, Valentine CC, Salk JJ, Prichard J, Radich JP, Jabbour E. Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Using Duplex Sequencing (DS). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Jain N, Keating MJ, Thompson PA, Burger JA, Ferrajoli A, Estrov ZE, Borthakur GM, Takahashi K, Bose P, Fowler NH, Kadia TM, Daver NG, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Montalban-Bravo G, Class C, Ganan-Gomez I, Kanagal-Shamanna R, Sasaki K, Richard-Carpentier G, Naqvi K, Wei Y, Yang H, Soltysiak K, Chien KS, Bueso-Ramos CE, K-H D, Kantarjian HM, Garcia-Manero G. Transcriptomic Analysis Implicates Necroptosis in Disease Progression and Prognosis in Myelodysplastic Syndromes. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Yilmaz M, Kantarjian HM, Wang X, Devendra KC, Khoury JD, Farhad Ravandi F, Short NJ, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Wierda WG, Khouri M, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien SM, Jabbour EJ. The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong Predictor for Survival. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Sakhdari A, Class C, Montalban-Bravo G, Sasaki K, Bueso-Ramos CE, Patel KP, Khoury JD, Kantarjian HM, Garcia-Manero G, Medeiros LJ, Kanagal-Shamanna R. Loss of EZH2 Protein Expression in Myelodysplastic Syndrome Correlates with EZH2 Mutation and Portends a Worse Outcome. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia TM, Naqvi K, Pierce SA, Takahashi K, DiNardo CD, Nogueras Gonzalez GM, Patel K, Sotysiak K, Sato J, Cortes JE, Kantarjian HM, Garcia-Manero G. Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Montalban-Bravo G, Jabbour E, Class C, Shrot NJ, Kanagal-Shamanna R, Kadia TM, Borthakur GM, Pemmaraju N, Sasaki K, Estrov ZE, Cortes JE, Ravanid F, Alvarado Y, Komrokji RS, Sekeres MA, Steensma DP, DeZern AE, Roboz GJ, Yang H, Kantarjian HM, Garcia-Manero G. Long-Term Follow up of a Randomized Phase 2 Study of Low-Dose Decitabine Versus Low-Dose Azacitidine in Lower-Risk Myelodysplastic Syndromes. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Samra B, Kantarjian HM, Sasaki K, Konopleva MY, Khouri R, O'Brien SM, Ferrajoli A, Nunez C, Kadia TM, Jabbour E. Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL). Blood 134 (Supplement 1), 2019. e-Pub 2019.
Montalban-Bravo M, Kanagal-Shamanna R, Benton CB, Class C, Chien KS, Sasaki K, Naqvi K, MD, Alvarado Y, Kadia TM, Ravandi F, Cortes JE, Daver NG, Takahashi K, DiNardo CD, Jabbour E, Borthakur GM, Pemmaraju N, Konopleva MY, Pierce SA, Bueso-Ramos CE, Andreeff M, Patel KE, Kantarjian HM, Garcia-Manero G. Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Jain N, Thompson PA, Burger JA, Ferrajoli A, Takahashi K, Estrov ZE, Borthakur GM, Bose P, Kadia TM, Pemmaraju N, Sasaki K, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian HM, O'Brien S, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Maiti A, DiNardo CD, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F, Garcia-Manero G, Borthakur GM, Naqvi K, Ohanian MN, Short NJ, Alvarado Y, Benton CB, Kadia TM, Takahashi K, Yilmaz ME, Jain N, Kornblau SM, Sasaki K, Andreeff M, Bose P, Ferrajoli A, Issa GC, Jabbour E, Masarova L, Rytting ME, Thompson PA, Wang SA, Konoplev S, ChenZ, Goswami M, Maduike R, Guerrero JA, Zhang Q, Cavazos A, Ma H, Bivins CA, Wade A, Adewale SL, Tse S, Thomas R, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, Konopleva MY. Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Kanagal-Shamanna R, Montalban-Bravo G, Class C, Sasaki K, Benton CB, Soltysiak K, Jabbour E, Kadia TM, Bueso-Ramos CE, Patel KP, Routbort M, Ganan-Gomez I, Wei Y, Borthakur GM, Ravandi F, K-A D, Medeiros LJ, Kantarjian HM, Garcia-Manero G. Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Ahaneku HO, Kantarjian HM, Nogueras Gonzalez GM, Borthakur GM, Verstovsek S, Kadia TM, Pemmaraju N, Garcia-Manero G, Konopleva MY, DiNardo CD, Naqvi K, Sasaki K, Issa GC, Jabbour E, Cortes JE. Outcomes of Patients with Suboptimal /Warning Response to Tyrosine Kinase Inhibitors: A Comparison of the 2009 and 2013 Guidelines of the European Leukemianet. Blood 134 (Supplement 1), 2019. e-Pub 2019.
Sasaki K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, Ravandi F, Kadia TM, Naqvi K, Pierce SA, Takahashi K, DiNardo CD, Nogueras Gonzalez GM, Patel K, Sotysiak K, Sato J, Cortes JE, Kantarjian HM, Garcia-Manero G. Response prediction by machine learning in patients with newly diagnosed myelodysplastic syndrome. The Japanese Society of Hematology Annual Meeting, 2019. e-Pub 2019.
Sasaki K, Kantarjian H, Ravandi F, Short N, Daver N, Pemmaraju N, Thomas D, Yilmaz M, Kadia T, Garris R, Garcia-Manero G, DiNardo C, Konopleva M, Estrov Z, Jain N, Wierda W, Jeanis V, Cortes J, O’Brien S, Jabbour E. Update Results of Hyper-CVAD with Ponatinib for Newly Diagnosed Ph+ ALL – Phase 2 Study. The Japanese Society of Hematology Annual Meeting, 2019. e-Pub 2019.
Kantarjian HM, Ravandi F, Short N, Daver N, Pemmaraju N, Thomas D, Yilmaz M, Kadia T, Garris R, Garcia-Manero G, DiNardo C, Konopleva M, Estrov Z, Jain N, Wierda W, Jeanis V, Cortes J, O'Brien S, Jabbour E. Update Results of Hyper-CVAD with Ponatinib for Newly Diagnosed Ph+ ALL- Phase 2 Study. The Japanese Society of Hematology Annual Meeting, 2019. e-Pub 2019.
Sasaki K, Kantarjian H, Richard-Carpentier G, Short N, Ravandi F, Khouri M, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Issa G, Jacob J, Garris R, Yilmaz M, Thompson P, Nasnas P, Pemmaraju N, Cortes J, O’Brien S, Jabbour E. Inotuzumab Ozogamicin Combined with Low-Intensity, with or without Blinatumomab vs. Intensive Therapy for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis. Clin Lymphoma Myeloma Leuk 19 Suppl 2:ALL-095, 2019. e-Pub 2019.
Short N, Jabbour E, Sasaki K, Ravandi F, Huang X, Kebriaei P, Jain N, Garcia-Manero G, Kadia T, Konopleva M, Jacob J, Garris R, Cortes J, O'Brien S, Kantarjian H. Reduced-Intensity Chemotherapy Plus Inotuzumab Ozogamicin, With or Without Sequential Blinatumomab, is Highly Effective as First Salvage Treatment in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 19 Suppl 2:ALL-170, 2019. e-Pub 2019.
Sasaki K, Kantarjian H, Richard-Carpentier G, Ravandi F, Short N, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Issa G, Estrov Z, Garris R, Khouri M, Nasnas P, Pemmaraju N, Cortes J, O’Brien S, Jabbour E. The Impact of Smoking on Relapse and Survival in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor. Clin Lymphoma Myeloma Leuk 19 Suppl 2:ALL-093, 2019. e-Pub 2019.
Yilmaz M, Kantarjian H, Wang X, Loghavi S, Khoury J, Jorgensen J, Ravandi F, Short N, Cortes J, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Wierda W, Khouri M, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O’Brien S, Jabbour E. The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia is a Strong Predictor for Survival. Clin Lymphoma Myeloma Leuk 19 Suppl 2:ALL-280, 2019. e-Pub 2019.
Sasaki K, Kantarjian H, Richard-Carpentier G, Ravandi F, Short N, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Issa G, Jeanis V, Alvarez J, Khouri M, Nasnas P, Garris R, Wierda W, Thompson P, Pemmaraju N, Cortes J, O’Brien S, Jabbour E. Dynamic Prediction of Outcome with Longitudinal BCR-ABL1 Levels in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 19 Suppl 2:ALL-094, 2019. e-Pub 2019.
Yilmaz M, Kantarjian H, Ravandi F, Thomas D, Khouri M, Garcia-Manero G, Garris R, Cortes J, Short N, Sasaki K, Issa G, Koller P, Schroeder H, Kadia T, Verstovsek S, Daver N, Jain N, Konopleva M, O’Brien S, Jabbour E. Hyper-CVAD Plus Ofatumumab as Frontline Therapy for Adults with CD20 Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 19 Suppl 2:ALL-156, 2019. e-Pub 2019.
Chien KS, Benton CB, Class CA, Kadia TM, DiNardo CD, Konopleva M, Andreeff M, Sasaki K, Naqvi K, Gomez IG, Wei Y, Yang H, Pierce SA, Patel KP, Kanagal-Shamanna R, Kantarjian HM, Garcia-Manero G, Montalban-Bravo G. Patterns of leukemic transformation in patients with TP53-mutant myelodysplastic syndromes. J Clin Oncol 37 Suppl:7054, 2019. e-Pub 2019.
Wei Y, Class C, Kanagal-Shamanna R, Zheng H, Estecio M, Lu Y, Soltysiak K, Yang H, Sasaki K, Montalban-Bravo G, Ganan-Gomez I, Do KA, Colla S, Bueso-Ramos C, Garcia-Manero G. IDENTIFICATION AND TARGETING OF MOLECULAR SIGNATURES OF HYPOMETHYLATING AGENT RESISTANCE IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA. European Hematology Association, 2019. e-Pub 2019.
Alfayez M, Dalle IA, Richard-Carpentier GA, Pak D, Ning J, Pierce SA, Sasaki K, Naqvi K, Daver NG, Cortes JE, Ravandi F, Pemmaraju N, Ferrajoli A, Garcia-Manero G, Konopleva M, Borthakur G, Kantarjian HM, Kadia T, DiNardo CD. Association of smoking with poor risk ELN 2017, cytogenetics/molecular profile, and survival outcomes in acute myeloid leukemia. J Clin Oncol 37 (suppl; abstr 7002), 2019. e-Pub 2019.
Shrot NJ, Kantarjian HM, Sasaki K, Kanagal-Shamanna R, Ravandi F, Cortes JE, Konopleva M, Issa G, Kornblau SM, Garcia-Manero G, Rivera V, Garris R, Salk J, Prichard J, Radich J, Jabbour E. Duplex Sequencing Identifies Low Level ABL 1 Kinase Domain Mutations in Untreated Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 19 Suppl 2, 2019. e-Pub 2019.
Sasaki K, Kantarjian HM, Short NJ, Ravandi F, Khouri M, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jacob J, Garris R, Yilmaz M, Thompson PA, Nasnas P, Pemmaraju N, Cortes JE, O'Brien S, Jabbour EJ. Frontline Inotuzumab with Low-Intensity vs. Intensive Therapy for Older Patients with Ph-neg ALL. The Japanese Society of Hematology Annual Meeting, 2019. e-Pub 2019.
Kanagal-Shamanna R, Jain P, Luthra R, Patel KP, Garcia-Manero G, Takahashi K, Ravandi F, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Estrov Z, Wierda WG, O'Brien SM, Cortes JE, Kantarjian HM, Jabbour EJ. Clinical Implications of TP53 Mutations in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with the Hypercvad-Based Regimens. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Short NJ, Jabbour EJ, Ravandi F, Huang X, Jain N, Sasaki K, Pemmaraju N, Daver NG, Khoury JD, Jorgensen JL, Alvarado Y, Konopleva MY, Garcia-Manero G, Kadia TM, Yilmaz M, Borthakur G, Burger JA, Kornblau SM, Wierda WG, DiNardo CD, Ferrajoli A, Nasnas P, Jacob J, Garris RE, O'Brien SM, Kantarjian HM. Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Maiti A, DiNardo CD, Cortes JE, Borthakur G, Pemmaraju N, Benton CB, Kadia TM, Takahashi K, Naqvi K, Ravandi F, Alvarado Y, Short NJ, Daver NG, Sasaki K, Ohanian MN, Garcia-Manero G, Thompson PA, Kornblau SM, Masarova L, Jain N, Jabbour EJ, Andreeff M, Maduike R, Guerrero JA, Zhang Q, Cavazos A, Ma H, Rausch CR, Bivins CA, Vaughan K, Pierce SA, Ning J, Qiao W, Welch JS, Kantarjian HM, Konopleva MY. Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Jain P, Kantarjian HM, Jabbour EJ, Gonzalez GN, Garcia-Manero G, Kanagal-Shamanna R, Patel KP, Hu S, DellaSala SE, Pierce S, Sasaki K, Konopleva M, Wierda WG, Daver N, Kadia TM, Borthakur G, Estrov Z, Ravandi F, O'Brien SM, Cortes JE. Factors Affecting Survival Outcomes in Patients with Blast Phase CML (CML-BP) in the Tyrosine Kinase Inhibitor (TKI) Era: A Cohort Study of 498 Patients. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Rausch CR, Paul S, Kantarjian HM, Ravandi F, Short NJ, Sasaki K, Khouri M, Jacob J, Montalbano KS, Thompson PA, Jain N, Yilmaz M, Naqvi K, Ohanian MN, Nasnas P, Estrov ZE, O'Brien SM, Jabbour EJ. Utility of Leucovorin Rescue in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with the Mini-Hypercvd Regimen. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Aboudalle I, Kantarjian HM, Short NJ, Ravandi F, Sasaki K, Garcia-Manero G, Montalban-Bravo G, Cortes JE, Benton CB, Issa GC, Khouri M, Nasnas P, O'Brien SM, Jabbour EJ. Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Cortes JE, Konopleva MY, Issa GC, Kanagal-Shamanna R, Kornblau SM, Garcia-Manero G, Rivera V, Garris RE, Salk J, Prichard J, Radich JR, Jabbour EJ. Ultrasensitive Duplex Sequencing of Pretreatment ABL1 Kinase Domain Mutations in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Naqvi K, Alfonso Pierola A, Yilmaz M, Short NJ, Assi R, Jabbour EJ, Ravandi F, Kadia TM, Pierce SA, Takashashi K, DiNardo CD, Ganzalez GN, Sakurai K, Patel KP, Cortes JE, Kantarjian HM, Garcia-Manero G. The Impact of Clonal Hematopoiesis of Indeterminate Potential on Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Garcia-Manero G, Sasaki K, Montalban-Bravo G, Daver NG, Jabbour EJ, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes JE, Kadia TM, Konopleva MY, Colla S, Yang H, Rausch CR, Gasior Y, Bueso-Ramos CE, Kanagal-Shamanna R, Patel KP, Kantarjian HM. A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS). Blood 132 (Supplement 1), 2018. e-Pub 2018.
Garcia-Manero G, Sasaki K, Montalban-Bravo G, Bodden KR, Bose P, Alvarado Y, Daver NG, Borthakur G, Ravandi F, Takahashi K, Cortes JE, Jabbour EJ, Naqvi K, DiNardo CD, Benton CB, Pemmaraju N, Kadia TM, Ohanian MN, Pierce SA, Kantarjian HM. Final Report of a Phase II Study of Guadecitabine (SGI-110) in Patients (pts) with Previously Untreated Myelodysplastic Syndrome (MDS). Blood 132 (Supplement 1), 2018. e-Pub 2018.
Yalniz F, Kantarjian HM, Kadia TM, Garcia-Manero G, Patel K, Loghavi S, Sasaki K, Daver NG, DiNardo CD, Pemmaraju N, Short NJ, Yilmaz M, Bose P, Naqvi K, Pierce SA, Cortes JE, Ravandi F. Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Richard-Carpentier G, Kantarjian HM, Short NJ, Ravandi F, Ferrajoli A, Schroeder HM, Khouri M, Garcia-Manero G, Montalban-Bravo G, Cortes JE, Jain N, Konopleva MY, Takahashi K, Sasaki K, Garris RE, Jabbour EJ. A Phase II Study of the Hyper-CVAD Regimen in Sequential Combination with Blinatumomab As Frontline Therapy for Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood 132 (Supplement 1), 2018. e-Pub 2018.
Jabbour EJ, Sasaki K, Ravandi F, Short NJ, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Estrov Z, Garris R, Khouri M, Nasnas P, Pemmaraju N, Cortes JE, O'Brien S, Kantarjian HM. Smoking Confers Poor Survival in Patients (Pts) with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with the Combination of Intensive Therapy with Tyrosine Kinase Inhibitor (TKI). Blood 132 (Supplement 1), 2018. e-Pub 2018.
Montalban-Bravo G, Benton CB, Kanagal-Shamanna R, Sasaki K, Assi R, Kadia TM, Ravandi F, Ganan-Gomez I, Cortes JE, Daver NG, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Pemmaraju N, Konopleva MY, Pierce SA, Bueso-Ramos CE, Kornblau SM, Patel K, Colla S, Kantarjian HM, Andreeff M, Garcia-Manero G. Landscape of TP53 Abnormalities and Their Clinical Relevance in Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Sasaki K, Jabbour E, Ravandi F, Short NJ, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Issa GC, Jeanis V, Alvarez J, Khouri M, Nasnas PE, Garris R, Wierda W, Thompson P, Pemmaraju N, Cortes JE, O’Brien S, Kantarjian H. Dynamic Personalized Assessment of Outcome in Patients with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Naqvi K, Sasaki K, Montalban-Bravo G, Alfonso A, Yilmaz M, Short NJ, Assi R, Jabbour EJ, Ravandi F, Kadia TM, Pierce SA, Takahashi K, González GMN, Kanagal-Shamanna R, Patel KP, Kantarjian HM, Garcia-Manero G. Imapct of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Sasaki K, Kantarjian HM, Short NJ, Ravandi F, Khouri M, Garcia-Manero G, Daver NG, Kadia TM, Konopleva MY, Jain N, Issa GC, Jacob J, Garris R, Yilmaz M, Thompson PA, Nasnas P, Pemmaraju N, Cortes JE, O'Brien S, Jabbour EJ. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian MN, Pemmaraju N, Jabbour EJ, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG. Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL). Blood 132 (Supplement 1), 2018. e-Pub 2018.
Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Colla S, Ganan-Gomez I, Sasaki K, Ravandi F, Kadia TM, Cortes JE, Daver NG, Takahashi K, DiNardo CD, Jabbour EJ, Borthakur G, Naqvi K, Konopleva MY, Pierce SA, Bueso-Ramos CE, Patel K, Kantarjian HM, Garcia-Manero G. Mutational and Clonal Landscape of Acute Myeloid Leukemia with Myelodysplastic Related Changes. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Garcia-Manero G, Montalban-Bravo G, Sasaki K, Daver NG, Jabbour EJ, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Bose P, Pemmaraju N, Naqvi K, Cortes JE, Kadia TM, Konopleva MY, Rausch CR, Gasior Y, Kantarjian HM. Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS). Blood 132 (Supplement 1), 2018. e-Pub 2018.
Sasaki K, Kantarjian HM, Ravandi F, Konopleva MY, Borthakur G, Garcia-Manero G, Wierda WG, Daver NG, Ferrajoli A, Takashashi K, Montalban-Bravo G, Rios MB, Pierce SA, Sakurai K, Jabbour EJ, Cortes JE. Dynamic Personalized Assessment in Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Swaminathan M, Kantarjian HM, Sasaki K, Ravandi F, Borthakur G, Kadia TM, Garcia-Manero G, DiNardo CD, Konopleva MY, Estrov ZE, Pemmaraju N, Daver NG, Wierda WG, Ferrajoli A, Pierce SA, Dellasala E, Jabbour EJ, Cortes JE. Efficacy of Ponatinib after Multiple Lines of Therapy for Chronic Myeloid Leukemia. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Sasaki K, Jabbour EJ, O'Brien SM, Ravandi F, Thomas DA, Garcia-Manero G, Daver N, Borthakur G, Jain N, Konopleva M, Short NJ, Pemmaraju N, Alvarado Y, Jacob J, Garris R, Thompson PA, Cortes JE, Kantarjian HM. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) As Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Bose P, McCue D, Wiederhold NP, Kadia TM, Borthakur G, Ravandi F, Yilmaz M, Takahashi K, Thompson PA, Pemmaraju N, Daver NG, Burger JA, Cortes JE, Garcia-Manero G, Verstovsek S, Konopleva MY, Jain N, DiNardo CD, Alvarado Y, Naqvi K, Kornblau SM, Ferrajoli A, Wierda WG, Estrov ZE, Benton CB, Masarova L, Montalban-Bravo G, Sasaki K, Rausch CR, Marx K, Qiao W, Huang X, Bivins CA, Pierce SA, Kantarjian HM, Kontoyiannis DP. Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Kanagal-Shamanna R, Sasaki K, Montalban-Bravo G, Benton CB, Jabbour EJ, Borthakur G, Kadia TM, Bueso-Ramos CE, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G. Evolutionary Action Score of Missense TP53 Mutations Can Predict Outcome in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Sasaki K, Kantarjian HM, Ravandi F, Shrot NJ, Kebriaei P, Huang X, Rytting ME, Jain N, Konopleva MY, Garcia-Manero G, Champlin RE, Kadia TM, Cortes JE, Estrov Z, Takahashi K, Mace M, Khouri M, Nasnas P, Jacob J, Garris R, Jabbour EJ. Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 Trial. Blood 132 (Supplement 1), 2018. e-Pub 2018.
Sasaki K, Kantarjian H, Ravandi F, Short N, Daver N, Pemmaraju N, Thomas D, Yilmaz M, Kadia T, Garris R, Garcia-Manero G, DiNardo C, Konopleva M, Estrov Z, Jain N, Wierda W, Jeanis V, Cortes J, O’Brien S, Jabbour E. Hyper-CVAD with Ponatinib for Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. The Japanese Society of Hematology Annual Meeting, 2018. e-Pub 2018.
Morita K, Kantarjian H, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa G, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo C, Konopleva M, Andreeff M, Ravandi F, Cortes J, Kadia T, Jabbour E, Garcia-Manero G, Patel K, Futreal PA, Takahashi K. Somatic mutations at remission serve as a minimal residual disease marker in acute myeloid leukemia. The Japanese Society of Hematology Annual Meeting, 2018. e-Pub 2018.
Sasaki K, Jabbour E, Khouri M, Thomas D, Garcia-Manero G, Ravandi F, Borthakur G, Short N, Issa G, Kadia T, Jones E, Garris R, Cortes J, O’Brien S, Kantarjian H. Hyper-CMAD with Liposomal Vincristine in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. The Japanese Society of Hematology Annual Meeting, 2018. e-Pub 2018.
Sasaki K, Kantarjian H, Ravandi F, Daver N, Kadia R, Khouri RB, Yesid A, Burger J, Thomas D, Garcia-Manero G, DiNardo C, Pemmaraju N, Short N, Schroeder H, Garris R, Bose P, Jain N, Naqvi K, Wierda W, Verstovsek S, Cortes J, Konopleva M, O’Brien S, Jabbour E. A Phase 2 Trial of Hyper-CVAD plus Ofatumumab for Newly Diagnosed CD20+ Acute Lymphoblastic Leukemia. The Japanese Society of Hematology Annual Meeting, 2018. e-Pub 2018.
Sasaki K, Kantarjian H, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Ferrajoli A, Takahashi K, Montalban-Bravo G, Rios MB, Pierce S, Sakurai K, Jabbour E, Cortes JE. Dynamic Personalized Assessment in Patients with Chronic Myeloid Leukemia in Chronic Phase. iCMLf International Conference CHRONIC MYELOID LEUKEMIA: Biology and Therapy, 2018. e-Pub 2018.
Bazarbachi AH, Yilmaz M, Ravandi F, Thomas DA, Khouri M, Garcia-Manero G, Garris RS, Cortes JE, Short NJ, Sasaki K, Issa GC, Koller PB, Kadia TM, Verstovsek S, Daver NG, Jain N, Konopleva M, O'Brien SM, Jabbour E, Kantarjian HM. A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results. J Clin Oncol 36 Suppl:7041, 2018. e-Pub 2018.
Ghorab A, Kantarjian HM, Jain P, Kanagal-Shamanna R, Jabbour E, Sasaki K, Kadia TM, Garcia-Manero G, Bose P, Yilmaz M, Naqvi K, Wierda WG, Verstovsek S, Jain N, Estrov Z, Ravandi F, O'Brien SM, Cortes JE. Concordant extra-medullary and bone marrow disease (EMD-BM) of blastic transformation of chronic myeloid leukemia (CML-BP) in the tyrosine kinase (TKI) era: Characteristics, treatments and outcomes. J Clin Oncol 36 Suppl:e19022, 2018. e-Pub 2018.
Yilmaz M, Jabbour EJ, Wang X, Loghavi S, Khoury JD, Jorgensen JL, Ravandi F, Short NJ, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Takahashi K, Khouri M, Jain N, Vertovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien SM, Kantarjian HM. Dynamics of Measurable Disease at Remission Determines Survival in Patients (pts) with Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia (ALL). Blood 130 (Supplement 1):1434, 2017. e-Pub 2017.
Maiti A, Kantarjian HM, Ravandi F, Khouri M, Thomas DA, Garcia-Manero G, Garris R, Cortes JE, Short NJ, Jain N, Bose P, Verstovsek S, Konopleva M, Sasaki K, Issa GC, Ghosn M, Schroeder HM, Kadia T, Daver N, O'Brien SM, Jabbour E. Hyper-CVAD Plus Ofatumumab As Frontline Therapy in CD20+ Acute Lymphoblastic Leukemia: Updated Results of a Phase II Trial. Blood 130 (Supplement 1):3876, 2017. e-Pub 2017.
Sasaki K, Kantarjian HM, O'Brien SM, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour EJ, Cortes JE. Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI). Blood 130 (Supplement 1):1609, 2017. e-Pub 2017.
Jain P, Kanagal-Shamanna R, Kantarjian HM, San Lucas FA, Ghorab A, Jabbour EJ, Issa G, Sasaki K, Kadia T, Estrov Z, Ravandi F, Cortes JE. Pattern of Mutational Changes in Patients with Chronic Phase CML Who Are Treated with Frontline TKI and Transform to Blast Phase CML. Blood 130 (Supplement 1):4172, 2017. e-Pub 2017.
Yilmaz M, Devendra KC, Akosile MA, Khoury JD, Short NJ, Cortes JE, Garcia-Manero G, Ravandi F, Kadia T, Sasaki K, Konopleva M, Wierda WG, Jain N, Verstovsek S, Estrov Z, Pierce S, O'Brien SM, Jabbour EJ, Kantarjian HM. The Prognostic Significance of Translocation (1;19) in Adult Patients (Pts) with B-Cell Acute Lymphoblastic Leukemia (ALL). Blood 130 (Supplement 1):2712, 2017. e-Pub 2017.
Alqam HM, Kantarjian HM, Chihara D, Sasaki K, Jabbour EJ, Cortes JE. Survival Outcome of Secondary Solid Cancer in Patients with Chronic Myeloid Leukemia. Blood 130 (Supplement 1):1623, 2017. e-Pub 2017.
Ghorab A, Jain P, Kantarjian HM, Kanagal-Shamanna R, Jabbour EJ, Sasaki K, Kadia T, Garcia-Manero G Bose P, Yilmaz M, Naqvi K, Wierda WG, Verstovsek S, Nitin Jain N, Estrov Z, Ravandi F, O'Brien SM, Cortes JE. Isolated Extramedullary (EMD) Blastic Transformation of Chronic Myeloid Leukemia (CML-BP) in the TKI Era: Characteristics, Treatments and Outcomes. Blood 130 (Supplement 1), 2017. e-Pub 2017.
Assi R, Kantarjian HM, Khouri R, Ravandi F, Kebriaei P, Short NJ, Thomas DA, Garcia-Manero G, Champlin RE, Kadia T, Cortes JE, Jain N, Konopleva M, Estrov Z, Takahashi K, Sasaki K, Jacob J, Manzoor A, Garris R, O'Brien SM, Jabbour EJ. Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL). Blood 130 (Supplement 1):2597, 2017. e-Pub 2017.
Short NJ, Kantarjian HM, Ravandi F, Huang X, Jain N, Daver N, Thomas DA, Pemmaraju N, Khouri R, Dhoury JD, Lorgensen JL, Alvarado Y, Sasaki K, Konopleva M, Garcia-Manero G, Kadia T, Cortes JE, Benton CB, Borthakur G, Burger JA, Ohanian M, Wierda WC, Estrov Z, Kornblau SM, DiNardo CD, Ferrajoli A, Bacob J, Manzoor A, Garris R, OBrien SM, Jabbour EJ. A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. Blood 130 (Supplement 1):2576, 2017. e-Pub 2017.
Naqvi K, Montalban Bravo G, Alfonso Pierola A, Yilmaz M, Sasaki K, Short NJ, Assi R, Jabbour EJ, Ravandi F, Benton CB, Kadia T, Pierce S, Borthakur G, Daver N, DiNardo CD, Takahashi K, Jain N, Pemmaraju N, González GN, Kantarjian HM, Garcia-Manero G. Clonal Hematopoiesis of Indeterminate Potential - Associated Mutations and Risk of Comorbidities in Patients with Myelodysplastic Syndrome. Blood 130 (Supplement 1):4258, 2017. e-Pub 2017.
Yilmaz M, Kantarjian HM, Wang X, Devendra KC, Khoury JD, Farhad Ravandi F, Short NJ, Cortes JE, Garcia-Manero G, Kadia T, Sasaki K, Konopleva M, Wierda WG, Khouri M, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Garris R, O'Brien SM, Jabbour EJ. Prognostic Index for Survival in Adult Patients with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia (ALL). Blood 130 (Supplement 1):1435, 2017. e-Pub 2017.
Sasaki K, Jabbour EJ, Khouri M, Thomas DA, Garcia-Manero G, Ravandi F, Borthakur G, Short NJ, Issa GC, Kadia T, Jones E, Garris R, Cortes JE, O'Brien SM, Kantarjian HM. Phase II Study of Hyper-Cmad with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL). Blood 130 (Supplement 1):2554, 2017. e-Pub 2017.
Sasaki K, Kantarjian H, O’Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takahashi K, Jain P, Rios MB, Pierce S, Jabbour EJ, Cortes J. Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI). 19th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, 2017. e-Pub 2017.
Sasaki K, Jabbour E, O’Brien S, Thomas D, Garcia-Manero G, Ravandi F, Borthakur G, Short N, Issa G, Gachimova E, Garris R, Cortes J, Kantarjian H. Phase II study of hyper-CMAD with Liposomal Vincristine (Marqibo) for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 17 Suppl 2, 2017. e-Pub 2017.
Short N, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver N, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia T, Wierda W, DiNardo C, Brandt M, O'Brien S, Cortes J, Jabbour E. A RANDOMIZED PHASE II STUDY OF IDARUBICIN AND CYTARABINE WITH EITHER CLOFARABINE (CIA) OR FLUDARABINE (FIA) IN ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA. European Society of Hematology:P209, 2017. e-Pub 2017.
Maiti A, Kantarjian HM, Ravandi F, Thomas DA, Khouri M, Garcia-Manero G, Garris RS, Cortes JE, Short NJ, Sasaki K, Issa GC, Koller PB, Schroeder HM, Kadia TM, Verstovsek S, Daver NG, Jain N, Konopleva M, O'Brien SM, Jabbour E. Updated Results of Frontline Ofatumumab-Hyper-CVAD in Adults with CD20+ Acute Lymphoblastic Leukemia. J Clin Oncol 35 Suppl:7033, 2017. e-Pub 2017.
Short NJ, Kantarjian HM, O'Brien SM, Ravandi F, Thomas DA, Garcia-Manero G, Daver NG, Borthakur G, Jain N, Konopleva M, Sasaki K, Pemmaraju N, Alvarado Y, Jacob J, Garris R, Thompson PA, Cortes JE, Jabbour E. Updated results of a phase I/II study of inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients with acute lymphoblastic leukemia. J Clin Oncol 35 Suppl:7014, 2017. e-Pub 2017.
Assi R, Kantarjian HM, Ravandi F, O'Brien SM, Kebriaei P, Thomas DA, Garcia-Manero G, Khouri IF, Champlin RE, Kadia TM, Cortes JE, Jain N, Konopleva M, Khouri R, Estrov Z, Takahashi K, Sasaki K, Jacob J, Garris R, Jabbour E. Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL). J Clin Oncol 35 Suppl:7025, 2017. e-Pub 2017.
Short N, Kantarjian H, Ravandi F, Daver N, Pemmaraju N, Thomas D, Yilmaz M, Kadia T, Sasaki K, Garris R, Garcia-Manero G, DiNardo C, Konopleva M, Estrov Z, Jain N, Wierda W, Jeanis V, Cortes J, O'Brien S, Jabbour E. UPDATED RESULTS OF A PHASE II STUDY OF HYPER-CVAD PLUS PONATINIB AS FRONTLINE THERAPY FOR ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA. European Hematology Association:P518, 2017. e-Pub 2017.
Short NJ, Kantarjian HM, Ravandi F, Daver NG, Pemmaraju N, Thomas DA, Yilmaz M, Kadia TM, Sasaki K, Garris R, Garcia-Manero G, DiNardo CD, Konopleva M, Estrov Z, Jain N, Wierda WG, Jeanis V, Cortes JE, O'Brien SM, Jabbour E. Frontline hyper-CVAD plus ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Updated results of a phase II study. J Clin Oncol 35 Suppl:7013, 2017. e-Pub 2017.
Sasaki K, Kantarjian HM, O'Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda WG, Daver N, Ferrajoli A, Takashashi K, Jain P, Rios MB, Pierce S, Jabbour EJ, Cortes JE. Prediction for Sustained Deep Molecular Response of BCR-ABL Levels in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Blood 128 (Supplement 1), 2016. e-Pub 2016.
Short NJ, Kantarjian HM, Jorgensen JL, Ravandi F, Yilmaz M, Khouri MR, Wang S, Thomas DA, Khoury JD, Champlin RE, Khouri IF, Kebriaei P, Marin D, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, DiNardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Jabbour EJ. Achievement of Minimal Residual Disease Negativity By Multiparameter Flow Cytometry Is an Important Therapeutic Endpoint in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Salvage Treatment. Blood 128 (Supplement 1):2916, 2016. e-Pub 2016.
Sasaki K, Kantarjian H, Jabbour E, O’Brien S, Ravandi F, Konopleva M, Borthakur G, Wierda W, Daver N, Takahashi K, Jain P, Skinner J, Rios MB, Pierce S, Garcia-Manero G, Cortes J. Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase. Blood 128 (Supplement 1), 2016. e-Pub 2016.
Jain P, Kantarjian HM, Ravandi F, Kanagal-Shamanna R, Khoury JD, Patel KP, Garcia-Manero G, Konopleva M, Jain N, Sasaki K, Kadia TM, Borthakur G, Garris R, Pierce S, Estrov Z, Wierda WG, Cortes JE, O'Brien SM, Jabbour EJ. Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL) with Hypercvad Based Regimens. Blood 128 (Supplement 1):2779, 2016. e-Pub 2016.
Jabbour EJ, Short NJ, Huang X, Maiti A, Kadia TM, Daver N, Borthakur G, DiNardo CD, Pemmaraju N, Sasaki K, Estrov Z, Verstovsek S, Ravandi F, Alvarado Y, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Miller D, Dong X, Kantarjian HM, Garcia-Manero G. A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium. Blood 128 (Supplement 1), 2016. e-Pub 2016.
Sasaki K, Jabbour E, O’Brien S, Ravandi F, Thomas D, Garcia-Manero G, Borthakur G, Jain N, Konopleva M, Short N, Jacob J, Garris R, Thompson P, Cortes J, Kantarjian H. Inotuzumab Ozogamicin in Combination with Low-intensity chemotherapy (mini-hyper-CVD) as Frontline Therapy for Older Patients with Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood 128 (Supplement 1), 2016. e-Pub 2016.
Patel YB, Voit KN, Sasaki K, Ravandi F, Thomas DA, O'Brien SM, Borthakur G, Garcia-Manero G, Cortes JE, Konopleva M, Jain N, Ohanian M, Garris R, Jacob J, Kantarjian HM, Jabbour EJ. Methotrexate Clearance in Adult Patients with B-Precursor Acute Lymphoblastic Leukemia Treated with the Mini-Hyper-CVD Regimen. Blood 128 (Supplement 1), 2016. e-Pub 2016.
Jabbour EJ, Kantarjian HM, Sasaki K, Kadia TM, Ravandi F, Cortes JE, Khoury JD, Patel KP, Bueso-Ramos CE, Daver NG, Borthakur G, Jain N, DiNardo CD, Konopleva M, Verstovsek S, Pemmaraju N, Estrov Z, Miller D, Maduike R, Faderl S, Garcia-Manero G. Clofarabine Plus Low-Dose Cytarabine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome (MDS) Who Have Been Relapsing after, or Are Refractory to, Hypomethylating Agent (HMA) Therapy. Blood 128 (Supplement 1), 2016. e-Pub 2016.
Short NJ, Jabbour E, Sasaki K, Patel K, O'Brien SM, Cortes JE, Garris R, Issa GC, Garcia-Manero G, Luthra R, Thomas D, Kantarjian H, Ravandi F. Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. Blood 128 (Supplement 1), 2016. e-Pub 2016.
Short NJ, Jabbour EJ, Sasaki K, Ko H, Ravandi F, Yin CC, Khouri MR, Cortes JE, Garris R, O'Brien SM, Patel KP, Garcia-Manero G, Thomas DA, Daver N, Naqvi K, Bose P, Jain N, Konopleva M, Kantarjian HM. Additional Chromosomal Abnormalities in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Tyrosine Kinase Inhibitors: Differential Outcomes According to Type of Chromosomal Abnormality. Blood 128 (Supplement 1), 2016. e-Pub 2016.
Sasaki K, Kantarjian H, Ravandi F, Daver N, Kadia T, Khouri RB, Yesid A, Burger J, Thomas D, Garcia-Manero G, DiNardo C, Pemmaraju N, Short N, Schroeder H, Garris R, Bose P, Jain N, Naqvi K, Wierda W, Verstovsek S, Cortes J, Konopleva M, O’Brien S, Jabbour E. Frontline Ofatumumab in Combination with Hyper-CVAD for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia (ALL): Interim Result of a Phase II Clinical Trial. Blood 128 (Supplement 1):2783, 2016. e-Pub 2016.
Sasaki K, Kantarjian H, Ravandi F, Daver N, Pemmaraju N, Thomas D, Khouri RB, Yilmaz M, Kadia T, Short N, Garris R, Garcia-Manero G, DiNardo CD, Konopleva M, Estrov Z, Jain N, Wierda W, Jeanis V, Cortes J, Kantarjian H, O’Brien S, Jabbour E. Phase II Study of the Frontline hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia. Blood 128 (Supplement 1), 2016. e-Pub 2016.
Sasaki K, Jabbour E, O’Brien S, Thomas D, Ravandi F, Garcia-Manero G, Cortes J, Short N, Verstovsek S, Yilmaz M, Wierda W, Borthakur G, Kadia T, Konopleva M, Khouri M, Ferrajoli A, Daver N, Pemmaraju N, DiNardo C, Jain N, Benton C, Takahashi K, Naqvi K, Bose P, Kornblau S, Andreeff M, Keating M, Freireich E, Kantarjian H. Outcome of Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) by Age Group over 35 Years: A Single Institution Experience. Blood 128 (Supplement 1), 2016. e-Pub 2016.
Sasaki K, Jabbour E, O’Brien S, Ravandi F, Thomas D, Kadia T, Garcia-Manero G, Burger J, Pemmaraju N, Alvarado Y, Daver N, Jain N, Konopleva M, Champlin R, Khouri I, Kebriaei P, Marin D, DiNardo C, Estrov Z, Takahashi K, Short N, Khouri M, Jacob J, Garris R, Cortes J, Kantarjian H. Phase II Study of mini-hyper-CVD in Combination with Inotuzumab Ozogamicin (InO) in Adult Patients with Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Blood 128 (Supplement 1):1606, 2016. e-Pub 2016.
Kanagal-Shamanna R, Jain P, Luthra R, Patel KP, Garcia-Manero G, Takahashi K, Ravandi F, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Estrov Z, Wierda WG, O'Brien SM, Cortes JE, Kantarjian HM, Jabbour EJ. Clinical Implications of TP53 Mutations in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with the Hypercvad-Based Regimens. Blood 128 (Supplement 1), 2016. e-Pub 2016.
Yilmaz M, Kantarjian H, Wang X, Cortes J, Garcia-Manero G, Khouri R, Short N, Ravandi F, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jane N, Verstovsek S, Estrov Z, Bose P, Schroeder H, Pierce S, O’Brien S, Jabbour E. Prognostic Index and Nomogram for Overall Survival (OS) of Adult Patients with Philadelphia-negative B-cell ALL. Clin Lymphoma Myeloma Leuk 16 Suppl 2:ALL-161, 2016. e-Pub 2016.
Short N, Jabbour E, O'Brien S, Sasaki K, Thomas D, Garcia-Manero G, Ravandi F, Borthakur G, Jain N, Konopleva M, Jacob J, Garris R, Cortes J, Kantarjian H. A Phase II Trial of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy for Patients with Relapsed/Refractory ALL. Clin Lymphoma Myeloma Leuk 16 Suppl 2:ALL-175, 2016. e-Pub 2016.
Sasaki K, Jabbour E, O’Brien S, Khouri MR, Thomas D, Garcia-Manero G, Ravandi F, Borthakur G, Short N, Issa G, Gachimova E, Garris R, Cortes J, Kantarjian H. Update Results of Frontline Therapy with Combination of Hyper-CMAD with Liposomal Vincristine in Patients with Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 16 Suppl 2:ALL-155, 2016. e-Pub 2016.
Sasaki K, Kantarjian H, Jabbour E, O’Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Takahashi K, Jain P, Rios MB, Pierce S, Cortes J. Prediction for sustained deep molecular response of BCR-ABL levels in patients with chronic myeloid leukemia in chronic phase. 18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, 2016. e-Pub 2016.
Yilmaz M, Kantarjian H, Thomas D, Kadia T, Garcia-Manero G, Khouri R, Ravandi F, Borthakur G, Cortes J, Ferrajoli A, Sasaki K, Autry J, Garris R, Voit K, O’Brien S, Jabbour E. Outcomes after Blinatumomab Failure in Patients with Relapsed/Refractory (R/R) B-cell ALL. Clin Lymphoma Myeloma Leuk 16 Suppl 2:ALL-157, 2016. e-Pub 2016.
Sasaki K, Jabbour E, Ravandi F, Short NJ, Khouri RB, Thomas D, Garcia-Manero G, Daver N, Kadia T, Konopleva M, Jain N, Issa GC, Jeanis V, Moore G, Garris R, Pemmaraju N, Cortes JE, O’Brien S, Kantarjian H. Propensity Score Analysis: Hyper-CVAD (HCVAD) + Ponatinib vs. HCVAD + dasatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 16 Suppl 2, 2016. e-Pub 2016.
Short N, Kantarjian H, Sasaki K, Khouri M, Cortes J, Ravandi F, Thomas D, Garcia-Manero G, Khouri I, Kebriaei P, Champlin R, Pierce S, Issa G, Konopleva M, Kadia T, Bueso-Ramos C, Khoury J, Jain N, O'Brien S, Jabbour E. Utility of Day 14 Bone Marrow Evaluation in Adults with Philadelphia Chromosone-Negative ALL: Relationship with Minimal Residual Disease Status. Clin Lymphoma Myeloma Leuk 16 Suppl 2:ALL-169, 2016. e-Pub 2016.
Sasaki K, Kantarjian H, Thomas D, Ravandi F, Khouri MR, Cortes J, Pemmaraju N, Kadia T, Short N, Issa G, Garris R, Moore G, Jeanis V, Garcia-Manero G, Borthakur G, Wierda W, O’Brien S, Jabbour E. Frontline Therapy with Combination of Hyper-CVAD with Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Phase II Study. Clin Lymphoma Myeloma Leuk 16 Suppl 2:ALL-154, 2016. e-Pub 2016.
Short N, Garcia-Manero G, Montalban-Bravo G, Sasaki K, Sekeres M, Komrokji R, Steensma D, DeZern A, Roboz G, Kadia T, Borthakur G, DiNardo C, Miller D, Estrov Z, Pemmaraju N, Daver N, Verstovsek S, Kantarjian H, Jabbour E. A Phase II Trial of Low-Dose Hypomethylating Agents in Patients with Low- or Intermediate-1-Risk MDS. Clin Lymphoma Myeloma Leuk 16 Suppl 2, 2016. e-Pub 2016.
Sasaki K, Kantarjian H, Jabbour E, O’Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Takahashi K, Jain P, Rios MB, Pierce S, Cortes J. Acceptable molecular response of BCR-ABL levels in patients with chronic myeloid leukemia in chronic phase. 18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, 2016. e-Pub 2016.
Issa G, Kantarjian H, Ravandi F, Thomas D, Khouri M, Garcia-Manero G, Garris R, Cortes J, Short N, Sasaki K, Schroeder H, Kadia T, Verstovsek S, Daver N, Jain N, Konopleva M, O’Brien S, Jabbour E. Update Results from the Phase II Study of Hyper-CVAD in Combination with Ofatumumab as Frontline Therapy for Adults with CD20 Positive (CD20+) ALL. Clin Lymphoma Myeloma Leuk 16 Suppl 2:ALL-068, 2016. e-Pub 2016.
Issa G, Kantarjian H, Yin CC, Qiao W, Ravandi F, Khouri R, Thomas D, Short N, Sasaki K, Garcia-Manero G, Kadia T, Cortes J, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin R, Pierce S, O’Brien S, Jabbour E. Complex Karyotype and Low Hypodiploidy/Near Triploidy are Adverse Prognostic Factors in Adult ALL Independent of MRD Status. Clin Lymphoma Myeloma Leuk 16 Suppl 2:ALL-070, 2016. e-Pub 2016.
Sasaki K, Kantarjian H, Jabbour E, O’Brien S, Ravandi F, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Takahashi K, Jain P, Rios MB, Pierce S, Cortes J. Clinical Application of Artificial Intelligence in Patients with Chronic Myeloid Leukemia in Chronic Phase. 18th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, 2016. e-Pub 2016.
Short NJ, Kantarjian HM, Sasaki K, Ravandi F, Garcia-Manero G, Thomas DA, Pierce S, Issa GC, Cortes JE, Kadia TM, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 (D14) bone marrow (BM) assessment in adult patients receiving induction for Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL). J Clin Oncol 34 Suppl:7035, 2016. e-Pub 2016.
Short N, Jabbour E, O'Brien S, Khouri R, Ravandi F, Thomas D, Garcia-Manero G, Sasaki K, Borthakur G, Jain N, Konopleva M, Jacob J, Garris R, Cortes J, Kantarjian H. A Phase I/II Trial of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy as Frontline Therapy for Older Patients with ALL. Clin Lymphoma Myeloma Leuk 16 Suppl 2:ALL-174, 2016. e-Pub 2016.
Hu B, Sasaki K, Bashir Q, Shah N, Patel KK, Popat UR, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen JL, Shah JJ, Manasanch EE, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Depth of response post autologous hematopoietic stem cell transplantation (auto-HCT) to predict outcome in high risk multiple myeloma (MM). J Clin Oncol 34 Suppl:8019, 2016. e-Pub 2016.
Sasaki K, Kantarjian H, Ravandi F, Thomas D, Daver N, Kadia T, Konopleva M, Jain N, Short N, Jeanis V, Moore G, Garris R, Garcia-Manero G, Cortes J, O’Brien S, Jabbour E. Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) + ponatinib vs. HCVAD + dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). J Clin Oncol 34 Suppl:7025, 2016. e-Pub 2016.
Short NJ, Jabbour E, Cortes JE, Garris R, O'Brien SM, Patel K, Sasaki K, Issa GC, Garcia-Manero G, Thomas DA, Kantarjian HM, Ravandi F. Impact of complete molecular response (CMR) on survival in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). J Clin Oncol 34 Suppl:7034, 2016. e-Pub 2016.
Sasaki K, Kantarjian H, Thomas D, Ravandi F, Cortes J, Pemmaraju N, Kadia T, Short N, Issa G, Garris R, Jeanis V, Garcia-Manero G, Borthakur G, Wierda W, O’Brien S, Jabbour E. Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). J Clin Oncol 34 Suppl:7036, 2016. e-Pub 2016.
Issa GC, Kantarjian HM, Yin CC, Ravandi F, Garcia-Manero G, Thomas DA, Cortes JE, Short NJ, Sasaki K, Qiao W, Takahashi K, Pierce S, Verstovsek S, Kadia TM, Borthakur G, O'Brien SM, Jabbour E. Prognostic impact of pre-treatment cytogenetics in adult acute lymphoblastic leukemia (ALL). J Clin Oncol 34 Suppl:7038, 2016. e-Pub 2016.
Issa GC, Kantarjian HM, Ravandi F, Thomas DA, Khouri M, Garcia-Manero G, Garris RS, Cortes JE, Short NJ, Sasaki K, Schroeder HM, Kadia TM, Verstovsek S, Daver NG, Jain N, Konopleva M, O'Brien SM, Jabbour E. Updated results from the phase II study of hyper-CVAD in combination with ofatumumab as frontline therapy for adults with CD20 positive (CD20+) acute lymphoblastic leukemia (ALL). J Clin Oncol 34 Suppl:7042, 2016. e-Pub 2016.
Qazilbash MH, Chen J, Valdez BC, Sasaki K, Kawedia JD, Bashir Q, Hosing C, Kebriaei P, Nieto Y, Shah N, Patel K, Shpall EJ, Anderson BS, Champlin R, Popat U. Myeloablative timed sequential busulfan is safe in patients with relapsed or high-risk multiple myeloma. BMT Tandem Meetings, 2016. e-Pub 2016.
Ramlal R, Sasaki K, Cerrada SL, Srour SA, Chen J, Rondon RG, Rezvani K, Oran B, Olson A, Shpall EJ, Champlin RE, Ciurea SO. Viral Reactivation in Haploidentical Transplants Using Post-Transplantation Cyclophosphamide – a Single Institution Experience. BMT Tandem Meetings, 2016. e-Pub 2016.
Sasaki K, Bashir Q, Shah N, Hosing C, Popat UR, Nieto Y, Parmar S, Shah JJ, Weber D, Weissinger D, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Multiple Myeloma By Race or Ethnicity in the Setting of Autologous Stem Cell Transplant. BMT Tandem Meetings, 2016. e-Pub 2016.
Issa G, Kantarjian H, Yin C, Sasaki K, Garcia-Manero G, DiNardo C, Takahashi K, Ravandi F, Cortes J, Daver N, Kadia T, Verstovsek S, Pierce S, Jabbour E. Prognostic Implications of Pre-treatment Hypodiploidy and Complex Cytogenetics in Adult Patients with Acute Lymphocytic Leukemia Treated with the HyperCVAD regimen. Blood 126 (Supplement 1), 2015. e-Pub 2015.
Short NJ, Garcia-Manero G, Montalban-Bravo G, Sasaki K, Sekeres MA, Komrokji RS, Steensma DP, DeZern AE, Roboz GJ, Kadia T, Borthakur G, DiNardo C, Miller D, Estrov Z, Pemmaraju N, Daver N, Verstovsek S, Kantarjian H, Jabbour E. Low-Dose Hypomethylating Agents Are Effective in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndrome: A Report on Behalf of the MDS Clinical Research Consortium. Blood 126 (Supplement 1), 2015. e-Pub 2015.
Jain PL, Sasaki K, Kantarjian H, Ravandi F, Cortes JE, Garcia-Manero G, Bose P, Daver N, Kadia T, Verstovsek S, Konopleva M, Jain N, Montalban-Bravo G, Pierce S, Jabbour E. Outcome of Adult Patients with Philadelphia Negative B Cell Acute Lymphoblastic Leukemia after Frontline Therapy Failure. Blood 126 (Supplement 1), 2015. e-Pub 2015.
Sasaki K, Jabbour E, Thomas DA, Khouri MR, Yilmaz M, Garcia-Manero G, Ravandi F, Borthakur G, Garris R, Gachimova E, Chahoud J, DiNardo C, Pemmaraju N, Cortes JE, Kantarjian HM, O'Brien S. Liposomal Vincristine (Marqibo) Combined with Hyper-CMAD As Frontline Therapy for Patients with Acute Lymphoblastic Leukemia: A Result of a Phase II Clinical Trial. Blood 126 (Supplement 1), 2015. e-Pub 2015.
Yilmaz M, Kantarjian H, Cortes J, Garcia-Manero G, Chahoud J, Ravandi F, Sasaki K, Konopleva M, Takahashi K, Wierda W, Jain N, Verstovsek S, Estrov Z, Bose P, Pierce S, Jabbour E. Results of Intensive Chemotherapy in 434 Adult Patients with Philadelphia-Negative Acute Lymphoblastic Leukemia: Predictive Prognostic Model for Survival. Blood 126 (Supplement 1)(23):3722, 2015. e-Pub 2015.
Yilmaz M, Kantarjian H, Ravandi F, Jorgensen J, Garcia-Manero G, Cortes J, Sasaki K, DiNardo C, Kadia T, Autry J, Garris R, Jabbour E. The Prognostic Value of Minimal Residual Disease after Salvage Therapy in Patients with Relapsed or Refractory (R/R) B-cell Acute Lymphoblastic Leukemia. Blood 126 (Supplement 1), 2015. e-Pub 2015.
Montalbán-Bravo G, Jabbour E, Short NJ, Sasaki K, Takahashi K, Ravandi F, Kadia TM, Cortes J, DiNardo CD, Konopleva M, Daver N, Verstovsek S, Kantarjian HM, Garcia-Manero G. Impact of Cytogenetic Abnormalities in Patients with Lower-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents. Blood 126 (Supplement 1), 2015. e-Pub 2015.
Jain P, Kantarjian H, Luthra R, Gonzalez GN, Patel KP, Jabbour E, Sasaki K, Romo CG, Kadia TM, Borthakur G, Estrov Z, Ravandi F, O’Brien S, Cortes J. Impact of the type of BCR-ABL fusion transcripts on response and survival in patients with chronic phase CML treated with four frontline TKI modalities. Blood 126 (Supplement 1), 2015. e-Pub 2015.
Sasaki K, Kantarjian HM, Luthra R, Patel KP, Garcia-Manero G, Verstovsek S, Estey EH, Kadia T, Brandt M, Pierce S, Estrov Z, Ferrajoli A, Borthakur G, Cortes JE, Ravandi F. Qualitative and Quantitative Correlation of PML-Rara Fusion Transcript from Peripheral Blood and Bone Marrow Samples By Quantitative Real-Time PCR in Patients with Acute Promyelocytic Leukemia. Blood 126 (Supplement 1), 2015. e-Pub 2015.
Chahoud J, Kantarjian H, Ravandi F, Sasaki K, Garcia-Manero G, Cortes J, Kadia T, Brandt M, Jabbour E. The Role of Additional Cytogenetic Abnormalities in Patients with 20q Deletion Acute Myeloid Leukemia: The University of Texas MD Anderson Cancer Center Experience. Blood 126 (Supplement 1), 2015. e-Pub 2015.
Dahl J, Kantarjian H, Yilmaz M, Kadia T, Garcia-Manero G, Ravandi F, Borthakur G, Cortes J, Ferrajoli A, Sasaki K, Chahoud J, Garris R, Autry J, Jabbour E. Outcome of Patients with Relapsed/Refractory B-cell Acute Lymphocytic Leukemia post Blinatumomab Failure. Blood 126 (Supplement 1)(23):1335, 2015. e-Pub 2015.
Sasaki K, Koller PB, Kantarjian HM, Thomas DA, Khouri MR, Garcia-Manero G, Garris R, Cortes JE, Schroeder H, Chahoud J, Kadia T, Ravandi F, Verstovsek S, Daver N, Jain N, Konopleva M, O'Brien S, Jabbour E. Phase II Study of the Frontline Hyper-CVAD in Combination with Ofatumumab for Adult Patients with CD-20 Positive Acute Lymphoblastic Leukemia. Blood 126 (Supplement 1), 2015. e-Pub 2015.
Sasaki K, Kantarjian HM, O'Brien S, Thomas DA, Ravandi F, Garcia-Manero G, Kadia T, Jain N, Konopleva M, Estrov Z, Takahashi K, Khouri MR, Jacob J, Garris R, Cortes JE, Jabbour E. Salvage Chemotherapy with Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD for Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Blood 126 (Supplement 1), 2015. e-Pub 2015.
Sasaki K, O'Brien S, Ravandi F, Thomas DA, Moore HG, Cortes JE, Pemmaraju N, Yilmaz M, Kadia T, Garris R, Garcia-Manero G, Jeanis TV, Chahoud J, Borthakur G, Wierda W, Ferrajoli A, Kantarjian HM, Jabbour E. Frontline Hyper-CVAD with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: Results of a Phase II Study. Blood 126 (Supplement 1), 2015. e-Pub 2015.
Sasaki K, Shah N, Bashir Q, Hosing CM, Popat UR, Nieto Y, Parmar S, Shah JJ, Weber D, Weissinger D, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant. Blood 126 (Supplement 1), 2015. e-Pub 2015.
Chahoud J, Kantarjian H, Sasaki K, Garcia-Manero G, Khouri M, Ravandi F, Cortes J, Dahl J, Daver N, Pemmaraju N, Borthakur G, Jacob J, Ferrajoli A, Garris R, Jabbour E. Outcome of Patients with Relapsed/Refractory Acute Lymphoid Leukemia after failure of Inotuzumab ozogamicin. Blood 126 (Supplement 1)(23):1298, 2015. e-Pub 2015.
Sasaki K, O’Brien S, Ravandi F, Thomas D, Moore HG, Cortes J, Pemmaraju N, Yilmaz M, Kadia T, Garris R, Garcia-Manero G, Jeanis V, Borthakur G, Wierda W, Ferrajoli A, Kantarjian H, Jabbour E. Phase II study of combination of hyper-CVAD with ponatinib in frontline therapy of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 15 Suppl 2, 2015. e-Pub 2015.
Sasaki K, Kantarjian H, O’Brien S, Thomas D, Ravandi F, Garcia-Manero G, Kadia T, Jain N, Konopleva M, Estrov Z, Takahashi K, Khouri M, Jacob J, Garris R, Cortes J, Jabbour E. Inotuzumab ozogamicin in combination with mini-hyper-CVD as salvage therapy for patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 15 Suppl 2:112, 2015. e-Pub 2015.
Tamamyan G, Kantarjian H, Sasaki K, McClain K, Allen C, Pierce S, Cortes J, Konopleva M, Rytting M, Jain N, Abdellal W, Konoplev S, Daver N. Secondary hemophagocytic lymphohistiocytoisis (HLH) in adults with hematological malignancies. The 31st Annual Meeting of the Histiocyte Society, 2015. e-Pub 2015.
Sasaki K, Kantarjian H, O’Brien S, Thomas D, Garcia-Manero G, Ravandi F, Dahl J, Jain N, Konopleva M, Jacob J, Garris R, Cortes J, Jabbour E. Inotuzumab ozogamicin in combination with mini-hyper-CVD as frontline therapy for older patients (≥60 years) with acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 15 Suppl 2:113, 2015. e-Pub 2015.
Sasaki K, O’Brien S, Thomas D, Khouri M, Yilmaz M, Garcia-Manero G, Ravandi F, Borthakur G, Garris R, Gachimova E, DiNardo C, Pemmaraju N, Cortes J, Kantarjian H, Jabbour E. Phase II study of hyper-CMAD with liposomal vincristine as frontline therapy for patients with acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 15 Suppl 2:111, 2015. e-Pub 2015.
Tamamyan G, Kantarjian H, Sasaki K, McClain K, Allen C, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Rytting M, Jain N, Abdellal W, Konoplev S, Daver N. Secondary Hemophagocytic Lymphohistiocytoisis (HLH) in Adults Patients. Clin Lymphoma Myeloma Leuk 15 Suppl 2:1002, 2015. e-Pub 2015.
Sasaki K, Yilmaz M, Kantarjian H, Thomas D, Khouri M, Garcia-Manero G, Garris R, Cortes J, Schroeder H, Kadia T, Ravandi F, Verstovsek S, Daver N, Jain N, Konopleva M, O’Brien S, Jabbour E. Ofautumumab in combination with hyper-CVAD regimen as frontline treatment for adults with CD-20 positive acute lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 15 Suppl 2:108, 2015. e-Pub 2015.
Sasaki K, Kantarjian H, Luthra R, Patel K, Garcia-Manero G, Verstovsek S, Estey E, Kadia T, Brandt M, Pierce S, Estrov Z, Ferrajoli A, Borthakur G, Cortes J, Ravandi F. Correlation between peripheral blood and bone marrow samples for detection of PML-RARA fusion transcripts by quantitative PCR in patients with acute promyelocytic leukemia. Clin Lymphoma Myeloma Leuk 15 Suppl 2:209, 2015. e-Pub 2015.
Yilmaz M, Sasaki K, Ravandi F, Cortes J, Garcia-Manero G, Kadia T, Daver N, Pemmaraju N, Borthakur G, DiNardo C, Takahashi K, O’Brien S, Estrov Z, Pike A, Brandt M, Kantarjian H, Jabbour E. Randomized phase II study of clofarabine or fludarabine combined with idarubicin and cytarabine for the treatment of newly diagnosed acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 15 Suppl 2:221, 2015. e-Pub 2015.
Jabbour E, O'Brien S, Thomas D, Sasaki K, Garcia-Manero G, Konopleva M, Kadia T, Ravandi F, Borthakur G, Garris R, Cortes J, Kantarjian H. INOTUZUMAB OZOGAMICIN IN COMBINATION WITH LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) FOR THE FRONTLINE THERAPY IN ELDERLY PATIENTS (≥60 YEARS) WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL). European Hematology Association Annual Meeting, 2015. e-Pub 2015.
Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Takahashi K, Konopleva M, Borthakur G, Garcia-Manero G, Wierda W, Daver N, Jain P, Pierce S, Rios MB, Cortes JE. Propensity score analysis: frontline therapy with high-dose imatinib vs. 2nd generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol 33 Suppl:7022, 2015. e-Pub 2015.
Sasaki K, Saliba R, Lu G, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Champlin R, Qazilbash M. Outcome of patients with multiple myeloma with t(4;14) after autologous hematopoietic stem cell transplantation. BMT Tandem Meetings, Annual Meeting:6077, 2015. e-Pub 2015.
Jabbour E, Sasaki K, Daver N, Pemmaraju N, DiNardo C, Kadia T, Miller D, Huang X, Borthakur G, Estrov Z, Kantrajian H, Garcia-Manero G. Initial results of a randomized phase II study of low dose decitabine versus low dose azacitidine in patients with low or intermediate-1- risk myelodysplastic syndromes. Blood 124 (Supplement 1), 2014. e-Pub 2014.
Jabbour E, O'Brien S, Thomas DA, Sasaki K, Garcia-Manero G, Kadia T, Jain N, York S, Garris R, Cortes J, Kantarjian HM. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as salvage therapy for adult patients with refractory/relapse acute lymphoblastic leukemia. Blood 124 (Supplement 1):794, 2014. e-Pub 2014.
Jabbour E, Sasaki K, Daver N, Pemmaraju N, Jain N, Kadia T, DiNardo C, Tuttle C, Borthakur G, Konopleva M, Faderl S, O’Brien S, Cortes J, Kantrajian H, Garcia-Manero G. Clofarabine plus low-dose cytarabine for the treatment of patients with higher-risk myelodysplastic syndromes who have relapsed or are refractory to hypomethylating agent therapy. Blood 124 (Supplement 1), 2014. e-Pub 2014.
Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Pierce S, Kantarjian H, Cortes JE. Chronic myeloid leukemia in chronic phase: survival in the era of tyrosine kinase inhibitors is similar to that of the general population in all age groups. Blood 124 (Supplement 1), 2014. e-Pub 2014.
Jabbour E, Sasaki K, Sekeres M, Komrokji R, Steensma D, Dazern A, Roboz G, Daver N, Pemmaraju N, Kadia T, Dinardo C, Wang X, Nogueras-González GM, Borthakur G, Estrov Z, Kantarjian H, Garcia-Manero G. Long-term outcome of patients with myelodysplastic syndromes treated with hypomethylating agents: a report on behalf of the MDS Clinical Research Consortium. Blood 124 (Supplement 1), 2014. e-Pub 2014.
Jabbour E, O’Brien S, Sasaki K, Huang X, Thomas D, Rytting M, Garcia-Manero G, Cortes J, Pierce S, Kadia T, Kantarjian H. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Blood 124 (Supplement 1), 2014. e-Pub 2014.
Duque AD, Cabrero M, Ravandi F, Pemmaraju N, Borthakur G, Kantarjian H, Cortes J, Kadia T, Daver N, Jabbour E, Garcia-Manero G, Sasaki K. Long-term outcome of chronic myelomonocytic leukemia patients treated with hypomethylating agents: a single-institution experience. Blood 124 (Supplement 1), 2014. e-Pub 2014.
Cabrero M, Garcia-Manero G, Sasaki K, Daver N, Borthakur G, DiNardo C, Cortes J, Bohannan Z, Sukholutsky V, Ravandi F, Pierce S, Kadia T, Pemmaraju N, Oran B, Champlin R, Kantarjian H, Jabbour E. Comparison of continuation of hypomethylating agent vs. allogeneic stem cell transplant and its timing in myelodysplastic syndromes: can it wait? results of a retrospective study. Blood 124 (Supplement 1), 2014. e-Pub 2014.
Jabbour E, Kantarjian H, Thomas D, Sasaki K, Ravandi F, Cortes J, Faderl S, Pemmaraju N, Kadia T, Garris R, Prescott H, Garcia-Manero G, Borthakur G, Wierda W, O’Brien S. Phase II study of combination of hyperCVAD with ponatinib in frontline therapy of patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 124 (Supplement 1):2663, 2014. e-Pub 2014.
Sasaki K, Rodriguez II, Kantarjian H, O’Brien S, Jabbour E, Borthakur G, Ravandi F, Burke M, Zweidler-McKay PA, Cortes JE. Correlation of lymphocyte count with treatment response to tyrosine kinase inhibitors in newly diagnosed chronic myeloid leukemia in chronic phase. Blood 124 (Supplement 1), 2014. e-Pub 2014.
Sasaki K, Jabbour E, Kantarjian H, Cortes J, Garcia-Manero G, Borthakur, G Pierce S, Pemmaraju N, O’Brien S, Ravandi F. Outcome of patients with therapy-related de novo acute myeloid leukemia: single institution experience. Blood 124 (Supplement 1), 2014. e-Pub 2014.
Sasaki K, Jabbour E, Pemmaraju N, Daver N, Kadia T, DiNardo C, Pierce S, Borthakur G, Kantarjian H, Garcia-Manero G. Predictive Factors for Response and Survival in Patients with Myelodysplastic Syndromes after Hypomethylating Agent Failure: Primary Resistance vs. Secondary Resistance. Blood 124 (Supplement 1), 2014. e-Pub 2014.
Jabbour E, O’Brien S, Thomas D, Sasaki K, Garcia-Manero G, Ravandi F, Borthakur G, York S, Garris R, Cortes J, Kantarjian H. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients and as salvage therapy for adult with relapsed/refractory acute lymphoblastic leukemia. Blood 124 (Supplement 1), 2014. e-Pub 2014.
Sasaki K, Jabbour E, O’Brien S, Huang X, Thomas D, Rytting M, Garcia-Manero G, Cortes J, Sherry P, Kadia T, Kantarjian H. Prognostic factors in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. Clin Lymphoma Myeloma Leuk 14 Suppl 2:138, 2014. e-Pub 2014.
Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M, Borthakur G, Pemmaraju N, Daver N, Pierce S, Kantarjian H, Cortes JE. Chronic myeloid leukemia in chronic phase: survival in the era of tyrosine kinase inhibitors is similar to that of the general population in all age groups. 16th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, 2014. e-Pub 2014.
Jabbour E, O’Brien S, Thomas D, Sasaki K, Garcia-Manero G, Ravandi F, Borthakur G, York S, Garris R, Cortes J, Kantarjian H. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-hyper-CVD) as frontline therapy for older patients and as salvage therapy for adult with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 14 Suppl 2:157, 2014. e-Pub 2014.
Sasaki K, Gotlib JR, Mesa RA, Ravandi F, Cortes JE, Kelly P, Kutok JL, Kantarjian HM, Verstovsek S. A phase 2 study of IPI-926, an oral hedgehog inhibitor, in patients with myelofibrosis. J Clin Oncol 32 Suppl:7111, 2014. e-Pub 2014.
Sasaki K, Kantarjian HM, Jain P, Jabbour E, Wierda W, Ferrajoli A, Dellasala SE, Pierce S, Verstovsek S, Ravandi F, O'Brien S, Cortes JE. Ten-year follow-up of patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with 400 mg or 800 mg of imatinib daily. J Clin Oncol 32 Suppl:7024, 2014. e-Pub 2014.
Sasaki K, Kantarjian H, Jabbour E, Ravandi F, Borthakur G, Wierda W, Garcia-Manero G, Estrov Z, Pierce S, O’Brien S, Cortes JE. LONG-TERM RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL OF HIGH-DOSE IMATINIB WITH OR WITHOUT INTERFERON-α IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE. European Hematology Association Annual Meeting:P888, 2014. e-Pub 2014.
Sasaki K, Kantarjian HM, Jabbour E, Quintas-Cardama A, Pierce S, Borthakur G, Kadia TM, Pemmaraju N, Ferrajoli A, O'Brien S, Cortes JE. Clinical safety and efficacy of nilotinib or dasatinib in patients with newly diagnosed chronic-phase chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Blood 122 (Supplement 1):1500, 2013. e-Pub 2013.
Sasaki K, Kantarjian HM, Jabbour E, Quintas-Cardama A, Pierce S, Borthakur G, Kadia TM, Pemmaraju N, Ferrajoli A, O’Brien S, Cortes JE. Nilotinib or dasatinib front-line therapy in patients with newly diagnosed chronic-phase chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Clin Lymphoma Myeloma Leuk 13 Suppl 2, 2013. e-Pub 2013.
Calabrese R, Davidson B, Sasaki K, Esposito A, Korman A. Acute esophageal necrosis presenting as otalgia and sore throat in a young woman. Journal of Hospital Medicine 7 Suppl 2:451, 2012. e-Pub 2012.
Sasaki K, Lu G, Hosing C, Popat U, Ahmed S, Shah N, Bashir Q, Dinh Y, Orlowski RZ, Champlin R, Qazilbash MH. Impact of t(11;14) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma. J Clin Oncol 30 Suppl:8040, 2012. e-Pub 2012.
Kumekawa H, Sasaki K, Murata Y, Yamamoto M, Ohki M, Kurosu T, Fukuda T, Arai A, Miura O, Murakami N. Marked reactive plasmacytosis in a patient with aplastic anemia. The Japanese Society of Hematology, 2010. e-Pub 2010.
Manabu O, Kumekawa H, Sasaki K, Murata Y, Yamamoto M, Kurosu T, Fukuda T, Arai A, Tohda S, Koyama T, Murakami N, Miura O. Case series of malignant lymphoma with central nervous system metastases after autologous stem cell transplant with BU/CY/TEPA. The Japan Society for Hematopoietic cell Transplantation, 32nd Annual meeting, 2010. e-Pub 2010.
Sasaki K, Kumekawa H, Murata Y, Yamamoto M, Ohki M, Kurosu T, Fukuda T, Arai A, Ohashi K, Akiyama H, Sakamaki H, Miura O. Marked improvement of refractory hemorrhagic cystitis after allogeneic stem cell transplant by hyperbaric oxygen therapy. The Japan Society for Hematopoietic Cell Transplantation, 2010. e-Pub 2010.
Fujita S, Sasaki K, Murata Y, Yamamoto M, Oki M, Fukuda T, Arai A, Murakami N, Miura O, Otani Y. A patient with myelodysplastic syndrome who improved interstitial pneumonia after stem cell transplant. The Japanese Society of Internal Medicine, 2009. e-Pub 2009.
Nakauchi Y, Oki M, Sasaki K, Kumekawa H, Murata Y, Yamamoto M, Kurosu T, Fukuda T, Arai A, Tohda S, Koyama T, Murakami N, Miura O, Hirooka S. A patient with Burkitt lymphoma who developed pericardial effusion and peripheral neuropathy during therapy. The Japanese Society of Hematology, Annual Meeting, 2009. e-Pub 2009.
Ohki M, Murata Y, Kumekawa H, Sasaki K, Nakauchi Y, Yamamoto M, Kurosu T, Fukuda T, Arai A, Miura O. Refractory CD4-/CD8-CD57+ Pre-T ALL after allogeneic stem cell transplant. The Japanese Society of Hematology, Annual Meeting, 2009. e-Pub 2009.
Sasaki K, Oshikawa G, Hirota A, Nagao T, Kakihana K, Kurosu T, Fukuda T, Arai A, Miki T, Tohda S, Koyama T, Murakami N, Ichinohasama R, Miura O. Primary multifocal osseous Hodgkin lymphoma. The Japanese Society of Hematology, Annual Meeting, 2008. e-Pub 2008.

Book Chapters

Sasaki K, Jabbour E, Cortes J, Kantarjian H. Chronic Myeloid Leukemia. In: The MD Anderson Manual of Medical Oncology. McGraw Hill / Medical, 2022.

Letters to the Editor

Bouligny, IM, MontalbanBravo, G, Sasaki, K, Daver, N, Jabbour, EJ, Alvarado, Y, DiNardo, C, Ravandi-Kashani, F, Borthakur, G, Bose, P, Pemmaraju, N, Kornblau, SM, Kadia, TM, Masarova, L, Takahashi, K, Andreeff, M, Bazinet, A, Yang, H, KanagalShamanna, R, Hosing, C, Pierce, S, Meyer, M, Huang, X, Garcia-Manero, G. A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome. Haematologica 110: 1628-1633, 2025.
Chien, KS, Braish, J, Li, Z, Loghavi, S, Bataller Torralba, A, Montalban Bravo, G, Sasaki, K, Kanagal Shamanna, R, Takahashi, K, DiNardo, C, Swaminathan, M, Kantarjian, HM, Garcia-Manero, G. Clinicopathologic characteristics and outcomes of patients with clonal hematopoiesis who progress to myeloid neoplasms. Leukemia 39: 1269-1272, 2025.
Bouligny, IM, Montalban-Bravo, G, Sasaki, K, Daver, N, Jabbour, EJ, Alvarado, Y, DiNardo, CD, Ravandi, F, Borthakur, G, Pemmaraju, N, Kadia, TM, Masarova, L, Takahashi, K, Andreeff, M, Bazinet, A, Yang, H, Kanagal, R, Pierce, S, Meyer, M, Huang, X, Garcia-Manero, G. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms. Leukemia 39: 524-528, 2025.
Kontoyiannis, PD, Peddireddy, A, Sasaki, K, Chien, KS, Senapati, J, Montalban Bravo, G, DiNardo, C, Borthakur, G, Kanagal-Shamanna, R, Bueso-Ramos, CE, Pierce, S, Kantarjian, HM, Garcia-Manero, G, Urrutia, S. Causes of death in patients with myelodysplastic syndrome and spliceosome mutations. Leukemia Research 147, 2024.
Montalban-Bravo G, Rodriguez-Sevilla JJ, Swanson DM, Kanagal-Shamanna R, Hammond D, Chien K, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Influence of co-mutational patterns in disease phenotype and clinical outcomes of chronic myelomonocytic leukemia. Leukemia 38: 1178-1181, 2024.

Less

CV information above last modified September 25, 2025

Koji Sasaki, MD, PhD

About Dr. Koji Sasaki

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Koji Sasaki, MD, PhD

About Dr. Koji Sasaki

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Extramural Institutional Committee Activities

Editorial Activities

Honors & Awards

Professional Memberships

Selected Presentations & Talks

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Invited Articles

Review Articles

Other Articles

Editorials

Abstracts

Book Chapters

Letters to the Editor

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop MD Anderson